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Abstract 
Inherited optic neuropathies represent an important cause of chronic visual morbidity among 
children and young adults. This group of disorders is genetically heterogeneous and it can be 
caused by pathogenic mutations within both the mitochondrial and nuclear genomes. The 
unifying pathophysiological theme is mitochondrial dysfunction, but the specific disease 
mechanisms that ultimately precipitate neuronal loss, particularly retinal ganglion cell (RGC) 
degeneration, still remain unclear. The work presented in this thesis provides further insight 
into the molecular and genetic basis of two classical forms of inherited optic neuropathy, 
namely autosomal dominant optic atrophy (DOA) and Wolfram syndrome. 
Dominant optic atrophy (DOA) secondary to pathogenic OPA1 mutations is the most 
common inherited optic neuropathy diagnosed in clinical practice. The pathology is 
characterised by the preferential loss of RGCs within the inner retina and optic nerve 
degeneration.  Although most OPA1 mutation carriers will only develop isolated optic 
atrophy, a subgroup of patients, referred to as DOA plus (DOA+), will develop more severe 
neuromuscular complications in addition to visual failure. The complexity of these clinical 
presentations may be due in part, to the various roles of OPA1 in the mitochondrial 
compartment such as regulating mitochondrial fusion and cristae structure,sequesterisation of 
pro-apoptotic molecules, mitochondrial DNA (mtDNA) maintenance,proper functioning of 
the oxidative phosphorylation system and calcium homoeostasis.  
To investigate the disease mechanisms that could explain the varying clinical 
manifestations and severity of OPA1 mutations, I made use of a cohort of eight fibroblast cell 
lines established from four patients with pure optic atrophy (OA) and four patients with 
DOA+ phenotypes. OPA1 expression and mitochondrial fragmentation patterns were 
compared between these two groups. There was no significant disruption in OPA1 
transcription, mitochondrial OXPHOS and mtDNA maintenance. DOA primary fibroblasts 
showed increased fragmentation of the mitochondrial network and cell lines established from 
patients with DOA+ phenotypes were found to be particularly susceptible to fragmentation 
under basal conditions, which had not been reported previously. 
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To further explore the findings obtained in OPA1 mutant fibroblasts, I made use of a 
cohort of nine myoblast cell lines that had previously been established from patient muscle 
biopsies. Interestingly, a similar mitochondrial fragmentation pattern was observed in OPA1 
mutant primary myotubes and this was associated with decreased mitochondrial DNA 
molecule number in DOA+ myotubes.  
I also investigated two sisters from a consanguineous Arab Muslim family who 
developed a fatal form of juvenile-encephalopathy complicated by optic atrophy and 
cardiomyopathy. Exome sequencing identified a putative homozygous OPA1 mutation, which 
was confirmed by both functional studies and in silico modelling.  
Whole-exome analysis was carried out on a cohort of fourteen patients with optic 
atrophy that had previously been found to be OPA1-negative. Pathogenic mutations in the 
Wolframin (WFS1) gene, which is known to cause Wolfram syndrome, were identified in 
3/14 (21%) patients. Based on our results, WFS1 mutations are an important cause of 
inherited optic atrophy and genetic testing should be considered in OPA1-negative patients. 
In conclusion, the body of work presented in my PhD thesis has provided further 
insight into the expanding genotypic and phenotypic spectrum of inherited optic neuropathies, 
which is highly relevant for clinical diagnosis and patient management. 
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1.1 Inherited Optic Neuropathies 
1.1.1 Epidemiology 
Mitochondrial diseases are now recognised as a major cause of chronic morbidity and the 
minimum prevalence has been estimated at 1 in 5,000 in the United Kingdom (Gorman et al., 
2015). Reflecting the ubiquitous nature of mitochondria and their fundamental roles in energy 
production, patients with mitochondrial genetic disorders often manifest a heterogeneous 
combination of tissue and organ involvement, which can lead to significant diagnostic delays. 
Optic nerve involvement is a major manifestation of mitochondrial diseases and it is an 
important cause of significant visual impairment. As a group, these inherited optic 
neuropathies affect approximately 1 in 10,000 individuals in the general population and there 
are currently limited treatment options (Yu-Wai-Man, 2010a; Newman and Biousse, 2004, 
Man et al., 2003). The pathological hallmark is the preferential loss of retinal ganglion cells 
(RGCs) within the inner retina, leading to progressive degeneration of the optic nerve and the 
onset of visual loss (Figure 1-1). Inherited optic neuropathies encompass a number of distinct 
clinical entities, but typically, the visual deterioration is bilateral and symmetrical with the 
development of a dense central or caecocentral scotoma (Yu-Wai-Man, 2009). 
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Figure 1-1 Anatomical structure of the human eye with a cross-section detailing the 
different retinal layers. 
Reproduced from Caspi, 2010. 
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1.1.2 Classification 
Historically, inherited optic neuropathies have been classified either based on their mode of 
inheritance, or on whether the optic atrophy was isolated or part of a more complicated 
syndromic presentation (Newman and Biousse, 2004). Mutations within the mitochondrial 
genome are maternally inherited whereas nuclear genetic defects are inherited either in a 
recessive or a dominant fashion (Table 1-1). However, with greater access to genetic testing 
and more careful phenotyping of affected patients with inherited forms of optic atrophy, these 
categorical distinctions have become more blurred. With the advent of next-generation exome 
and whole genome sequencing, the list of nuclear genes that cause inherited optic atrophy has 
also expanded markedly over the past few years. Three important groups have emerged, 
namely Leber hereditary optic neuropathy (LHON), autosomal dominant optic atrophy 
(DOA), and Wolfram syndrome (Yu-Wai-Man et al., 2011). These specific disorders will be 
described in more detail to highlight some of the key clinical and pathological manifestations, 
as well as the gaps in our current knowledge. 
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Table 1-1 Nuclear mitochondrial/ ER disorders with prominent optic nerve involvement 
          
Inheritance Locus Gene OMIM Phenotype 
Dominant 1p36.2 MFN2 601152 Hereditary motor and sensory neuropathy type 6 (HMSN-6,CMT2A) 
 
3q28-q29 OPA1 165500 Isolated optic atrophy (OA) and syndromal dominant optic atrophy (DOA+) 
 
4p16.1 WFS1 600965 Wolfram syndrome spectrum disorders 
 
16q24.3 SPG7 607259 Hereditary spastic paraplegia type 7 (HSP-7) 
 
18p11.21 AFG3L2 610246 Spinocerebellar ataxia 
 
19q13.2-q13.3 OPA3 165300 Autosomal dominant optic atrophy and early-onset cataracts (ADOAC) 
 
22q13.2 ACO2 614559 Infantile-cerebellar retinal degeneration 
Recessive 1q23.3 NDUFS2 252010 Optic atrophy-dystonia-deafness (Mohr-Tranbjaerg syndrome) 
 
4p16.1 WFS1 222300 Wolfram syndrome 1 
 
4q24 CISD2/WFS2 604928 Optic atrophy,neuropathy, deafness, diabetes mellitus, ulcer bleeding 
 
5q.22.1 SLC25A46 616505 Optic atrophy, peripheral neuropathy 
 
6q21 RTN4IP1 616732 Optic atrophy, seizures, mental retardation +/- ataxia 
 
9q13-q21.1 FXN 229300 Friedreich's ataxia (FRDA) 
 
9q22.31 AUH 250950 Type I-III methylglutaconic aciduria 
 
10p11.23 MTPAP 613672 Optic atrophy, dysarthria,spastic paraparesis, cerebellar ataxia +/-nystagmus 
 
11q14.1-q21 TMEM126A 612989 Optic atrophy +/- auditory neuropathy 
 
12p11.21 DRP1 614388 Optic atrophy, lactic acidemia, hypotonia, microcephaly 
 
12q24.31 C12ORF65 615035 Optic atrophy, peripheral neuropathy,spasticity+/- intellectual disability 
 
19q13.2-q13.3 OPA3 258501 Type III 3-methylglutaconic aciduria (Costeff syndrome) 
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1.2 Leber Hereditary Optic Neuropathy (LHON)  
1.2.1 Epidemiology 
Leber hereditary optic neuropathy (LHON) is a primary mitochondrial DNA (mtDNA) 
disorder that predominantly affects young adults with a peak age of onset in the second and 
third decades of life. The minimum prevalence of LHON has been estimated at about 1 in 
31,000 of the population with a much higher prevalence in men at about 1 in 14,000 (Man et 
al., 2003; Mascialino et al., 2012). 
 
1.2.2 Molecular genetics 
Three point mutations within the mitochondrial genome (m.3460G>A, m.11778G>A and 
m.14484T>C) account for about 90% of cases (Figure 1-2) with the m.11778G>A mutation 
being the most prevalent (60-80%) cause of LHON worldwide. Two peculiarities of this 
mitochondrial optic neuropathy are the marked incomplete penetrance and the male bias for 
visual loss (Johns et al., 1993; Nikoskelainen, 1994). Although there can be wide intra- and 
inter-familial variability, the lifetime risk of visual loss is about 50% for male carriers and 
about 10% for female carriers (Yu-Wai-Man et al., 2011).  
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Figure 1-2 Schematic illustrating the three common pathogenic mitochondrial DNA 
mutations found in LHON.  
Schematic illustrating the mitochondrial genome and the location of the three most common 
mtDNA LHON mutations, which all affect critical subunits of complex I. Reproduced from 
DiMauro et al., 2013. 
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1.2.3 Clinical manifestations 
Patients with LHON classically present wth subacute, painless, central visual loss in one eye, 
which is followed 2-4 months later by the fellow eye. Unilateral optic nerve involvement in 
LHON is exceptionally rare and another underlying pathological process should be actively 
excluded in these atypical cases. Bilateral simultaneous onset probably occurs in about 25% 
of patients and it is unusual for LHON carriers to experience visual loss beyond 50 years of 
age. The visual loss in LHON is severe and it usually plateaus over the next six months with 
most patients achieving visual acuities of 6/60 or worse (Figure 1-3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Acute and chronic stages of LHON 
A and B. Classical fundoscopic appearance in acute LHON with optic disc hyperaemia, 
swelling of the peripapillary retinal nerve fiber layer, prominent vascular tortuosity and fine 
telangiectatic vessels. C and D. Marked pallor of the neuroretinal rim in chronic LHON. 
A B 
C D 
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1.2.4 LHON plus phenotypes 
LHON is monosymptomatic in the majority of patients with pure optic nerve involvement. 
However, a minority of LHON carriers can develop a more severe syndromic phenotype, 
known as LHON plus (LHON+), where the optic atrophy is associated with cardiac 
arrhythmias, peripheral neuropathies, myoclonus, juvenile-onset encephalopathy, ataxia and 
spastic dystonia (Yu-Wai-Man et al. 2011; Gropman et al., 2004; Howel et al., 1991). There is 
also a well-reported association between the three primary mtDNA LHON mutations 
(m.3460G>A, m.11778G>A and m.14484T>C) and a multiple sclerosis-like illness, 
especially among female carriers (Harding’s disease) (Pfeffer et al., 2013a).  
 
1.2.5 Pathophysiology 
The mechanisms that underpin the preferential loss of RGCs in LHON have not yet been fully 
elucidated and the pathological triggers are likely to be multifactorial. The axons of RGCs are 
unmyelinated until they reach the lamina cribosa and to sustain efficient neuronal conduction, 
there is a relatively high concentration of mitochondria in the prelaminar segment. 
Furthermore, the axons with the papillomacular bundle, which subserve the central vision, are 
relatively small and this anatomical characteristic is thought to result in a reduced 
mitochondrial reserve, which would put them at increased risk under pathological conditions 
that impair mitochondrial function (Pan et al., 2012). The two main pathological factors that 
have been put forward is impaired mitochondrial oxidative phosphorylation (OXPHOS) 
precipitating a bioenergetics crisis and the increased chronic release of reactive oxygen 
species (ROS) (Carelli et al., 2004). These are not mutually exlusive and once a threshold is 
reached, which exceeds the cell’s innate compensatory mechanisms, an irreversible cascade of 
events is initiated that precipitate apoptotic cell death. The incomplete penetrance observed in 
LHON reflects this precarious balancing act and the likelihood of a carrier losing vision is 
likely to be influenced by secondary genetic factors, both mitochondrial and nuclear, and 
environmental exposures. There is mounting evidence that smoking significantly increases the 
risk of disease conversion by further exacerbating the underlying mitochondrial bioenergetic 
deficit and unaffected carriers should, therefore, be strongly advised not to smoke (Kirkman et 
al., 2009). An attractive explanation that has been put forward to explain the marked male 
predominance observed in LHON is the neuroprotective influence of oestrogen hormones on 
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RGCs when under conditons of heightened mitochondrial stress (Giordano et al., 2011; 
Pisano et al., 2015) 
 
1.2.6 Other mtDNA mutations causing optic neuropathies  
Optic nerve involvement is also seen with other pathogenic mtDNA mutations, but visual loss 
is frequently a secondary disease manifestation overshadowed by more severe neurological 
deficits. An important category is the mitochondrial encephalomyopathies, which encompass 
several distinct phenotypes such as mitochondrial encephalomyopathy, lactic acidosis, and 
stroke-like episodes (MELAS), myoclonic epilepsy and ragged-red fibers (MERRF), 
maternally inherited Leigh syndrome (MILS), and mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE) (Figure 1-4). Although variable and not a disease-defining 
feature, the occurrence of optic atrophy is well described in this group of patients (Man et al., 
2002; Sitarz et al., 2012). 
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Figure 1-4 Mitochondrial genome illustrating the marked phenotypic heterogeneity 
observed in patients with primary mitochondrial disease.  
Colour-coded sections: pink – complex I (ND) subunits; light blue – complex III (cyt b) 
subunits; purple – complex IV (CO) subunits; yellow – complex V (A6,A8) subunits; green –  
12S and 16S rRNA; blue – 22 tRNA with corresponding 3-letter amino acid code. Circles: 
blue – mutations that impair protein synthesis; pink – mutations in OXPHOS subunit proteins. 
The number within the circle indicated the location of the pathogenic mutation wthin the 
mitochondrial genome. Reproduced from DiMauro et al., 2013. 
Abbreviations: Cyt b – Cytochome b; FBSN – familial bilateral striatal necrosis; LHON – 
Leber hereditary optic neuropathy; LS – Leigh syndrome; MELAS – mitochondrial 
encephalomyopathy, lactic acidosis, stroke-like episodes; MERRF – myoclonus epilepsy and 
ragged red fibers; MILS – maternally inherited Leigh syndrome; NARP – neuropathy, ataxia 
and retinitis pigmentosa; ND – NADH – dehydrogenase; PEO –  progressive external 
ophthalmoplegia.  
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1.3 Autosomal Dominant Optic Atrophy  
1.3.1 Epidemiology  
DOA is the most common inherited optic neuropathy in the general population and the 
prevalence has been estimated at 1 in 25,000 in the north east of England (Figure 1-5) (Yu-
Wai-Man et al., 2010a; Yu-Wai-Man et al., 2013). An even higher prevalence of 1 in 10,000 
has been reported in the Danish population, which is likely due to a founder event (Thiselton 
et al., 2002). 
 
 
 
 
Figure 1-5 Epidemiological study of DOA in the North East of England.  
Reproduced from Yu-Wai-Man et al., 2014. 
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1.3.2 Molecular genetics 
OPA1 is the primary causative gene accounting for ~ 60% of cases of DOA (Delettre et al., 
2000; Cohn et al., 2007). There are 30 exons spanning over 100 kb of genomic DNA and it 
codes for a 960-amino acid, dynamin-related GTPase protein that localises to the inner 
mitochondrial membrane. Disease penetrance is high with 80-90%, of mutation carriers 
developing optic atrophy and visual failure (Thiselton et al., 2002; Toomes et al., 2001; Cohn 
et al., 2007) Over 200 OPA1 pathogenic mutations have been reported and these cluster in 
two specific regions: the GTPase domain (exons 8-15) and the C-terminus, which is the 
proposed site of the GTPase effector domain (GED) (Figure 1-6). The majority of OPA1 
mutations (~ 50%) lead to premature termination codons (PTCs) as a result of nonsense 
mutations, frameshifts from small insertions or deletions, or splice-site mutations. The 
resulting truncated mRNAs are unstable and they are degraded by nonsense mediated mRNA 
decay (NMD), which are in-built protective cellular mechanisms against mutant proteins with 
possible dominant negative or gain-of-function effects. The role of haploinsufficiency in 
DOA is further substantiated by reports of patients with large-scale OPA1 rearrangements, 
including the complete loss of one copy of OPA1 in one family (Marchbank et al., 2002). The 
functional roles of OPA1 are discussed from Sections 1.7.2-1.7.7. 
 
 
Figure 1-6 Schematic representation of the OPA1 gene.  
Basic domain = exons 1-3; coiled coil domain = exons 5b-7; GTPase domain = exons 7-15; 
middle domain = exons 16-25; GTPase effector domain = exons 27-28. Adapted from Yu-
Wai-Man et al., 2010b. 
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1.3.3 Clinical manifestations 
Visual decline in DOA usually starts in early childhood and the majority of patients are 
symptomatic before the age of 20 years old (Cohn et al., 2008; Yu-Wai-Man et al., 2010a). 
The average visual acuity is between 20/80 and 20/120, but there is wide intra- and 
interfamilial variability with disease severity ranging from 6/6 to light perception (Cohn et al., 
2007; Kjer et al., 1996; Votruba et al., 1998a). In a study of 21 DOA pedigrees, 80% of 
individuals maintained a stable visual acuity of 20/200 or better (Votruba et al., 1998a). The 
reasons for these phenotypic variations are not fully understood, but secondary genetic, 
epigenetic and/or environmental factors have been implicated. Although the rate of visual loss 
is usually slow, the majority of patients are eventually registered legally blind and the 
prognosis is guarded. Patients with DOA will also manifest other features pointing towards 
optic nerve dysfunction, including dyschromatopsia and central or centrocaecal scotomas due 
to the primary involvement of the papillomacular bundle (Lenears et al., 2012; Smith, 1972; 
Puomila et al., 2005). The optic disc pallor in DOA falls into two main categories: diffuse 
pallor involving the entire neuro-retinal rim in about half of all cases or a temporal wedge of 
pallor in the remainder (Figure 1-7). Excavation of the optic nerve head in DOA can 
sometimes lead to a clinical misdiagnosis of normal tension glaucoma (Fournier et al., 2001; 
Buono et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 15 
    
 
 
 
 
 
 
 
Figure 1-7 Optic disc appearance in a patient carrying a confirmed pathogenic OPA1 
mutation.  
There is bilateral global optic disc pallor, which is more marked in the temporal quadrant 
consistent with the more severe involvement of papillomacular bundle (RE- Right eye, LE- 
Left eye).  
 
1.3.4 DOA plus phenotypes 
DOA can present either with isolated optic nerve involvement (pure DOA) or with additional 
neuromuscular features which include visual failure, sensorineural deafness, 
ataxia/myopathy/neuropathy and PEO (DOA plus, DOA+) (Figure 1-8). Previous work from 
our group have shown that ~ 20% of patients harbouring pathogenic OPA1 mutations develop 
the more severe DOA+ phenotype (Yu-Wai-Man et al., 2010b). These neuromuscular 
complications cause major functional disability in patients who are already severely visually 
impaired (Amati-Bonneau et al., 2005; Bailie et al., 2013).  
 
RE LE 
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Figure 1-8 Age of onset for clinical features associated with DOA plus phenotypes.  
PEO:  progressive external opthalmoplegia. Reproduced from Yu-Wai-Man et al., 2010b. 
 
These syndromic variants of DOA have been linked with the secondary accumulation of 
multiple mtDNA deletions and with the presence of cytochrome c oxidase (COX)-deficient 
fibres in skeletal muscle biopsies obtained from affected mutation carriers (Amati-Bonneau et 
al., 2008; Hudson et al., 2008). There is a threefold increased risk of developing the more 
severe DOA+ phenotype with missense OPA1 mutations involving the GTPase domain 
compared with other mutational subgroups (Yu-Wai-Man et al., 2010b). The deleterious 
consequences of this specific group of OPA1 mutations on RGC survival is therefore clearly 
linked to the development of multisystem organ involvement in DOA+, suggesting a possible 
dominant negative effect. However the fundamental question still remains – why does a 
subgroup of patients with OPA1 mutations develop DOA+ features, leading to an increased 
neurological disability in addition to a worse visual prognosis? 
 
1.3.5 Recessive OPA1 mutations 
Recently the clinical spectrum of DOA+ was further expanded with the description of Behr 
syndrome (Marelli et al., 2011). Behr syndrome is an autosomal recessive disorder originally 
classified by the German ophthalmologist Carl Behr, and describes an infantile form of optic 
atrophy compounded with mental retardation, ataxia, spasticity and peripheral neuropathy.  
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Most known cases of DOA are due to dominant inheritance which can either lead to an 
isolated optic nerve involvement or a syndromic optic atrophy. However, in rare instances, 
patients with compound heterozygous OPA1 variants with either recessive or semi dominant 
inheritance have been identified with severe visual loss and/ or ataxia, cortocospinal tract 
involvement, peripheral neuropathy and myopathy (Pesch et al., 2001; Marelli et al., 2011; 
Schaaf et al., 2011; Carelli et al., 2015a, Bonneau et al., 2014; Bonifert et al., 2014). 
Although both heterozygous and compound heterozygous OPA1 mutations have been 
detected in patients presenting with Behr syndrome, pathological homozygous variants have 
yet to be clinically identified. Three OPA1 mouse models have been developed with 
truncative OPA1 variants located in exons 8 (c.1051C>T) (Davies et al., 2007), intron 10 ( 
c.1065+5 G> A) (Alavi et al., 2007) and exon 27 ( c.2708-2711delTTAG) (Sarzi et al., 2012). 
These heterozygous models faithfully replicate the visual deterioration found in DOA. 
However, strikingly, homozygous models died in utero suggesting that OPA1 is highly 
relevant for early development. Based on this observation of embryonic lethality, it is 
therefore not surprising that compound heterozygous or homozygous pathogenic deletions or 
duplications have yet to be found in DOA affected individuals. 
 
1.3.6 Other DOA genes 
Additional prominant genes associated to a dominant form of congenital optic neuropathy 
include MFN2, OPA3, AFG3L2, SPG7 and ACO2 (Table 1-1). These are translated and 
dispatched to the mitochondrial compartment where they are primarily involved in 
mitochondrial fission/fusion dynamics and/or disparate functions of mitochondrial 
metabolism and quality control. Pathological mutations in these genes can lead to a syndromal 
form of optic atropy similar to the DOA+ phenotype which includes visual loss, spastic 
paraplegia and ataxia among other unique neuropathological presentations. 
1.3.7 OPA3 
About 40% of clinically diagnosed DOA patients do not harbour pathogenic variants in OPA1 
(Yu-Wai-Man et al., 2011). The causative nuclear defects in a small number of families have 
been mapped to other chromosomal loci; OPA3, OPA4, OPA5, OPA8,OPA9 and OPA10 of 
which only the OPA3 gene has been characterised (Section 1.5; Table 1-3) (Garcin et al., 
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1961; Reynier et al., 2004; Kerrison et al., 1999; Barbet at al., 2005; Carelli et al., 2007; 
2011b;Angebault et al., 2015). 
  OPA3 was originally identified in 8 Iraqi Jewish families with an autosomal recessive 
form of optic atrophy, associated with neuro-cognitive deficits, elevated urinary excretion of 
3-methyl glutaconic acid and increased plasma 3-methylglutaric acid levels (Type III 3-
methylglutaconic aciduria or Costeff syndrome) (Anikster et al.,2001). Subsequent case series 
also identified heterozygous mutations in OPA3 which can be responsible for dominant cases 
of either isolated or complex multi-systemic bilateral optic atrophy (Grau et al., 2013; Reynier 
et al., 2004; Sergouniotis et al., 2015). Patients typically present with optic atrophy and 
infantile-onset cataracts but may display other visual and ocular abnormalities such as 
dyschromatopsia and temporal optic disk pallor. Additional neurological features may also 
include sensorineural deafness, spasticity and extrapyramidal dysfunction.  
Functional investigation of OPA3 has shown that it is expressed as two different 
isoforms (A and B) of which isoform OPA3-A has a greater level of expression than its 
counterpart (Huizing et al., 2010) (Figure 1-9). A recent homozygous (c.365T>C; 
p.Leu122Pro) OPA3 mouse line has been developed modelling the type 3-methylglutaconic 
aciduria condition found in humans and will be invaluable in dissecting the molecular 
mechanisms of recessive and complex OPA3- related optic disorders (Davies et al., 2008; 
Wells et al., 2012).  
 
 
Figure 1-9 Schematic diagram of OPA3 illustrating the two alternative isoforms OPA3A and 
OPA3B.  
Adapted from Huizing et al., 2010. 
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1.3.8 MFN2 
MFN2 is a GTPase known to be involved in OMM fusion, ER-mitochondrial interaction, 
mitochondrial axonal transport and mitophagy. Mutations found in the gene encoding this 
GTPase are responsible for an optic neuropathy known as Charcot Marie Tooth 2A( 
CMT2A). It is the most common axonal CMT disorder responsible for at least 20% of known 
cases. Similar to DOA, CMT2A has a complex presentation, most notably with foot 
deformities, walking difficulty, areflexia, sensory loss, physical weakness and in some cases 
sensorineural hearing loss and optic atrophy. The inheritance of CMT with optic atrophy can 
be due to both dominant and recessive inheritance of defective MFN2. 
 
1.3.9 SPG7 
SPG7 encodes for paraplegin, a primary constituent of the m-AAA (mitochondrial-AAA) 
protease responsible for both degrading aberrant mitochondrial proteins and maturation of 
specific polypeptide substrates such as OPA1. In rare cases, mutations in SPG7 are associated 
with a dominant form of OA which can either present as an isolated OA or OA complicated 
with cerebellar atrophy and peripheral neuropathy (Klebe et al., 2012). 
 
1.4 Wolfram Syndrome 
1.4.1 Epidemiology 
In some conditions with optic neuropathy, the optic degeneration is not the primary symptom 
and is associated with other primary manifestations as is the case in Wolfram syndrome. 
Wolfram syndrome, also described as DIDMOAD or diabetes insipidus, diabetes mellitus, 
optic atrophy and deafness (Bessahraoui et al., 2014), has a prevalence of 1 in 770,000 
individuals in the United Kingdom with most cases described as recessive or sporadic (Barrett 
et al., 1995). Some cases with dominant inheritance have also been identified (Bai et al., 
2014; Bonnycastle et al., 2013). 
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1.4.2 Molecular genetics 
The genetic component of Wolfram syndrome, WFS1 was first identified in 1998 through 
genetic mapping and a candidate gene approach. Mutations within WFS1 have been found in 
most recorded cases of Wolfram syndrome (Inoue et al., 1998; Strom et al., 1998;  de Heredia 
et al., 2013). A wide variety of mutations have been detected in WFS1 which include splice-
site, stop and frameshift mutations. However no mutational hotspot has been located in the 
WFS1 gene (De Heredia et al., 2013). Currently most pathogenic variants described in 
patients diagnosed with Wolfram Syndrome are loss of function (90%). There are <200  total 
variants reported (www.euro-wabb.org -June 2015) in WFS1 with 51.8% substitutions, 37% 
deletions, 9.1% duplications, 1.6% insertions and 0.4% insertion/deletion. 
Another manifestation of Wolfram Syndrome was reported in a Jordanian family and 
the genetic component designated WFS2 (El-Shanti et al., 2000). The locus for WFS2 was 
mapped to chromosome 4q22-24. Clinical presentation involved the classical symptoms of 
Wolfram syndrome which included optic atrophy and diabetes mellitus. There was however, 
no incidence of diabetes insipidus and a few patients were bleeding and had upper 
gastrointestinal ulceration with/without sensorineural hearing loss (Rigoli et al., 2011; El-
Shanti et al., 2000; Amr et al., 2007). Linkage analysis identified CISD2 as the causative 
genetic factor. Similar to WFS1, CISD2 encode for a protein located within the ER 
compartment.  
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1.4.3 Clinical manifestations 
The progression of Wolfram syndrome is variable with, in most cases, onset occurring in the 
first or second decade of life. Either a loss in visual acuity and optic atrophy may precede 
other syndromic features, or a mild dyschromatopsia or optic atrophy may occur initially 
followed by visual loss (Barrett et al., 1997). In the latter stages of the condition, visual loss is 
extreme and there is an obstruction of visual fields with a pathological cupping of the optic 
disc. Although the ‘minimum ascertainment’ of wolfram syndrome was initially optic atrophy 
and juvenile diabetes mellitus (<16 years) (Table 1-2), investigation into the underlying 
genetic aetiology of this condition has highlighted cases of Wolfram syndrome without 
characteristic diabetes insipidus or diabetes mellitus (Barrett et al., 1995; Khanim et al., 2001; 
Chaussenot et al., 2015; Marshall et al., 2013; Kytovuori et al., 2013).  
 
Table 1-2 Minimum ascertainment parameters for the diagnosis of Wolfram syndrome.  
Reproduced from http://www.orpha.net/national/data/IE-EN/www/uploads/Wolfram2014.pdf  
 
1.4.4 Pathophysiology 
WFS1 is localised to the ER where it is involved in polypeptide quality control in the 
unfolded protein response (UPR) (Hofmann et al., 2003; Takeda et al., 2001). The UPR 
consists of post translational modifications (PTMs), folding and assembly of functional 
cellular proteins. WFS1 is a component of the UPR negative feedback loop and interacts with 
the transcription factor ATF6α which is responsible for the upregulation of chaperones, the 
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mediators of protein folding (Osman et al., 2003). Disturbed ER mechanics can culminate in 
ER stress due to the accumulation of malformed polypeptides and ultimately upregulate the 
apoptotic response. Pancreatic β cells, retinal ganglion cells and cochlear cells have all shown 
to have a greater susceptibility to this stress response than other tissue types (Example of 
human retinal layers from Wolfram syndrome diagnosed patients in Figure 1-10). Additional 
functions of WFS1 include protein trafficking, calcium homoeostasis and cell signalling 
pathways (Zatyka et al., 2008; Yamaguchi et al., 2004; Fonseca et al., 2005; Yamada et al., 
2006; Hofmann and Bauer, 2006)  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-10 Light micrographs derived from paraffin-embedded sections of human 
retina from a patient with Wolfram syndrome.  
Haematoxylin and eosin stained Cross-sections taken 3.5mm from optic nerbe centre from (A) 
Control human macula and (B) Macula from patient suffering from Wolfram Syndrome. 
Control (A) shows normal staining of human retinal layers while retinal layers from patient 
with Wolfram Syndrome (B) displays loss of retinal ganglion cell layer. Figure adapted from 
Ross-Cisneros et al., 2013. 
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1.5 Other Inherited Optic Neuropathies 
Other genetic loci have been identified in patients with dominant and recessive inherited optic 
neuropathies (Table 1-1). Intriguingly, the pathophysiology of these disorders typically 
involves either mitochondrial or ER function suggesting a unifying biochemical theme for this 
clinically heterogenous group of disorders. As for OPA1 mutation carriers, the reported cases 
are either characterised by isolated optic atrophy or more severe syndromc manifestations 
complicated by varying combinations of sensorineural deafness, peripheral neuropathy, 
cognitive decline, seizures, hypotonia, ataxia and spasticity. About half of all patients with 
suspected inherited optic neuropathies do not yet have a confirmed molecular diagnosis and 
the hope is that more of these cases will be resolved in the next few years with the greater 
availability of next-generation exome and whole genome sequencing (Allen et al., 2015) 
(Table 1-3). Case series of isolated optic nerve involvement have also been described, such as 
autosomal recessive chiasmal optic neuropathy (Pomeranz et al., 1999) and apparent sex-
linked optic atrophy (Went et al., 1975; Assink et al., 1997), but the genetic basis still remains 
unknown.   
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         Locus Chromosome Gene Inheritance Pattern References 
OPA1 3q28-29 OPA1 Dominant 
Delettre et al., 2000 
Alexander et al., 2000 
OPA2 Xp11.4-p11.21 - X-linked recessive Assink et al., 1997 
OPA3 19q13.2-q13.3 OPA3 Dominant / Recessive Reynier et al., 2004; Anikster et al.,2001 
OPA4 18q12.2-q12.3 - Dominant Kerrison et al., 1999 
OPA5 22q12.1-q13.1 - Dominant Barbet, 2005 
OPA6 8q21-q22 - Recessive Barbet, 2003 
OPA7 11q14.1-q21 TMEM126A Recessive Hanein et al., 2009 
OPA8 16q21-22 - Dominant Carelli et al., 2011 
OPA9 6q21 RTN4IP1 Recessive Angebault et al., 2015 
     
Table 1-3 Mapped genetic loci and nuclear genes identified in patients with inherited optic neuropathies. 
Adapted from Wiggs, 2015 
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1.6 Mitochondria in Health and Disease 
Mitochondria are cellular organelles, which primary function is to produce chemical energy in 
the form of adenosine triphosphate (ATP) in the process of aerobic respiration. These 
organelles exist in an intricate interconnected dynamic network known as the mitochondrial 
reticulum (Chen and Chan et al., 2005). Mitochondria do not exist as discrete organelles but 
instead are in a constant state of dynamic fission or fusion with other members of the 
reticulum. They are found in the cytoplasm of most eukaryotic cells and their number varies 
from a few hundred to several thousand depending on the cell’s energy requirements.         
(Figure 1-11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-11 Structure of the mitochondrion. Depiction of the structure of mitochondrial 
cristae and the position of the mitochondrial respiratory chain supercomplexes. Reproduced 
from Saxton and Hollenbeck, 2012. 
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1.6.1 Origin  
The current hypothesis known as endosymbiotic theory, suggests that mitochondria arose 
from aerobic α-proteobacteria which were gradually assimilated by primitive glycolytic 
eubacteria (Lang et al., 1997). Over the course of evolution, much of the genetic material 
from these aerobic α-proteobacteria were transferred to the genome of the eubacterion which 
formed a symbiotic relationship. This is evidenced by phylogenetic study of Alphaprobacteria 
– Rickettsia prowazekii and mitochondria which lends support to a common evolutionary 
origin (Lang et al., 1997; Gray et al., 1999; Margulis et al., 1971). 
 
1.6.2 Structure 
Each mitochondrion is bounded by an outer and an inner membrane, and these are separated 
by an intermembrane space (Frey and Mannella, 2000). The outer mitochondrial membrane 
allows the free diffusion of molecules of ≤ 5 kDa. These molecules cross through 
membranous channels which are either formed by integral proteins known as porins or 
voltage dependent anion channels (VDACs). The inner membrane lacks porins and is rich in 
cardiolipin, which makes it highly impermeable. Molecules therefore need to be actively 
transported via specific active transport channels from the intermembrane space (IMS) into 
the matrix compartment. This allows the establishment of an electrochemical gradient. The 
inner membrane is compartmentalized into structures called cristae which increase the 
effective surface area for ATP production by the respiratory chain complexes (Perkins et 
al,1997). The mitochondrial matrix contains soluble enzymes involved in the -oxidation of 
fatty acids,the citric acid cycle and the intricate machinery required for the replication and 
transcription of mtDNA which are packaged into structures known as nucleoids (Alberts et 
al., 2002). Mitochondria also play an important role in calcium handling (Herrington et al., 
1996), apoptosis (Green, 1998), and the metabolism of amino acids, lipids, cholesterol and 
nucleotides (McBride et al., 2006). 
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1.6.3 Mitochondrial genetics 
The mitochondrial genome is a circular double stranded DNA molecule of 16,569 base pairs 
(bp) (Anderson et al., 1981). Originally it was thought that these genomic molecules were 
naked DNA backbones with a protective coat in the form of histone proteins similar to nuclear 
DNA (Nass et al., 1969, Iborra et al.,2004). It is now known that mtDNA molecules are 
instead contained within nucleoprotein structures known as nucleoids which are 
approximately 100 nm (Kukat et al., 2011). A recent investigation has suggested that each 
nucleoid contains a single mtDNA genome. There are approximately 1-10 mtDNA copies in 
each mitochondrion. Thousands of mtDNA molecules can exist in a cell depending on its 
metabolic requirements (Kukat et al., 2011). 
The structure of the mitochondrial genome consists of a purine-rich heavy chain (H-
strand) and a pyrimidine-rich light chain (L-strand) (Anderson et al., 1981). Unlike nuclear 
DNA, this genome contains no introns but instead has a 1.1kb region known as the 
displacement loop (D-loop) (Figure 1-12). This is a non-coding triple-stranded region which 
is involved in processes such as transcription and replication (Sbisa et al., 1997; Roberti et al., 
1998). This region has numerous regulatory elements such as binding sites for transcription 
factor A (TFAM-A), a termination associated sequence (TAS) and conserved sequence blocks 
(CSB1, CSB2 and CSB3) (Suissa et al., 2009; Sbisa et al., 1997). The origin of the H-strand  
is located within the D-loop. Most of the genes encoded by mtDNA are found on the H-strand 
and include two ribosomal RNAs (12S and 16S rRNA), 14 transfer RNAs (tRNAs) and 12 
subunits of the oxidative phosphorylation (OXPHOS) complexes. There are additional genes 
on the L-strand which include ND6 and eight tRNA genes. Other mitochondrial proteins are 
encoded by the cell’s nuclear genome and are targeted to the mitochondrial organelles. Due to 
the relatively small size of the mtDNA molecule and the lack of intronic sequences, many of 
these genes are overlapping and produce polycistronic transcripts. The tRNA genes found on 
both the H- and L-strand regulate this polycistronic transcriptional processing (Ojala et al., 
1980). Other unique features of the mitochondrial genome include the presence of only two 
stop codons (AGA and AGG) while the nuclear genome contains three (UAA, UGA, UAG) 
(Barrell et al., 1979. In addition the nuclear stop codon UGA instead transcribes for 
tryptophan in mtDNA (Barrell et al., 1979).  
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Figure 1-12 Schematic illustration of the human mitochondrial genome. 
MtDNA contains of 16,569 bps and is composed of two strands known as the heavy and light 
strand. Two promoters known as IH1 and IH2 are found on the heavy strand while one promoter 
IL on the light strand and these promoters are responsible for mtDNA replication. Promoters 
and other elements required for mtDNA replication are all found in the D-loop in an 
untranslated region of mtDNA mtDNA transcription occurs on both strands to encode 
required OXPHOS, ribosomal and t-RNA mRNAs. Reproduced from DiMauro et al., 2013. 
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1.6.4 Mitochondrial nucleoids 
The mitochondrial nucleoid is a nucleoprotein structure which encapsulates the mtDNA 
molecule (Spelbrink et al., 2010). Analysis of nucleoid aggregates with stimulated emission 
depletion microscopy (STED) has revealed that these structures are relatively uniform in size, 
however there is controversy as to the number of mtDNA per nucleoid. STED microscopy 
suggests that each nucleoid only contain a single mtDNA genome (Kukat et al., 2011), but 
another study using super resolution photoactivated localisation microscopy (PALM) found at 
least three mtDNA molecules per nucleoid (Brown et al., 2011). The latter study also found 
that the size of these nucleoids was dependent on the number of mtDNA molecules that they 
contained. Recent observation also demonstrates that nucleoids retain and regulate their own 
mtDNA and do not freely distribute it amongst other nucleoids (Gilkerson et al., 2008).  
Transcription factor-A (TFAM) is the primary protein which comprises the nucleoid 
and is involved in compartmentalising and organising mtDNA. Other subsidiary proteins 
contained within this structure include T7-like helicase (Twinkle, PEO1), mtSSB protein, 
Lon, DEAD-box protein 28 (DDX28), suv3-like helicase, POLRMT, and mtDNA polymerase 
γ (POLG) (Figure 1-13) (Y.Wang and Bogenhagen, 2006).  
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Figure 1-13 Mitochondrial nucleoid illustrating both the core (gold) and peripheral (blue) 
constituents. 
Core constituents (POLG, POLRMT, mtSSB, TFAM, TWINKLE, Lon) are capable of 
binding to mtDNA molecules and regulating transcription, translation and replication. 
Peripheral components (ATAD3, M19, PHB, and OPA1) are associated with integrating 
mtDNA and the nucleoid with global cellular signalling. Black rectangles indicate known 
protein and DNA interactions. Adapted from Gilkerson et al., 2013 
 
An additional group of proteins are transiently associated with a subset of mitochondrial 
nucleoids at any given time in order to perform a necessary function. An example of this are 
the mtDNA repair proteins and others involved on the process of mtDNA replication such as 
ATAD3. Although the mechanism of mtDNA copy number maintenance has still to be 
elicited, preliminary findings suggest that ATAD3 and POLG2 are some of the primary 
regulators involved. ATAD3 knockdown has also demonstrated an association with nucleoid 
formation (He et al., 2007; Holt et al., 2007.)  
These nucleoids are functionally diverse and promote mtDNA transcription and 
replication at the nucleoid core, while translation of mtDNA occurs on the outer periphery of 
these structures. The nucleoid is also believed to be involved in the organisation and 
distribution of mtDNA in dividing mitochondria by localizing to a tethered ER-mitochondrial 
complex, the ERMES complex as observed in a yeast model (Murley et al., 2013). These 
relocalised nucleoids are primarily the ones which are in the process of replicating new 
mtDNA. This allows mitochondrial nucleoids to segregate evenly following mitochondrial 
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division within each daughter mitochondria and allows maintenance of functioning newly 
developed organelles. The exact mechanism of how actively replicating nucleoids associate 
with these mitochondrial division sites is an active area of research.  The ERMES complex 
has not been found in mammalian cells but present research suggests that a similar structure 
may exist. Genetic knockdown of DRP1, a regulator of mitochondrial fission, promotes the 
aggregation of nucleoids (Ban-Ishihara et al., 2013). MIRO-1 has also been observed to co-
localise to ER-mitochondrial contacts where mitochondrial fission takes place. (Kornmann et 
al., 2011). MIRO-1 is a homologue of gem1 in yeast which is a RHO-like small GTPase 
responsible for releasing the mitochondrial –ER contacts.  
There is evidence from studies in yeast that the nucleoid also undergo remodelling 
under different metabolic conditions. Nucleoids may play a similar role to histones, which are 
protein structures binding to nuclear DNA and providing an additional level of complex 
regulation. Kucej and colleagues studied the yeast protein Abf2, which is an homolog of 
Human mTF1 and similar in function to human TFAM s using a Chip-on -chip assay (Kucej 
et al., 2008). They demonstrated that Abf2 was not as tightly bound and concentrated along 
mtDNA and formed a less compact nucleoid structure under conditions of respiration and 
growth which may potentially promote transcription of mtDNA. Greater accessibility of 
mtDNA may also promote regulation and binding of other factors but this remains to be 
elicited. Under conditions of glucose or amino acid starvation, factors such as hsp60 and ilv5 
are recruited to nucleoids (Kucej et al., 2008). These factors are believed to be involved in 
nucleoid/mtDNA maintenance. This preliminary research in yeast would suggest that the 
nucleoid is a dynamic structure which regulates mtDNA in response to metabolic 
homeostasis. These observations have yet to be extended into the human model but because of 
the high degree of functional conservation between yeast and higher order organisms, it is 
conceivable that such mechanisms may play a role in human health and disease states.  
  
1.6.5 Mitochondrial heteroplasmy 
The mitochondrial genome has a greater susceptibility to acquire genetic variants than the 
nuclear genome due to a number of factors. The close proximity of mtDNA to high levels of 
reactive oxygen species (ROS) produced as a byproduct of the OXPHOS system, the lack of 
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protective histones and the high replication rate of mtDNA molecules which promote 
replication error all contribute to polymorphism generation. The primary source of ROS is 
derived from the OXPHOS system, particularly from H2O2 species generation which together 
with redox-active metals such as Fe2+ undergo Fenton chemistry to create free radicals which 
effectively damage mtDNA (Thomas et al., 2009; Droge, 2002).  
As a cell comprises hundreds to several thousand mitochondria and each organelle 
contains between 2-10 mitochondrial genomes, mtDNA molecule are present in high copy 
number in individual cells. As a result of mutations caused by ROS, mtDNA population can 
be described as either homoplasmic or heteroplasmic. A homoplasmic mtDNA population is 
composed of mtDNA molecules with an identical genetic sequence. A heteroplasmic 
population comprises mtDNA molecules with different variants in the mtDNA genetic code 
(Wallace and Chalkia, 2013). Pathogenic mtDNA mutations are due to deleterious variants in 
a heteroplasmic population of mtDNA. In heteroplasmic populations, a minimum critical 
threshold of pathogenic mutated mtDNA molecules compared to wild-type (approximately 
60-80%) is necessary before biochemical defects and tissue dysfunction become apparent 
(Figure 1-14) (Wallace and Chalkia, 2013; Stewart and Chinnery. 2015). This threshold level 
varies depending on the mutation and differs amongst tissues, depending on their level of 
reliance on OXPHOS metabolism. 
 
 
 
Figure 1-14 Biochemical threshold of mutant mtDNA species.  
Reproduced from Stewart and Chinnery, 2015. 
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1.6.6 Mitochondrial DNA maintenance 
To combat genetic damage, the mitochondrial genome employs a number of DNA repair 
strategies which include mismatch repair and base excision repair of the mtDNA molecule. 
Base excision repair (BER) is the predominant and most well characterised mtDNA repair 
pathway (Alexeyev et al., 2013). This pathway is divided into two generalised mechanisms of 
BER, SP-BER (short-patch base excision repair) and LP-BER (long-patch base excision 
repair) (Svilar et al., 2011). The factors influencing the initiation of SP-BER or LP-BER are 
still being investigated but may be associated with the specific type of lesion, whether the cell 
is actively dividing or senescent and what stage of the cell cycle the lesion occurs.  BER is 
achieved by (i) detection of the DNA lesion (ii) Strand scission/ gap tailoring and (iii) DNA 
synthesis/ligation (Figure 1-15). (Alexeyev et al., 2013)  
In SP-BER, detection of the genetic lesion is facilitated by monofunctional or 
bifunctional glycosylases which introduce a single stranded break (SSB) (Anderson and 
Friedberg, 1980; Ohtsubo et al., 2000; Dodson and Lloyd, 2002). This SSB is further 
processed by AP-endonuclease-1 (APE1) or polynucleotide kinase 3’-phosphatase (PNKP) 
and ligated by the activity of POLG (Figure 1-15). 
LP-BER is the most common repair strategy for oxidative damage. It differs from SP-
BER because the DNA polymerase forms a ‘flap’ which is 6-9 nucleotides long from the 
point of excision. This ‘flap’ is processed by two nucleases FEN1 and DNA2 which create a 
DNA duplex which is ligated by LIG3 (Figure 1-15) (Alexeyev et al., 2013).  
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Figure 1-15 Mechanisms protecting against genetic damage to mtDNA.  
Reproduced from Alexeyev et al., 2013. 
 
1.6.7 Mitochondrial haplogroups 
The mitochondrial genome has a greater susceptibility to acquire genetic variants than the 
nuclear genome (Howell et al., 1996; Jazin et al., 1998). This is due to a number of factors. 
The close proximity of mtDNA to high levels of ROS, a byproduct of the OXPHOS system, 
the lack of histones which protect against genetic damage and the high replication rate of 
mtDNA molecules which promote replication error all contribute to polymorphism generation 
(Raha and Robinson, 2000, Alexeyev et al., 2013). MtDNA is inherited through a maternal 
lineage and it is through these genetic lines that different mtDNA polymorphisms have been 
acquired and fixed by distinct human populations (Cann, 2001). These fixed polymorphisms 
follow the pattern of human migration from Africa some 150,000 years ago into each of the 
different continents. Eighteen major phylogenetic haplogroups have been categorised in the 
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human species which comprise 497 unique haplogroup polymorphisms. Within Europe there 
are nine distinct haplogroups defined as H,I,J,K,T,U,V,W and X. H is the most common 
European haplogroup accounting for over half the population (Torroni and Wallace,1994; 
Herrnstadt and Howell, 2004, Herrnstadt et al., 2002). 
 
1.6.8 Mitochondrial DNA replication 
MtDNA replication is a process controlled by proteins encoded by the nuclear genome but is 
asynchronous to the cell cycle in mitotic and post-mitotic cells (Bogenhagen and Clayton, 
1977). It is regulated by the mitochondrial replisome, which is a complex composed of four 
different proteins which include POLG, mtSSB, TFAM and TWINKLE HELICASE 
(Wanrooij et al., 2010) and replication occurs at differential rates dependent on tissue type.  
The model which describes mtDNA replication is currently a controversial issue with 
three distinct mechanisms proposed. These three mechanisms are (i) asymmetric strand 
displacement (ASD) model (Clayton, 1982), (ii) synchronous strand coupled bidirectional 
(SSCB) model (Holt et al., 2000; Bowmaker et al., 2003)  and (iii) asymmetric strand 
displacement model combined with the incorporation of RNA at the lagging strand of 
replication (RITOLS model) (Figure 1-16) (Yasukawa et al., 2006).  
The ASD model, originally described by Clayton (1982), suggests that replication 
commences at the origin of replication (OH) on the leading\heavy strand (H-strand) and 
proceeds in a clockwise manner. This clockwise replication expands the D-region and exposes 
a second origin of replication (OL) on the inner lagging\light strand (L-strand). When H-strand 
clockwise replication has successfully replicated two thirds of the circular leading strand, anti-
clockwise replication of the inner L-strand begins. This form of replication generates two 
daughter mtDNA molecules but due to the asynchronous timings of the H and L strand, one 
daughter mtDNA is fully generated while the second daughter mtDNA is still replicating its 
L-strand.  
The synchronous strand coupled bidirectional (SSCB) model of mtDNA replication by 
Holt and colleagues is one that describes synchronous replication of both the H- and L-
strands (Holt et al., 2000). This conclusion resulted from the examination of replicative 
intermediates of mammalian mtDNA found in 2D agarose gel electrophoresis. Their proposed 
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model suggests that replication begins on both the H and L strand simultaneously at a region 
known as OZ, a single origin of replication where commences coupled strand replication. This 
generates two replication forks which expand and create two daughter mtDNA molecules 
simultaneously. Holt and colleagues propose that this model may occur independent or 
concurrent with the original strand displacement model (Holt et al., 2000) 
The RITOLS model of replication is mechanistically similar to the original ASD 
model which describes differential replicative timing of the leading and lagging mtDNA 
strand. However the RITOLS model proposes that mtDNA is first transcribed to RNA and 
subsequently reverse transcribed to the newly formed DNA strand (Yasukawa et al., 2006). 
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Figure 1-16 Alternative proposed models of mtDNA replication  
(i) Assymetric Strand displacement model: (Left panel) Replication begins at OH and 
replicates clockwise until OL is revealed on the light strand. A second replication event 
commenses on the light strand at OL in an anti-clockwise manner to generate two daughter 
mtDNA molecules. (ii) Synchronous Strand coupled bidirectional model: (middle panel) 
Replication on the heavy and light strand commenses simultaneously at OZ producing two 
coupled replication forks and generates two daughter mtDNA molecules. (iii) RITOLS model: 
(Right panel) Similar to the assymetric strand displacement model, replication on heavy and 
light strands occurs in an asynchronous manner however mtDNA is instead transcribed to 
RNA before being transcribed into two mtDNA daughter molecules. Reproduced from 
Kasiviswanathan et al., 2011. 
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1.6.9 Mitochondrial transcription 
Transcription of mtDNA can be initiated independently on the H and L strands. H-strand 
transcription can occur on two separate promotor sites, 150bp apart (Figure 1-17) These 
initiation sites are known as HSP1 and HSP2 and are differentially regulated (Litonin et al., 
2010; Lodeiro et al., 2012). Most often, the HSP1 promoter is initiated to create two tRNAs 
and two mitochondrial rRNAs. The HSP2 promoter alternatively produces a large 
polycistronic transcript which is punctuated by tRNA sequences, necessary to define rRNA 
and mRNA transcripts. The H-strand is responsible for transcribing twelve mRNA, fourteen 
tRNA and two rRNA species. The L-strand has only a single promoter initiation site 
designated LSP. It is responsible for transcribing a single mRNA and eight tRNA species. All 
three transcription initiation promoters are contained within the mitochondrial D-loop and 
each contains a 15bp consensus sequence (Cantatore et al., 1980; Montoya et al., 1982; 
Martin et al., 2005) 
The intricate mitochondrial transcription machinery is composed of POLRMT 
(mitochondrial RNA polymerase) and two initiation factors designated transcription factor A 
(TFAM) and transcription factor B2 (TFB2M) (Morozov et al., 2014). This model for 
mitochondrial transcription involves a simple mechanism where TFAM binds to a recognition 
site upstream of the D-loop transcriptional promoter. TFAM is required for transcription 
specificity at the transcription promoter sites. This TFAM bends the mtDNA and permits 
recruitment and interaction of POLRMT to form the pre-initiation complex (Morozov et al., 
2014). This pre-initiation complex in turn recruits TFB2M to form the initiation complex 
which is required for melting of the mtDNA and commencement of transcription.  
The concentration of TFAM is also believed to have a relationship on transcription 
promoter regulation. There are currently two models which describe this process, the 
cooperative looping monomer-dimer model and the cooperative spreading dimer model. 
These models describe how the binding of TFAM, initially at the LSP promoter site and 
subsequently at the inter- promoter region, drive structural changes of the mtDNA molecule 
and as a consequence adjust activation of the mitochondrial transcriptional promoter (Wong et 
al., 2009; Gangelhoff et al., 2009; Campbell et al., 2012).  
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Figure 1-17 Schematic of the mechanism of mtDNA transcription  
The intricate mitochondrial transcription machinery is composed of POLRMT (mitochondrial 
RNA polymerase) and two initiation factors designated transcription factor A (TFAM) and 
transcription factor B2 (TFB2M). Reproduced from Litonin et al., 2010.  
 
1.6.10 Mitochondrial translation 
The mitochondrion possess over 1000 different proteins, most of which are encoded by the 
eukaryotic translation machinery found in the cytoplasm (Endo et al., 2011). However a 
subset of these proteins are synthesised by a distinct mitochondrial translation system encoded 
by the mitochondrial genome. These proteins include 22 tRNAs, 2 rRNAs and 13 OXPHOS 
complex subunits.  
The mitochondrial translation system is not well characterised but close parallels have 
been noted between mitochondrial and prokaryotic translation machineries. This is primarily 
due to the lack of a proper in vitro model of mitochondrial protein synthesis. The subunits of 
the mitochondrial ribosome are mostly encoded by the nuclear genome. Recent efforts have 
defined the structure of the mitochondrial ribosome at a resolution of 3.5 angstrom (Amunts 
et al., 2015). This analysis has determined that this ribosome is a complex of approximately 
80 proteins including three ribosomal RNA proteins, 12S, 16S and mt-tRNAVal.  
Protein translation involves three steps, initiation, elongation and termination (Figure 
1-18). The initiation step is catalysed by initiation factors mtIF2 and mtIF3 which are 
orthologous to the IF1 and IF2 initiation factors in prokaryotes (Myasnikov et al., 2009). The  
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initiation factor mtIF3, dissociates the 55S ribosomal subunit into two smaller subunits 
39S and 28S to facilitate formation of the initiation complex. The mtIF2 factor is responsible 
for initiating an interaction between fMet-tRNA (tRNA carrying the first amino acid for 
protein synthesis) and the 28S subunit to form this initiation complex (Myasnikov et al., 
2009). Elongation involves three elongation factors similar to prokaryotes, mtEFTu, mtEFTs 
and mtEFG which promote mRNA read-through by coding-anticoding interaction, amino acid 
peptide bond formation and peptide elongation (Hammarsund et al., 2001; Ling et al., 1997; 
Xin et al., 1995). Termination of mitochondrial translation is regulated by two release factors 
MtRF1 and MtRF2 and a recycling factor mtRRF. This process begins at a mitochondrial stop 
codon (UAA, UAG, AGA or AGG). When this stop codon is recognised, the peptide is 
released from the tRNA (Smits et al., 2010). 
Interestingly, over 200 pathogenic mutations which affect tRNA processing enzymes and 
aminoacyl-tRNA synthases (ARS) of mitochondrial translation have been implicated in 
complex clinical diseases (Abbott et al., 2014). Mutations in tRNA enzymes typically disrupt 
aminoacylation and can impact the expression of OXPHOS complex subunits in these 
mitochondrial disorders. 
 Two classical and most well characterised cases associated with mitochondrial translational 
defects include mitochondrial encephalomyopathy, lactic acidosis and strike like symptoms 
(MELAS) and myoclonic epilepsy and ragged red fibres (MERRF) (Kobayashi et al., 1990; 
Shoffner et al., 1990). Intrigingly, presentation of these two diseases is predominantly due to 
defects at a tRNA anticodon wobble position (mt-tRNALEU- MELAS; mt-tRNALYS- MERRF). 
In addition to these phenotypes, other more rare tissue specific presentations with alternative 
mutations can afflict the auditory or visual system, similar to optic neuropathies (Yan et al., 
2011a; Crimi et al., 2003) 
.Mutations in mitochondrial tRNA modifying factors like glycl-tRNA synthase (GARS) and 
lysyl-tRNA synthase (KARS), which are encoded solely by mtDNA, can lead to diseases of 
the peripheral nervous system such as Charcot-Marie-Tooth. Other mitochondrial nuclear 
encoded modifying factors such as HARS2 (histidyl-tRNA synthetase 2), LARS2 (leucyl-
tRNA synthetase 2), DARS (aspartyl-tRNA synthetase), RARS2 (arginyl-tRNA synthetase 2), 
YARS2 (tyrosyl-tRNA synthetase 2 ), SARS2 (seryl-tRNA synthetase 2), AARS2 (alanyl-
tRNA synthetase 2), MARS2 (methionyl-tRNA synthetase 2), FARS2 (phenylalanine-tRNA 
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synthetase 2), EARS2 (glutamyl-tRNA synthetase 2), VARS2 (valyl-tRNA synthetase 2) and 
TARS2 (threonyl-tRNA synthetase 2) have also all been implicated in other mitochondrial 
related disorders demonstrating the complexity of mitochondrial translation in disease (Abbott 
et al., 2014).  
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Figure 1-18 Schematic of the three stages (initiation, elongation and termination) 
involved in mitochondrial translation.  
Adapted from Smits et al., 2010.  
1.6.11 Mitochondrial oxidative phosphorylation  
The majority of the cells energy requirement in the form of ATP is provided by the 
mitochondrial respiratory chain. OXPHOS is regulated by five protein transmembrane 
complexes bound to the matrix side of the IMM (Inner Mitochondrial Membrane) (Bellance et 
al., 2009). These complexes are NADH ubiquinone oxidoreductase (complex I), succinate 
ubiquinone oxidoreductase (complex II), ubiquinol cytochrome c reductase (complex III), 
cytochrome c oxidase (complex IV) and ATP synthase (complex V). Each complex is 
composed of multiple subunits which are encoded by either the mtDNA or the nuclear 
genome. The only exception to this is complex II, whose subunits are entirely transcribed 
from the nuclear genome.  This chemical energy 'production line' is intrinsically linked to the 
Krebs cycle located within the mitochondrial matrix. The Krebs cycle produces cofactors 
known as Reduced Nicotinamide Adenine Dinucleotide (NADH2+H
+ ) and Reduced Flavin 
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Adenine Dinucleotide (FADH2) and these molecules are oxidised when they interact with 
complexes I and II, respectively. The donated electrons are transported along the 
mitochondrial OXPHOS chain by coenzyme Q10 and cytochrome c and protons are pumped 
across the intermembrane space to generate an electrochemical gradient. This proton gradient 
is employed by ATP synthase (complex V) to generate ATP from the constituents’ adenosine 
diphosphate ADP and inorganic phosphate Pi (Figure 1-19). 
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Figure 1-19 The mitochondrial respiratory chain complexes. 
Reproduced from Nijtmans et al., 2004 
 
1.6.12  Complex I: NADH ubiquinone oxidoreductase 
Complex I is an L-shaped multiprotein structure composed of 47 subunits and is the largest 
complex of the OXPHOS system with a molecular weight of 980kDa. The hydrophobic 
components of this complex are embedded in the IMM while the hydrophilic arm extends into 
the mitochondrial matrix (Grigorieff, 1999). The subunits which compose this structure are 
composed of 7 mitochondrial and 40 nuclear encoded proteins which are shuttled and 
imported into the mitochondrion. The complex contains the co-enzyme Flavin 
mononucleotide (FMN) and up to nine iron sulphur clusters (Hinchliffe and Sazanov, 2005; 
Koopman et al., 2007). NADH is oxidised to NAD+ at complex I and two electrons are 
transferred to coenzyme Q10 (ubiquinone). Ubiquinone is reduced to ubiquinol and diffused 
within the IMM.  Each molecule of NAD
+ is then used to pump four protons across the IMM 
to form an electrochemical gradient (Raha and Robinson, 2000).  
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1.6.13  Complex II: succinate ubiquinone oxidoreductase 
Complex II (succinate-ubiquinone oxidoreductase or succinate dehydrogenase; SDH) is 
unique because it is the only complex to be completely composed of nuclear encoded 
subunits. Structurally, it is the smallest complex and is constructed of only four subunits. 
Subunits A (73KDa) and B (27KDa) are hydrophilic with subunit A containing a covalently-
bound flavin adenine dinucleotide coenzyme and subunit B with three iron-sulphur clusters 
(Hatefi and Galante, 1980; Lancaster and Kroger, 2000). The remaining subunits C and D 
contain heme groups. Similar to complex I, it produces electrons through the process of 
oxidation to reduce ubiquinone to ubiquinol. These electrons are derived from succinate 
which is oxidised to fumarate at the FAD coenzyme and transferred by the iron-sulphur 
clusters to ubiquinone. However unlike complex I, this oxidation process in not accompanied 
by proton transfer. 
 
1.6.14  Complex III: ubiquinol cytochrome c reductase 
Complex III has a dimeric structure and is composed of eleven subunits. Ten are nuclear 
encoded while a single subunit, cytochrome b, is mitochondrial. Three subunits of this 
complex, cytochrome b (which contains two haem groups), cytochrome c1 (with a covalently 
bound haem c) and an iron-sulphur protein (Rieske protein) are components of a functional 
catalytic core known as the cytochrome bc1 complex (Yu et al., 1999). The primary function 
of complex III is to transfer electrons to cytochrome c through a series of oxidation/reduction 
reactions of ubiquinol and ubiquione in a mechanism known as the Q cycle (Mitchell et al., 
1976). This occurs in conjunction with protein pumping across the IMM which establishes an 
electrochemical gradient (Acin-Perez et al., 2004). 
 
1.6.15 Complex IV: cytochrome c oxidase 
Complex IV (cytochrome c oxidase; COX) is composed of thirteen subunits and is a soluble 
haemoprotein structure with a molecular weight of 204kDa. Ten subunits are nuclear encoded 
while the remaining three are mitochondrial (COX1, COXII and COXIII). It is the terminal 
electron acceptor of the OXPHOS system (Kadenbach et al., 1983). The complex spans the 
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inner membrane facing both the mitochondrial matrix and the IMS. It contains two copper 
centres (CUA and CUB) and two heme groups (cytochrome a and a3). Cytochome a3 and CUB 
create a binuclear centre required for the reduction of molecular oxygen to water. This process 
occurs by the transfer of electrons from cytochrome c to this binuclear centre which reduces 
oxygen. Two protons are transferred to this reduced oxygen molecule to form water. In 
conjunction with this process, four additional protons are translocated across the IMM 
forming an electrochemical gradient (Saraste et al., 1999). 
 
1.6.16 Complex V: ATP synthase 
Complex V (F0F1-ATP synthase) is composed of seventeen different subunits and has an 
approximate molecular weight of 500kDa (Von Ballmoos et al., 2009) Fifteen of these 
subunits are nuclear encoded while two are mitochondrial (ATP6 and ATP8) (Boyer, 1997) 
The ATP synthase complex is composed of two primary structures, the F0 motor which is 
located in the IMM and the F1 motor, a structure with a catalytic domain located in the 
mitochondrial matrix. F1 is a cylindrical structure derived from α, β, γ ,δ and ε subunits in an 
α3β3γε stoichiometry (Abrahams et al., 1994; Yoshida et al., 2001). Alternative α and β 
subunits form a cylinder bounding the γ subunit. The F0 motor has an a1b2c12 stoichiometry 
with c subunits forming a cylindrical structure and bounded by a and b subunits. The F0 and 
F1 motors are connected by a ring of subunit c which links the γ subunit through mutual 
contacts with ε subunit. Together these F0 and F1 moieties of ATP synthase form a rotor-stator 
model where protons are translocated along the cylindrical F0 structure which acts as a 
channel through the mitochondrial membrane and turns this F0 motor (Gibbons et al., 2000; 
Ko et al., 2000). These protons are generated through the electrochemical gradient established 
by complexes I, III and IV. Rotation of the F0 motor subsequently rotates the catalytic F1 
motor which binds ADP and Pi and generates ATP (Kayalar et al., 1977). 
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1.7 Mitochondrial dynamics 
Mitochondrial dynamics is a term describing the fusion and fission processes which occur 
between intracellular mitochondrial organelles. These dynamic processes mediate a broad 
variety of cellular functions. These functions include the maintenance of the mitochondrial 
genome, adaptation to extracellular stress, localizing mitochondria in areas of high energy 
demand, regulation of programmed cell death and calcium buffering between the endoplasmic 
reticulum and the mitochondrial compartments. (Ferree and Shirihai, 2012; Mcbride et al., 
2006). 
 
1.7.1 Mitochondrial fusion 
Fusion of adjacent mitochondria involves the coordinated fusion of the OMM and IMM 
(Meeusen et al, 2006; Song et al., 2007). Although these two fusional steps occur 
independently, OMM and IMM fusion usually occur in a synchronous manner through the 
tightly regulated interactions of OPA1 on the IMM, and the mitofusin complex (MFN1 and 
MFN2) on the OMM. OPA1, MFN1 and MFN2 regulate both transient and complete fusion 
of the mitochondrial network. Transient fusion is defined as an event in which only the OMM 
is fused while complete fusion involves both the outer and inner mitochondrial membranes. 
Transient or ‘kiss and run’ fusion is used to distribute mRNAs, small solutes and proteins 
between two mitochondria while complete fusion allows the distribution of both soluble and 
essential components required for mitochondrial survival. 
 
1.7.2  OPA1 
 OPA1 is a nuclear encoded gene of approximately 100kb (30 exons) which lies on 
chromosome 3.  Early linkage association studies mapped OPA1 to a locus at chromosomal 
position 3q28 (Eiberg et al., 1994) and subsequenct studies performed by both Delettre et al. 
and Alexander et al. (2000) identified the OPA1 gene. OPA1 belongs to the dynamin protein 
family and contains a putative conserved GTPase, a middle and GTPase effector domain. It is 
transcribed into eight different mRNA species which are alternatively spliced at exons 4, 4b 
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and 5b and translated by cytosolic ribosomes into OPA1 precursor (Figure 1-20). These 
OPA1 transcripts are constitutively expressed in all human tissues but are mostly abundant in 
heart, brain, testis, retina and muscle (Alexander et al., 2000). 
Downregulation of OPA1 protein levels caused by mutations or RNAi knockdown can 
result in mitochondrial network fragmentation (Griparic et al., 2004; Olichon et al., 2003) 
Knockdown of OPA1 to suboptimal levels (i.e. haploinsufficiency) can disrupt the formation 
of a stable fusion complex with MFN1 and MFN2, an essential step necessary for both 
transient and complete mitochondrial fusion (Cipolat et al., 2004). More recently, 
experimental data has emerged showing that OPA1 level is a critical factor in the formation 
and stability of mitochondrial respiratory chain complexes I, II and III. Reduced OPA1 levels 
or aberrant mutant proteins can therefore disrupt OXPHOS, leading to protein leakage as well 
as loss of mitochondrial membrane potential (Zanna et al., 2008). 
 
1.7.3 Proteolytic processing of OPA1 
The OPA1 precursor is targeted to the mitochondrial compartment by a mitochondrial 
targeting sequence (MTS) at the N-terminus which is cleaved upon import  by the matrix 
metalloprotease mitochondrial processing pepsidase (MPP) to produce the long isoform of 
OPA1 (L-OPA1) (Olichon et al., 2002; Satoh et al., 2003). L-OPA1 is embedded in the IMM 
and it is further processed by three additional proteases to produce OPA1 protein isoforms 
(Figure 1-20). These proteases target conserved S1 and S2 cleavage sites located at exons 5 
and 5b, respectively (Figure 1-21). The rhomboid protease PARL and the (matrix-AAA 
protease) mAAA-protease paraplegin cleave OPA1 at S1 (Cipolat et al.,2006; Ishihara et al., 
2006) and the (intermembrane-AAA protease) i-AAA protease YME1L cleaves OPA1 at S2 
site (Song et al., 2007) to produce short isoforms of OPA1 (S-OPA1). OMA1 also cleaves 
OPA1 at the S1 site under basal conditions but as it is an inducible protease, it can upregulate 
cleavage at this site and promote mitochondrial fission. Both long and short isoforms of 
OPA1 are localised to the IMS and are required for proper mitochondrial fusion to take place. 
It is thought that L-OPA1 is anchored to the IMM while the S-OPA1 is only peripherally 
associated with the IMM and can diffuse through the IMS to the OMM (Olichon et al., 2002; 
Satoh et al., 2003; Griparic et al., 2004; Ishihara et al., 2006; Ciplolat et al., 2006).  
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Figure 1-20 Eight isoforms of OPA1 generated through alternative splicing at S1 and S2.  
Reproduced from Song et al., 2007 
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Figure 1-21 Schematic of the structure of the Opa1 gene containing exons 1-30 inclusive 
of exons 4b and 5b.  
The structure of Opa1 is similar to other dynamins and contains a GTPase domain (exons 7-
15), middle domain (exons 16-25) and a GTPase Effector domain (exons 27-28). S1 and S2 
are proteolytic cleavage sites for paraplegin, OMA1 and YME1L required to produce mature 
Opa1 mRNA transcripts. OPA1 also contains a mitochondrial importer sequence (MIS), a 
carboxy-terminal coiled coil domain (Cc), a transmembrane domain (TM1) and an amino-
terminal CC which is present on all eight isoforms of OPA1. Reproduced from Landes et al., 
2010. 
1.7.4 - OPA1 processing and OXPHOS 
The balance between mitochondrial fusion and fission is tightly regulated by these long and 
short OPA1 isoforms. The metalloproteases YME1L and OMA1 alter the cleavage pattern of 
OPA1 depending on the efficiency and rate of ATP production through the OXPHOS system 
(Mishra et al., 2014; Anand et al., 2014).  
OMA1 is a metalloprotease responsible for cleaving OPA1 at the S1 site to produce 
short isoforms of OPA1 (S-OPA1). It is tuned to the electrochemical gradient produced 
through proton pumping of complexes I, III and IV. If this electrochemical potential is 
significantly decreased which may occur due to a defect in the rate of ATP production along 
OXPHOS, OMA1 is upregulated to enhance cleavage of OPA1 at the S1 site. This proteolytic 
processing of OPA1 produces an abundance of S-OPA1 isoforms which is thought to promote 
mitochondrial fragmentation (Anand et al., 2014).  
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In a study to examine of the mechanism of OPA1 cleavage by YME1L, Mishra and 
colleagues (2014) demonstrated that cleavage of OPA1 at the S2 site was tuned to OXPHOS 
activity. This cleavage mediates IMM fusion and proposes a mechanism in which metabolic 
signals may trigger differential cleavage of OPA1 and regulate IMM fusion. OMM fusion was 
not found to be triggered through cleavage of OPA1 by YME1L. The short (S2-OPA1) 
isoforms generated by YME1L may work in concert with long isoforms of OPA1 (L-OPA1) 
to promote this fusion, however this requires further investigation (Mishra et al., 2014). 
Interestingly, inhibition of ATPase activity to hyperpolarise the IMM demonstrated that 
YME1L activity is not tuned to the electrochemical gradient of OXPHOS as a measure of 
OXPHOS activity. Preliminary evidence indicates that YME1L may instead directly interact 
with subunits of ATPase (Stiburek et al., 2012).  
Additional studies also found that cells with primary defects of the OXPHOS system 
had a lower capacity to upregulate YME1L and promote IMM fusion (Mishra et al., 
2014).The mechanism of how these metalloproteases mediate metabolic signalling and 
mitochondrial dynamics is still under intense investigation. 
 
1.7.5 OPA1 processing and mitochondrial fragmentation 
Studies investigating the role of OMA1 and YME1L found no morphological difference in 
mitochondria between wild type and OMA1-/- primary mouse embryonic fibroblasts (Anand et 
al., 2014). However, investigation of YME1L-/- primary mouse fibroblasts produced excessive 
fragmentation of the mitochondrial network. Similar levels of L-OPA1 were detected in wild-
type and YME1L -/- cells. This would suggest that upregulation of OMA1 cleavage at the S1 
site promotes mitochondrial fragmentation which is supported by in vitro localisation studies. 
These studies suggest that S-OPA1 and L-OPA may form punctuate structures which 
colocalise with fission machinery and mitochondrial-ER contact sites (Anand et al., 2014). 
OMA1 may respond to both a transient decrease of IMM potential to cleave OPA1 
during the rapid depolarisation of a mitochondrial fission/fusion event and it may respond to a 
more chronic decrease in IMM potential due to impaired OXPHOS. This cleavage of OPA1 
serves to inhibit fusion and isolate damaged mitochondria from the network. These 
mitochondria are then targeted for destruction by the mitophagic quality control mechanism. 
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1.7.6 OPA1 and apoptosis  
The majority of OPA1 protein (~90%) localises to the cristae junctions on the IMM and is 
thought to play a structural role in maintaining the shape and organisation of these cristae 
folds (Perkins et al., 2009). OPA1 isoforms containing exon 5b are likely involved in the 
sequestering of cytochrome c in these specialised IMM folds. OPA1 is proposed to form an 
oligomeric complex at cristae junctions which may act as a dam and prevent the passage of 
large proteins and macromolecules (Perkins et al., 2009). Disruption of these oligomeric 
OPA1 complexes facilitates the widening of cristae junctions. But electrostatic interaction 
between cardiolipin and cytochrome C within the IMM prevents cytochrome C’s release 
(Rytomaa and Kinnunen, 1995; Rytomaa et al., 1992; Tuominen et al., 2002). tBID has been 
observed to associate with cardiolipin on the IMM to produce condensed mitochondria, 
reversing the curvature of cristae membranes at contant sites which may facilitate cytochrome 
C release (Gonzalves et al., 2005; Kuwana et al., 2002; Lutter et al., 2000). Disruption of 
these regulatory mechanisms unsurprisingly leads to increased rates of apoptotic cell death 
(Olichon et al., 2007) (Figure 1-22). 
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Figure 1-22 Maintenance of cristae junctions on the IMM is facilitated by OPA1 which 
aids in sequestering cytochrome c. 
Reproduced from Ramonet et al., 2013. 
 
1.7.7  OPA1 and mtDNA maintenance 
OPA1 is classified as a nuclear gene associated with mtDNA stability. Pathogenic variants in 
OPA1 have been shown to disrupt the stead-state of mtDNA through either a depletion of 
mtDNA as seen in an OPA1 mouse model with late-onset cardiomyopathy (Chen et al., 
2012), proliferation of mtDNA (Sitarz et al., 2012; Yu-Wai-Man et al., 201b) or multiple 
mtDNA deletions (Hudson et al., 2008) in human patients. Recent studies investigating the 
mechanistic link between OPA1 and mtDNA maintenance has found that OPA1 isoforms 
which contain exon 4b are involved in anchoring the mitochondrial nucleoid to the IMM 
(Elachouri et al., 2011). Anchoring the nucleoid is required to replicate mtDNA and is 
reminiscent of the chromosome replication mechanism found in bacteria (Thanbichler and 
Shapiro, 2006). Interestingly, YME1L which is linked to IMM fusion and OXPHOS by 
cleaving OPA1 is also responsible for producing the mature OPA1 exon 4b-containing 
isoform to facilitate mtDNA replication (Elachouri et al., 2011; Anand et al., 2014; Mishra et 
al., 2014; Kukat et al, 2011). 
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1.7.8 Mitofusins 
MFN1 and MFN2 both contain GTPase functional domains required for the fusion of the 
OMM. These proteins share approximately 60% homology and their structure is also highly 
complementary with that of OPA1 (Figure 1-23). Both MFN1 and MFN2 form multimeric 
complexes with OPA1 to regulate complete fusion (Chen et al., 2003). MFN2 regulates other 
cellular functions in addition to mitochondrial fusion. More recently MFN2 was observed to 
also be localised to the endoplasmic reticulum (ER) where it regulates ER morphology. Since 
MFN2 is located on both the ER and the mitochondrion, it is involved in the tethering of these 
two structures with each other. MFN2 plays a fundamental role in calcium homeostasis and is 
also involved in the maintenance of cellular glucose levels. Other functions of MFN2 include 
regulation of the OXPHOS system by influencing the expression of the respiratory chain 
subunits and maintenance of the mitochondrial genome (Sitarz et al., 2012; Rouzier et al., 
2012). 
 
 
 
 
 
 
 
 
Figure 1-23 Depiction of the conserved structures found in MFN proteins and their 
respective functions.  
Reproduced from Santel, 2006.  
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1.7.9 Mitochondrial fission 
Mitochondrial fission is regulated by Dynamin related protein 1 (DRP1) and this key protein 
is recruited from the cytosol by human Fission 1 protein (hFIS1) and mitochondrial fission 
factor (MFF). hFIS1, which is located on the outer mitochondrial membrane, forms a complex 
with DRP1 at sites of mitochondrial fission (Loson et al., 2013). A spiral of DRP1-hFIS1 
complexes wrap around these sites to trigger mitochondrial fission. To ensure complete 
mitochondrial fission, fusion must be downregulated at the same time and this is achieved by 
cleavage of the long form of OPA1 (Olichon et al., 2007). 
 
1.7.10 Mitochondrial quality control  
The mitochondrial quality control system employs a number of different and sophisticated 
strategies to maintain cellular homeostasis in the reticulum. These strategies include local 
quality control mechanisms such as regulating mitochondrial protein stability through 
proteases such as AFG3L2 and paraplegin which remove unstable N-terminal residues, 
effectively stabilising mitochondrial proteins and other more global mechanisms which 
regulate the mitochondrial dynamic machinery to identify and remove dysfunctional 
mitochondria from the cellular network (Rugarli and Langer, 2012).  
OPA1 is involved in many mitochondrial processes such as mitochondrial dynamics, 
replication of the mitochondrial genome, OXPHOS, maintenance of cristae structure and 
sequestering of cytochrome c (Olichon et al., 2003; Elachouri et al., 2011; Zanna et al., 2008; 
Cogliati et al., 2013; Ramonet et al., 2013). Its role in many of these processes make it a 
prime candidate for involvement in mitochondrial quality control. OPA1 has been shown to 
be regulated by a sophisticated cascade of proteases such as paraplegin, AFG3L2, PARL, 
OMA1 and YME1L (Section 1.7.3-1.7.5), which can alter the ratio of long and short isoforms 
and as a consequence, bias the mitochondrial network toward increased fission or fusion.  
The role of mitochondrial dynamics in cellular quality control and homeostasis is 
highlighted through pathological conditions such as Parkinson and Alzheimer diseases which 
display increased fragmentation of the mitochondrial network promoting mitochondrial 
autophagy (mitophagy) and apoptosis (Rugarli and Langer, 2012). Furthermore, events such 
as mitochondrial fission are tightly coupled with mitosis to maintain an adequate number of 
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mitochondria for cellular functioning in daughter cells. These observations suggest that 
regulators of mitochondrial dynamics are themselves maintained by cellular homeostatic 
pathways. 
 
1.7.11 Mitochondrial autophagy  
Mitophagy and apoptosis serve as additional quality control mechanisms under a persistent 
stress. Selective mitophagy is a mechanism which specifically isolates and targets damaged 
mitochondria for degradation in cellular lysosomes (Ding and Yin, 2012). Depolarisation of 
the mitochondrial membrane is an important trigger for the detection of dysfunctional 
mitochondria (Rodriquez-Enriquez et al., 2006). In healthy mitochondria, membrane potential 
is maintained by an active OXPHOS system which produces cellular ATP. Pathogenic 
variants in mtDNA can compromise the OXPHOS system by disrupting the production of 
OXPHOS protein subunits. This can lead to decreased activity of the OXPHOS system and 
reduced membrane potential Gilkerson et al., 2012.  
Reduced potential can trigger a mechanism of selective mitochondrial degradation 
which involves both the regulators of mitochondrial fission and fusion dynamics. As 
mentioned in Section 1.7.4, OPA1 can be selectively cleaved at the S1 position by OMA1, a 
protease recruited through reduced mitochondrial membrane potential. This cleaves L-OPA1 
and helps to inhibit mitochondrial fusion. In this manner, the damaged organelle is isolated 
from the mitochondrial network (Anand et al., 2014; Twig and Shirihai, 2011).  
Concurrently, a second mechanism specifically targets these dysfunctional 
mitochondria for degradation. PTEN-induced putative kinase 1 (PINK1) and PARKIN are 
mediators of targeted mitochondrial degradation (Figure 1-24). PINK1 normally is 
sequestered to the mitochondrial outer membrane where it is degraded by PARL (Jin et al., 
2010). Upon collapse of membrane potential, this degradation is obstructed and PINK1 
accumulates on the outer mitochondrial membrane where it phosphorylates OMM proteins. 
Phosphorylated MFN2 acts as a receptor for an E3-ubiquitin ligase known as PARKIN, which 
is recruited to the outer membrane and proceeds to ubiquinate outer mitochondrial membrane 
proteins in a non-selective manner (Jin et al., 2010). Ubiquinated proteins on the outer 
membrane attract autophagosomes which begin the process of mitophagy. Dysfunctional 
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mitochondria are consumed by autophagosomes and transported to lysosomes where they are 
degraded and their constituent components recycled.  
 
 
 
 
 
 
 
 
 
Figure 1-24 Schematic illustrating the mechanism of PINK1/PARKIN in mitophagy  
After membrane fission, daughter mitochondria both maintain an optimal membrane potential 
subsequent to depolarisation and can fuse with other organelles of the mitochondrial 
reticulum or there is membrane potential collapse due to a defective OXPHOS system. This 
triggers the sequesterisation of OMA1 into the IMM to cleave L-OPA1 and inhibits further 
mitochondrial fusion. Concurrently PINK1 is allowed to accumulate on the OMM and 
phosphorylate MFN2 which acts as a receptor for PARKIN, a protein ubiquitinator. 
Ubiquitination of OMM proteins signals for organelle degradation through autophagy and 
mitochondria are transported to and degraded by cellular lysosomes. Reproduced from Kubli 
and Gustafsson, 2012. 
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1.7.12 Mitochondrial dynamics and apoptosis 
Mitochondrial fission plays a significant role in cell death pathways. It occurs in concordance 
with disrupted cristae structure along the IMM, release of numerous pro-apoptotic factors:  
cytochrome c, SMAC/DIABLO HtrA2/omi and permeabilisation of the mitochondrial 
membrane. These events evoke a response from the CASPASE family to trigger apoptotic cell 
death. The mitochondrial apoptotic pathway involves both anti (BCL-2) and pro apoptotic 
(Bax, Bak) mediators which have roles in regulating mitochondrial morphology (Figure 1-
25). Pro-apoptotic proteins Bax and Bak inhibit MFN2 leading to a bias towards 
mitochondrial fragmentation (Karbowski et al., 2006) These mediators have also been found 
to colocalise with DRP1 on the OMM at sites of mitochondrial fragmentation (Karbowski et 
al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-25 Mechanism of apoptotic cell death triggered by mitochondrial dysfunction.  
Reproduced from Czabotar et al., 2014. 
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1.7.13 Stress induced mitochondrial hyperfusion  
The current mitochondrial dynamic model for adapting cellular homeostasis to metabolic 
demand suggests that under acute stress or nutrient deprivation, the mitochondrial network 
will undergo stress induced mitochondrial hyperfusion (SIMH). This process increases 
mitochondrial fusion through inactivation of DRP1 by protein kinase A which phosphorylates 
DRP1 at residue Ser637 and acts to inhibit GTPase activity. This serves to downregulate 
mitochondrial fission. Concurrently the prohibitin-related protein SLP-2 interacts with OPA1 
to prevent stress-induced cleavage of OPA1 long isoforms. (Tondera et al.,2009). The 
involvement of SLP-2 appears to be a requisite for SIMH and the mechanism of how it 
prevents stress-induced cleavage by OMA1 is under current investigation. It is hypothesised 
that the mitochondrial dynamic fusion machinery is upregulated, however the mechanism of 
this upregulation is currently unknown.  
Increased SIMH is believed to act as a transient cellular protective mechanism and 
current research is focused on the relationship between apoptosis, mitophagy and 
mitochondrial fusion (Tondera et al., 2009). Several mechanisms have been put forward to 
explain the protective effects of SIMH, namely: 
(i) Fusion of the mitochondrial network to inhibit mitophagy.  
Increasing fusion between mitochondria in the network serves to block their engulfment by 
autophagosomes and their subsequent delivery to lysosomes for degradation and recycling of 
constituent components.  
(ii) Increased fusion to promote mitochondrial content-mixing. 
Increasing the fusion between mitochondrial organelles results in the distribution of proteins, 
RNA, lipids and mtDNA within the reticulum. This may help to ‘buffer’ mitochondrial 
organelles which have damaged components which may otherwise ultimately lead to 
dysfunctional ATP production through OXPHOS.  
(iii) Increased fusion as a response to other cellular protective pathways 
Recent research also suggests that mitochondrial dynamics and anti-oxidant gene expression 
are coupled. This idea is exemplified through the stabilisation of nrf2 under conditions of 
oxidative stress (Ma, 2013) Nrf2 is a transcription factor which upregulates anti-oxidant 
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defences such as superoxide dismutase and glutathione associated protective enzymes. This 
may serve to decrease cellular damage and return the morphology of the mitochondrial 
network from a hyperfused state to more normal homoeostatic fission/fusion dynamics. 
 Chronic stress of the mitochondrial network would ultimately lead to a loss of SIMH 
and increased fragmentation due to the accumulation of damaged organelles or depolarisation 
of the mitochondrial membrane. Whether this fragmentation would lead to mitochondrial 
clearance through mitophagy or cellular apoptosis would depend on the nature and duration of 
the stress.  
 
1.8 Mechanism of Nonsense-Mediated Decay 
Eukaryote cells contain a tightly regulated control quality system against error-prone DNA 
expression to limit the effects of misfolded proteins due to pathogenic mutations. During 
transcription, pre-mRNA is first transcribed by polymerase II to form a messenger 
ribonucleoprotein complex. This pre-mRNA is processed into mature mRNA through a series 
of steps. A 5’-m7GpppN cap and a poly(A) tail are attached to protect the mRNA from 
degradation. Other factors also contribute to protect mRNA from degradation such as the 
CBC (CBP80-CBP20) complex at the 5’ cap and PABPN1 and PABPC1 at the poly(A) tail. 
Pre-mRNA is composed of both exons and introns and these introns must be spliced out by 
the exon junction complex (EJC) to form alternative isoforms. Splicing factors play an 
important role in isoform specific nonsense-mediated decay (NMD). Intron-less isoforms are 
invulnerable to NMD.  
Translation begins when one or more ribosomes bind to these ribonucleoprotein 
complexes and the CBC is replaced by a translation initiation factor. Degradation of mRNA 
by the NMD mechanism occurs at the first round of translation during ribosome stalling. This 
stalling occurs if there is a truncation 50-55 nucelotides upstream of an exon junction 
complex (EJC) bound region. The truncated site is positioned at the ribosomal ‘A’ site where 
it is bound by the NMD SURF (SMG1-UPF1-Erf1-Erf3) complex (Schweingruber et al., 
2013). This triggers a process to detach the ribonucleoprotein complex from the ribosome and 
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prevent further translation (Figure 1-26). The ribonucleoprotein complex is subsequently 
degraded by SMG5-7, XRN1 and the exosome complex. 
One of the factors that contribute to clinical variability is the position dependent 
mechanism of NMD. If a frameshift or nonsense variant occurs 5’ of the NMD detection 
boundary, the ribonuceoprotein complex is subsequently degraded preventing the expression 
of the mutated allele. In the case of heterozygous mutations, haploinsufficiency could result in 
a milder clinical phenotype. However, if a pathological variant lies 3’ to this detection 
boundary, it is not recognised by the NMD machinery, resulting in a possible dominant-
negative effect and a more severe clinical phenotype.  
 
 
 
Figure 1-26 Schematic diagram of SURF complex assembly upsteam of the exon 
junction complex (EJC).  
The EJC inhibits translation of the faulty mRNA and subsequently leads to its degradation by 
the exosome complex. Reproduced from Schweingruber et al., 2013. 
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1.9 Mitochondrial Disease Mechanisms in OPA1-related DOA 
1.9.1 Disturbance of the mitochondrial network 
As described in Section 1.7 OPA1, MFN1 and MFN2 are primary regulators of mitochondrial 
fusion in the reticulum. Therefore, it is not surprising that pathogenic mutations in these genes 
can give rise to disturbed mitochondrial dynamics. In patient tissue, the pathological hallmark 
of OPA1 and MFN2 mutations is a striking fragmentation of the mitochondrial reticulum. 
Pathological variants in OPA1 also result in disrupted cristae along the IMM and proapoptotic 
calcium and cytochrome c release. 
 
1.9.2 Bioenergetic dysfunction 
 OXPHOS is tightly regulated by mitochondria in the production of ATP which produces 
most in vivo energetic requirements (Yu-Wai-Man, 2009). OPA1 pathological variants have 
been described in the context of OXPHOS dysfunction. OPA1 has been shown to directly 
interact with OXPHOS complexes (Zanna et al., 2008; Cogliati et al., 2013). This interaction 
was hypothesised to facilitate structural stability of the OXPHOS system. It may be possible 
that deleterious mutations which affect the stabilisation of these OXPHOS complexes, such as 
those found in DOA may cause exasperated proliferation of mtDNA to account for this 
structural instability. Although proliferation of mtDNA has been noted in DOA, the precise 
sensing mechanisms responsible for mtDNA steady state remain to be investigated.   
Studies have identified impairment of complex activity although conflicting reports 
point to either a complex I or COX deficiency (Amati-Bonneau et al., 2005; Chevrollier at al., 
2008). This decrease in activity has been observed in conjunction with a decrease in 
membrane potential due to proton leakage and increased fragmentation of the mitochondrial 
reticulum (Amati-Bonneau et al., 2005). This deficit in OXPHOS appears to disrupt the rate 
of ATP synthesis but does not culminate in a significant decline of gross ATP level in patient 
fibroblasts (Zanna et al., 2008; Amati-Bonneau et al., 2005). Compensatory mechanisms may 
contribute to maintaining a steady state of ATP such as mtDNA proliferation.  
Severe bioenergetic defect culminating in apoptotic cell death may be tissue specific. 
RGCs require a higher level of ATP synthesis and may be more susceptible to this deficit in 
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ATP production contributing to optic nerve degeneration. However dysfunction of the 
OXPHOS system alone cannot explain the increased susceptibility of the optic nerve. 
Preliminary evidence suggests that OPA1 isoforms directly interact with complexes of this 
pathway. Dysregulation of OPA1 may alter complex assembly and stability although further 
research is required (Zanna et al., 2008).  
 
1.9.3 Oxidative stress 
Elevated ROS production secondary to pathogenic variants in OPA1 and dysfunction of the 
OXPHOS system may further contribute to apoptotic cell death of RGCs. Investigation of 
pathogenic homozygous OPA1 generated through somatic mutagenesis in a drosophila model 
(dOPA1), demonstrated a significant rise in ROS which may have deleterious consequences 
for mitochondrial components and contribute to an already compromised subcellular 
environment (Tang et al., 2009). Enhanced mitochondrial fragmentation and an ommatidial 
phenotype was also noted in this model. Other models of OPA1 dysfunction have also noted 
an increase in ROS production, most noticeably in a OPA1 mouse model with late onset 
cardiomyopathy and primary lymphoblast lines (Chen et al., 2012; Kao et al., 2015). 
 
1.9.4 MtDNA instability 
The mitochondrial genome is packaged into nucleoids contained within the mitochondrial 
matrix. These nucleoids are associated with several proteins involved in mitochondrial DNA 
replication which include POLG, TWINKLE, the mtSSB, ligase proteins and topoisomerases 
(Gilkerson et al., 2013). Under mtDNA maintenance dysregulation conditions, mtDNA can 
either be depleted (Kim et al., 2005; Chen et al., 2012) or proliferated due to clonal expansion 
of deleterious mtDNA molecules; both states have a detrimental effect on the OXPHOS 
system (Hudson et al., 2008; Amati-Bonneau et al., 2005). This biochemical defect can be 
demonstrated diagnostically through the use of COX-SDH staining of patient muscle tissue. 
COX/SDH (cytochrome c oxidase)-negative muscle fibres which harbour high levels of 
mtDNA deletions are stained blue as opposed to the characteristic brown stain of non-
OXPHOS compromised tissue.  
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Patients with DOA have a marked increase in deleterious mtDNA molecules which 
have been identified in skeletal muscle biopsies (Yu-Wai-Man et al., 2010b). This observation 
may indicate that these mutations contribute to the clinical phenotype of DOA. Strikingly, the 
number of COX negative fibres in DOA+ patients was over four times higher than in pure 
optic atrophy which may indicate the importance of deleterious mtDNA proliferation in multi-
systemic disease (Yu-Wai-Man et al., 2010b).  
 
1.9.5 Calcium homeostasis 
Interaction between the endoplasmic reticulum and the mitochondrion has been a recent hot 
topic of interest. Recent investigation has highlighted signalling pathways at these interfaces. 
Most of the intracellular calcium is buffered either within the ER or the mitochondrion 
(Romagnoli et al., 2007). Mitochondria-associated membranes (MAMs) are sub-domains of 
the ER which are responsible for creating microenvironments for lipid and calcium flux 
between these two cellular compartments (Giorgi et al., 2015). This process is regulated by 
the mitochondrial calcium uniporter (MCU) and mitochondrial calcium uptake protein 1 
(MICU1). Calcium performs a variety of functions which include intracellular signalling, 
engagement and facilitation of apoptosis and a response to neurotransmitter excitotoxicity.  
Deleterious mutations in OPA1 and MFN2 have been shown to disrupt the machinery 
within these MAMs which highlight the importance of mitochondrial profusion regulators in 
calcium homeostasis and lipid biosynthesis (Dayanithi et al., 2010; Singaravelu et al., 2011; 
Kushnareva et al., 2013). Both calcium flux and storage within the ER and mitochondrion 
buffer the cell against calcium spiking which may promote apoptotic cell death. Disruption of 
this process, especially in the optic nerve which is also susceptible to glutamate excitotoxicity 
may sensitise RGCs to degeneration (Kushnareva et al., 2013). Mutations in mtDNA 
associated with complex I or COX are also known to disrupt this calcium homeostasis and 
may possibly contribute to DOA pathogenesis through dysfunction of OXPHOS (Trevelyan et 
al., 2010) in RGCs. 
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1.10 Overlapping Disease Mechanisms Leading to RGC Loss 
The optic nerve is composed of 1.2 million retinal ganglion fibres and is a susceptible target 
of degeneration due to pathological primary or secondary mitochondrial variants present in 
optic neuropathy. Both structural and biochemical parameters contribute to this predilection 
for RGC death (Maresca et al., 2013). The distribution and structure of RGCs are not 
homogenous throughout the retina. Smaller RGCs containing shorter axons and dendritic 
fields are located near the fovea and the papillomacular bundle (PMB) consists of densely 
packed parvocellular (P) and magnocellular (M) RGC subtypes. The density of RGCs 
decreases peripherally and there is a concomitant increase in axonal size. Both the density and 
the anatomical structure of RGCs might be relevant to the high prevalence of optic 
neuropathy in patients with mitochondrial disease. A relatively small axon could impose 
physical constraint on mitochondrial motility, which is a vital mechanism for transporting 
these organelles from the RGC soma where they undergo biogenesis, to more energetically 
dependent areas of the axon. RGCs are typically sheathed with myelin posterior to the lamina 
cribosa which have efficient saltatory conduction.  Unmyelinated axons require a greater 
concentration of mitochondrial organelles to facilitate conduction velocities and as a 
consequence may present a structural vulnerability, particularly for mitochondrial dysfunction 
(Carelli et al., 2004; Andrews et al., 1999; Bristow et al., 2002). These smaller RGCs within 
the PMB are also preferentially lost due to the limited mitochondria energy reserve of these 
smaller axons (Pan et al., 2012; Ross-Cisneros et al., 2013). However these reasons alone do 
not completely explain RGC susceptibility to apoptotic cell death. 
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Figure 1-27 Depiction of capillaries and mitochondrial abnormalities present in a LHON 
patient with the m.11778G>A mtDNA mutation.  
(A) Optic nerve head capillaries in a healthy control; (B) Disruption of optic nerve head 
capillaries and mitochondrial proliferation; (C) Swollen cristae indicative of a metabolic 
mitochondrial defect. Reproduced from Carelli et al., 2009. 
 
Additional observed structural abnormalities include edematous appearance of surrounding 
nerve fibres and tortuous and often enlarged vessels (Nikoskelainen et al., 1982). Upon 
examination of the visual field, there is usually a caecocentral scotoma and limited but 
variable peripheral vision (Carelli et al., 2004; Yu-Wai-Man et al., 2011). This finding is 
highlighted through histopathological investigation showing a severe loss of central RGCs 
with cell sparing in the ocular periphery. Other common structural features highlight axon 
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degeneration, differential myelin thickness, proliferation and build-up of swollen 
mitochondria in the post-laminar ocular area (Figure 1-27). Cytoskeletal condensation and 
debris are also observed. These characteristics are suggestive of a progressive low-grade optic 
degeneration. Unusually, histopathological investigation also demonstrated sparing of 
melanopsin RGCs in both classical paradigms of optic neuropathy, LHON and DOA, 
however the reason for this has yet to be investigated (Sitarz et al., 2012).  
 The precise biochemical mechanisms that lead to optic degeneration have not yet been 
clarified. Unfortunately, research in this area has been limited by the lack of human tissues 
and the inability to study the optic nerve directly. The investigation of factors leading to RGC 
loss has primarily been limited to the use of both cell and animal models. Typical biochemical 
parameters that contribute to classical models of optic neuropathy include a dysfunction of 
OXPHOS-driven ATP synthesis, enhanced ROS production and sensitivity to excitotoxic 
stimuli. Investigation of OXPHOS dysfunction and how it may lead to degeneration of the 
optic nerve is still an active area of research (Yu-Wai-Man et al., 2011; Barbiroli et al., 1995; 
Loiseau et al., 2007; Amati-Bonneau et al., 2005; Chevrollier et al., 2008). Current 
hypotheses include a prolonged decrease of ATP synthesis which may compromise high-
intensive energy dependent tissue such as RGCs in the optic nerve (Zanna et al., 2008). This 
hypothesis is partially supported by in vitro investigations of DOA showing a consistent 
defect in the rate of ATP synthesis due to either decreased activity of complex I or IV (Zanna 
et al., 2008; Chevrollier et al., 2008). However, this again, does not fully explain why RGCs 
are particularly susceptible to degeneration, especially considering other tissue with high 
energy demand which remain unaffected (Zanna et al., 2008; Lodi et al., 2004). 
A partial explanation may involve the anterograde-retrograde transport of 
mitochondria from the soma to unmyelinated axonic regions of the RGC (Figure 1-28). It is 
possible that a depletion in OXPHOS ATP could affect this process and interfere with the 
efficiency of synaptic transmission. This point may be particularly important in cells with 
relatively high rate of synaptic firing as seen in RGCs. This is supported by mitochondrial 
clumping, debris and loss of microtubules in spared RGCs shown through histochemical 
staining of LHON tissue (Sadun et al., 1994; Carelli et al., 1999). This suggests that 
dysfunction of axonal transport may be another common biochemical feature of optic 
neuropathy. 
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Figure 1-28 Schematic of mitochondrial anterograde/retrograde signalling mechanism 
required for synaptic transmission in retinal ganglion cells. 
(+) and (-) symbols illustrate the direction of mitochondrila transport along the microtubule 
with kinesin-1 and dyenin motors driving mitochondrial movement along these tubules from 
the RGC Soma alon the axons to regions of high energy demand required for synaptic 
transmission. Ancillary proteins linking kinesin-1 include Milton, Miro and syntabulin which 
are required for kinesin-1 recruitment and local mitochondrial fusion. Reproduced from 
Saxton and Hollenbeck, 2012.  
 
Other common themes associated with OXPHOS dysfunction involve a chronic 
increase in ROS production (ROS). Increased ROS levels contribute to activation of cell death 
pathways and also affect the myelin sheath, specifically the retrolaminar myelinated region of 
the optic nerve. Such effects would culminate in an enhanced susceptibility to pathological 
dysfunction in the papillomacular bundle (PMB).  
A recent LHON mouse model developed by Lin and colleagues successfully 
recapitulated the severe visual deficit of LHON due to a dysfunction of complex I (Lin et al., 
2012). An excess of ROS production, disrupted cristae, mitochondrial proliferation and axon 
swelling were noted. However ATP homeostasis was maintained leading to the conclusion 
that ROS production and oxidative damage was more pertinent to visual failure than a defect 
in ATP synthesis rate, at least for this ND6 P25L model. This observation is contrasted with 
other biochemical assays which demonstrate an impairment of complex I-driven ATP 
synthesis in LHON (Parker et al., 1989; Majander et al., 1991; Carelli et al., 1997; Baracca et 
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al., 2005). Further research is required to clarify these secondary mechanisms and establish 
their contribution to RGC death ‘in vivo’. 
 
1.11 Animal models of inherited optic neuropathies 
Both in vitro modelling of disease pathology and limited access to post mortem patient 
tissue may only provide partial insight into the pathomechanisms for this group of diseases. 
The use of transgenic or pharmacologically treated animal models in tangent with these 
other paradigms can therefore provide a more robust picture of the presentation and 
progression of optic neuropathies. Different animal models have been generated for both 
LHON and DOA.  
In order to mimic the selectivity of RGC degeneration found in LHON, rotenone, an 
inhibitor of OXPHOS complex I, was injected through the murine vitreous and more 
recently, the use of rotenone loaded microspheres which are uptaken into murine RGCs have 
both been used as pharmacological options which recapitulate the selective degeneration of 
the optic nerve (Zhang et al., 2002; Marela et al., 2010). In parallel, a transgenic LHON 
mouse, discussed briefly in Section1.10, with the G14600A mutation, equivalent to the 
human ND6 P25L, has also been generated and presents with common hallmarks of LHON. 
These hallmarks include demyelinating axons, mitochondrial proliferation and degeneration, 
axonal swelling and loss and increased ROS (Lin et al., 2012).  
In DOA, as mentiond in Section 1.3.5, three different truncative OPA1 models have been 
developed which include exons 8 (c.1051C>T) (Davies et al., 2007), intron 10 (c.1065+5 
G> A) (Alavi et al., 2007) and exon 27 (c.2708-2711delTTAG) (Sarzi et al., 2012). These 
models mimic both many of the ocular and extraocular clinical features found in DOA 
patients which include an age –dependent severe ocular nerve degeneration, visual loss, 
deafness, encephalomyopathy, peripheral neuropathy, cardiomyopathy, demylination of the 
optic nerve and mitochondrial ultrastructural abnormalities. Increased mitophagy was also 
noted.  In conjunction, drosophila melanogaster has also been used to model the role of 
abnormal ROS production in OPA1 DOA disease progression (Tang et al., 2009). 
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 Finally, both a DOA murine mouse model (c.365T>C) and zebrafish model (engineered 
with 5.2kb DNA insertion downseam of the mitochondrial leader sequence) has also been 
developed for OPA3,a paradigm for Costeff syndrome (Davies et al., 2008; Pei et al., 2010) 
. A significant loss of RGCs as well as impaired swimming behaviour due to ataxia, los of 
buonancy and hypokinesia have been determined in OPA3 zebrafish mutants while 3-
methylglutaconic aciduria type III, impaired visual acuity, optic nerve degeneration, 
cardiomyopathy, neuromuscular defects,extrapyramidal dysfunction amd elevated serum 
lactate have been noted in the murine model . Currently, the role of OPA3 is still unknown 
and these models will prove invaluably in delinating its precise mitochondrial function.  
 
1.12 Therapeutic strategies for inherited optic neuropathies 
Effective therapeutic strategies directed against optic neuropathy are still within the early 
stages of development. To combat degeneration of the optic nerve, a number of different 
avenues are being explored. These include pharmacological treatment, genetic therapy and the 
therapeutic potential of stem cells (Yu-Wai-Man et al., 2014; Sadun et al., 2012; Newman et 
al., 2012; Guy et al., 2002). Patients who present with optic neuropathy represent an excellent 
cohort for clinical studies due to both the localised dysfunction of many of these disorders 
within the eye and the organs ease of accessibility for assessment and treatment.  
 
1.12.1 Pharmacological options 
Current drug use designed to improve the clinical phenotype of optic neuropathies has been 
met with limited success. Such drugs include mitochondrial vitamin cocktails (B2,B3,B12,C,E 
and folic acid), the use of ubiquinone analogues like coenzyme Q10, Idebenone, EP1-743, the 
use of steroids and immuno-suppressants (Pfeffer et al., 2013; 2012; Newman et al., 2012; 
Porcelli et al., 2009) and finally the use of both compounds and molecules to activate 
mitochondrial biogenesis such as bezafibrate, rogsiglitazone, AICAR (5-aminoimidazone-4-
carboxamide ribonucleoside) and resveratrol (La Morgia et al., 2014). Some of these 
therapeutic compounds have been clinically tested but were investigated on a small, 
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statistically underpowered cohort of patients with no objectively significant benefit that 
improved visual function. 
Idebenone is an antioxidant that has shown limited success in visual recovery if 
treatment commenced at an early stage and patients receive a prolonged treatment (greater 
than 24 weeks) (Carelli et al., 2011a). Similarly, EPI-743 is another anti-oxidant which is 
similar in structure to Co-enzyme Q10. Although it has been tested on only a small cohort (5 
patients) with mitochondrial dysfunction, it shows promising results with noted improvement 
in field, colour vision and acuity (Sadun et al., 2012). More rigorous testing is required to 
determine the most effective, dose and time-course for treatment. 
Increased mitochondrial biogenesis is assocated with unaffected LHON carriers and is 
proposed to act as a compensatory mechanism through hightened OXPHOS capacity (La 
Morgia et al., 2014). Pharmacological stimulators of biogenesis such as AICAR, bezafibrate, 
rogsiglitazone and resveratrol may act to improve the clinical presentation of various optic 
neuropathies.  
 
1.12.2 Gene therapy paradigms 
Gene therapy is a potential strategy to halt optic nerve degeneration in inherited optic 
neuropathies because the RGC layer is easily accessible to manipulation (Yu-Wai-Man et al., 
2014). However, the fact that many optic neuropathy-related genes are encoded by the 
mitochondrial genome presents a technical hurdle. To overcome this obstacle, an associated 
viral vector (AAV) is being devised to transfect functional mitochondrial genes efficiently 
into the nuclear compartment to compensate for defective genetic material found in the 
mtDNA population. Such a strategy would be particularly effective for conditions such as 
LHON where pathogenic variants lie on mtDNA (Guy et al., 2002).  
The most recent research has successfully imported mitochondrial proteins in this 
manner in plants (Pineau et al., 2005), yeast (Roucou et al., 1999) and cultured mammalian 
cells (Guy et al., 2002; Oca-Cossio et al., 2003). Current research has also successfully 
imported the ND4 protein to compensate for a mtDNA defect G11778A in a rodent model of 
LHON (Guy et al., 2009; Ellouze et al., 2008; Qi et al., 2007a). However before this 
technique can be used in a clinical setting, further research is needed to demonstrate that this 
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allotopically expressed protein is fully integrated into complex IV of the OXPHOS system. Dr 
Patrick Yu-Wai-Man is currently involved in clinical trials to assess this mt-ND4 construct in 
patients presenting with LHON (> 1 year).  
Additionally, control of allotopic gene expression is required before it could be used 
as a feasible strategy for LHON patients with a G11778A mtDNA defect. Clinical trials are 
currently underway to assess patient safety and efficacy using this approach. A similar 
alternative strategy to replace the defective mitochondrial gene includes transfection of the 
ROS scavenger gene SOD2, which would mop up excess ROS and promote cell survival. Qi 
and colleagues (2007b) successfully demonstrated this in LHON cybrid cell lines. 
 
1.12.3 Stem cells and regenerative medicine  
Current research into stem cell therapeutics is divided into two different strategies. One 
consists in both differentiating and transplanting RGCs to directly replace damaged cells of 
the optic nerve. The alternative is to grow lines of differentiated RGCs which would produce 
trophic factors. These trophic factors would then be used to promote RGC survival within the 
optic nerve (Marchetti et al., 2010; Dahlmann-Noor et al., 2010). Currently, development of 
effective clinical stem cell therapeutics is still in its infancy. Obstacles include the efficient 
generation of mature RGCs and their introduction in vivo to promote the appropriate 
topographical connections. The most likely use of these human-derived RGCs is as a tool to 
explore RGC physiology through drug screening and biochemical analysis in the near future. 
This may help to both understand how RGCs are affected in different disease states and also 
refine RGC development and incorporation into the optic nerve. 
 
1.12.4 Genome editing and mitochondrial donation 
Unlike LHON which tends to be monosymptomatic with no impact on life expectancy, a 
subset of patients harbouring more deleterious mtDNA mutations or nuclear genetic defects 
that result in severe mtDNA depletion can develop an aggressive disease course, frequently 
starting in early childhood, and characterised by irreversible encephalopathy, intractable 
epilepsy, liver failure and multisystem organ failure. The outcome of these mitochondrial 
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syndromes is invariably fatal and in the absence of effective treatments, significant effort has 
been invested in developing tractable means of selectively eliminating these pathogenic 
mutations through germline genome editing, or in preventing the maternal transmission of 
pathogenic mtDNA mutations from mother to child. 
Several research groups worldwide are working on mitochondrial-targeted nucleases 
that have been engineered to selectively eliminate mutated mtDNA molecules. Zinc finger 
nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) are able to 
recognise these altered DNA sequences and they create double-strand breaks that effectively 
eliminate the mutated mtDNA molecules (Minczuk et al., 2008; Bacman et al., 2010, 
2013).The ability to shift the level of heteroplasmy could be used to reduce the overall mutant 
load in the oocyte of a woman carrying a known pathogenic mtDNA mutation to subthreshold 
level, thereby eliminating the risk of her child developing overt mitochondrial disease. The 
use of ZFNs or TALENs as a reproductive tool for manipulating levels of heteroplasmy is still 
in early stages of development and a number of technical difficulties need to be resolved. 
Germline genome editing, namely with the CRISPR/Cas9 system, could also be used to 
correct for pathogenic mutations within the nuclear genome (Jinek et al., 2012; Yin et al., 
2014).  
The elimination of mutated mtDNA molecules to shift the level of heteroplasmy to 
subthreshold level is an attractive strategy to prevent a biochemical deficit and rescue the 
cellular phenotype. However, in some mitochondrial diseases, such as LHON, the majority of 
carriers harbour homoplasmic mtDNA mutations and a different experimental strategy is 
needed to prevent the transmission of a pathogenic mtDNA mutation from mother to child. 
Two related in vitro fertilisation (IVF) techniques have been developed that involves 
transferring the parental nuclear genetic material into a donor cytoplast containing a normal 
wild-type mtDNA population (Tachibana et al., 2009; Craven et al., 2010). Although 
encouraging, further work is needed to explore the safety implications of these IVF 
techniques for embryo development, including the concerns that have been raised about 
epigenetic abnormalities and the possibility of nuclear-mitochondrial genetic mismatch 
leading to unforeseen negative consequences (Chinnery et al., 2014). The Nuffield Council on 
Bioethics has concluded that mitochondrial replacement might be appropriate within a strictly 
regulated research environment, and with the prospective parents being fully informed about 
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the potential risks, both real and theoretical. In February 2015, both Houses of Parliament in 
the UK have voted strongly in favour of mitochondrial donation to prevent the maternal 
transmission of mitochondrial disease paving the way for future clinical implementation 
(http://www.parliament.uk/business/news/2015/february/lords-mitochondrial-donation-si/, 
accessed on 28 December 2015). 
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The central aim of my PhD project was to investigate the disease mechanisms that contribute 
to RGC loss and optic nerve neurodegeneration in inherited optic neuropathies. To achieve 
this goal, I performed a series of studies that made use of tissue samples collected from 
patients carrying confirmed pathogenic OPA1 mutations. I also made use of whole-exome 
sequencing (WES) to investigate a cohort of patients with a suspected genetic basis for their 
optic atrophy, but who do not have a confirmed molecular diagnosis.  
 
Study Aims: 
1. To explore the biochemical differences that might explain disease severity in OPA1 
disease by comparing primary fibroblasts established from patients with DOA+ and OA 
phenotypes.   
2. To quantify the morphology of the mitochondrial network and the distribution of 
nucleoids in differentiated myotubes established from primary myoblasts of patients with 
DOA+ and OA phenotypes. 
3. To confirm the pathogenic nature of a novel homozygous OPA1 variant identified in two 
affected sisters presenting with lethal infantile encephalopathy, hypertrophic 
cardiomyopathy and optic atrophy. 
4. To identify potentially pathogenic disease variants in a cohort of patients with suspected 
inherited optic atrophy by using WES analysis. 
5. To further investigate the pathogenic nature of WFS1 variants identified with WES. 
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3.1 Fibroblast Cell Line  
3.1.1 Fibroblast line maintenance  
Fibroblasts were grown as a monolayer until 70-80% confluence. The cells were grown in 
glucose (5mM) MeM media (Gibco, Life Technologies,Paisley, UK) with 10% Foetal Bovine 
Serum (FBS) (Gibco, Life Technologies, Paisley, UK). The media was supplemented with 1% 
L-glutamine, 1% sodium pyruvate, 1% non-essential amino acids , 1% Penicillin-
streptomycin and 1% Vitamins ( All obtained from Gibco, Life Technologies, Paisley, UK). 
These cells were grown in a T25 flask until 70% confluence was reached then seeded in a T75 
flask for further growth. These flasks were stored at 37°C in 5% CO2 humidified air. Media in 
these flasks was changed every fourth day to allow an increased concentration of growth 
factors. 
 
3.1.2 Subculture of fibroblast cells 
When the cells in each respective flask reached 80% confluence, they were harvested in 1x 
trypsin (Gibco, Life Technologies, Paisley, UK) and PBS (Oxoid). They were then 
centrifuged at 1200 rpm for five minutes in 10 ml media. This media was aspirated, fresh 
media was added to the cellular pellet and these cells were homogenised and re-seeded into 
new T75 flasks. 
 
3.1.3 Fibroblast cryostorage  
For longer term storage, the cells in a T75 flask were harvested and re-suspended in 1 ml FBS  
(Gibco, Life Technologies, Paisley, UK) with 10% DMSO (Freezing solution- Sigma 
Aldrich). These cells were stored in cryovials and transferred to a larger cryostorage container 
containing isopropanol (Greiner) in a -80 freezer. Freezing solution was added dropwise to 
the cryovials to prevent bubble formation. The isopropanol container allowed for the gradual 
decrease in temperature to prevent excessive cell death. After 24 hours storage at -80°C, the 
cells were then transferred to liquid nitrogen storage.  
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3.1.4 Thawing of cryo-preserved fibroblasts 
When these cells were retrieved, they were thawed as fast as possible in a water bath at 37°C. 
Once the freezing media with fibroblasts was defrosted, it was added dropwise to 10 mls 
(millilitres) pre-warmed media and centrifuged for 5 minutes at 1200 rpm to pellet these cells. 
The supernatant was aspirated to remove DMSO (Sigma-Aldrich) and cells were suspended in 
fresh media. They were then transferred to a T25 flask. This flask was left at 37°C in 5% CO2 
humidified air overnight. The media in this T25 was removed to discard cell debris from this 
defrosting process. When cell confluence in this flask reached 70-80%, cells were trypsinised 
and transferred to a T75 flask for further growth. 
 
3.1.5 Mycoplasma detection  
All primary cell lines were routinely checked for the presence of mycoplasma using a 
luminescent detection kit (Lonza, UK) according to the manufacturer’s instructions. All 
incubation steps took place at room temperature. Approximately100ul of cell line media taken 
from primary line flasks (<48 hours) was transferred to a 1.5ml eppendorf tube. One volume 
of re-constituted MycoAlertTM reagent was added and the sample was allowed to incubate for 
5 minutes. A Fluoroskan Ascent (Thermo Scientific, Paisley, U.K.) was then used to detect 
luminescent signal denoted ‘reading A’.  
In the second stage, 100µl of MycoAlertTM substrate was added to the sample and 
allowed to incubate for 10 minutes. A second luminescent reading was detected and denoted 
‘reading B’. To determine if the sample was contaminated with mycoplasma, a ratio between 
reading B and reading A is calculated. If this ratio >1, the sample is deemed mycoplasma 
negative. A sample ratio of 1 is deemed borderline and a re-test is taken of the sample. If the 
ratio is <1, the sample is deemed mycoplasma positive and the primary lines are destroyed 
using 2% (w/v) Virkon® (Du Point, Hertfordshire, UK).  
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3.1.6 Cell seeding 
All cell counting and seeding was achieved using a haemocytometer chamber (AC1000 
Improved Neubauer; Hawksley, Lancing, UK). Briefly, primary cell lines were harvested as 
described in Section 3.1.2. Cell pellets were resuspended in 1 ml media. This media was 
homogenised and 100µl of sample was transferred to a fresh eppendorf tube where it was 
mixed with 100µl Trypan Blue (Sigma-Aldrich), a stain which is absorbed by apoptotic or 
necrotic cells. 10µl of this mixture was then added to a haemocytometer chamber complete 
with coverslip. The number of viable cells was counted in four squares of the haemocytometer 
chamber grid and averaged. This average value was then multiplied by 2 to account for the 
dilution of sample with Trypan Blue (Sigma-Aldrich) and then multiplied by a factor of 1x104 
to determine the number of viable cells per ml of media.  
 
3.2 Protein Extraction 
3.2.1 Protein extraction from muscle tissue 
Muscle tissue was thawed on dry ice before it was cut and weighed in an eppendorf tube. This 
cut muscle tissue was resuspended in ripa buffer (Sigma-Aldrich) with complete mini, EDTA-
free protease inhibitor cocktail (Roche Diagnostics) on ice. Tissue homogenisation and 
performed with a motor-driven Teflon pestle at 600 rpm at 4˚C. The sample was transferred to 
an eppendorf tube where it underwent centrifugation at 13,000 rpm at 4˚C. Supernatant 
containing the protein extract was transferred to a fresh eppendorf tube and kept on ice. 
Protein samples were aliquoted and stored at -80˚C. 
3.2.2 Protein extraction from fibroblast line  
Cells were grown in T75 flasks until 70-80% confluence was reached. These cells were then 
tripsinised and transferred to 10 ml of media. The cells were centrifuged at 1200 rpm for 5 
minutes. The media was aspirated and 1 ml of PBS (Oxoid) was added to the cell pellet in the 
container. The pellet was homogenised, transferred to a sterile eppendorf tube and centrifuged 
for a second time at 300g for 5 minutes. The PBS (Oxoid) was aspirated and the cell pellet 
was transferred to cold storage at -80 degrees for future experiments.  
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These cell pellets were lysed to extract protein using lyses buffer. This lyses buffer is 
composed of 500 µl Tris PH 7.5, 260 ul 5M NaCl (BDH AnalaR), 20 ul 1M MgCl2 (BDH 
AnalaR), 1 ml Triton (10%) ( All obtained from Sigma-Aldrich), 8.2 ml dH2O and 1 tablet of 
Roche protease inhibitor (Roche Diagnostics).  
50 µl of this lyses buffer was added to the cell pellets of each respective line. These 
pellets were vortexed for 30 seconds and incubated on ice for 30 minutes to allow for the 
chemical lyses of the cellular membrane. This homogenate was then spun down at 4 degrees 
for 2 minutes and the pellet discarded. 
 
3.3 Western Blotting 
3.3.1 Bradford assay  
The protein concentration from these cell pellets was measured using a Bradford assay. A 
1:30 dilution of each of these cell pellets was prepared by adding 3 µl of lyses buffer/ protein 
homogenate with 87 µl nanopure water in eppendorf tubes. This solution was vortexed and 10 
µl per well of each sample was transferred to a 96 well plate. Each cell line was repeated in 
triplicate. A calibration curve was used to provide a standard baseline against which to 
measure protein concentration. This calibration curve was created using defined dilutions of 
BSA (Bovine Serum Albumin- Sigma-Aldrich). This calibration curve was plated in duplicate.  
200 µl of Bradford solution (BioRad) was added to each well using a multichannel. 
Protein concentration was measured by using absorbance of each protein sample and the BSA 
calibration curve. These absorbencies were measured using a spectrophotometer microplate 
reader at 595 nm. The absorbencies were calculated using the Beer- Lambert law A = εlc. 
 
3.3.2  SDS-PAGE electrophoresis 
The level of protein expression was measured using a western blotting technique. Once the 
protein concentration of each of the samples was determined, the amount of loading due and 
lyses buffer to be loaded into each of the wells of a precast agarose gel ( mini-protean 4-15% 
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precast gels, Biorad) was determined. Each sample to be loaded was prepared with protein 
sample, lyses buffer, 6x loading dye, and benzonase with Mg2+ (Sigma-Aldrich) .  
 Lysis buffer was used to equalise the volumes in each well of the precast dye. This 
mixture was heated at 37 degrees for 30 minutes on a heating block to prevent aggregation of 
COX I. The samples were then boiled at 95 degrees to alter the conformation of protein and 
allow passage through the porous agarose gel (BioRad). These protein samples were then 
flash spun and left on ice prior to well loading of the precast gels. 
Ten-well precast gel electrophoresis was used to separate protein based on size and 
molecular weight. These gels were also loaded with 10 µl seablue coloured protein ladder 
(Life Technologiesnologies) and 5µl biotinylated ladder (New England Biolabs). This 
biotinylated ladder was boiled for 5 minutes at 95 degrees prior to loading. Gel 
electrophoresis was conducted in 1x running buffer ( 10x running buffer is composed of 30.3g 
Trizma base , 144g Glycine  and 10g SDS (all obtained from Sigma-Aldrich) made up to 1 
litre with nanopure water. A 1:10 dilution in nanopure water of this 10x running buffer is used 
in gel electrophoresis at 150 V for approximately 1 hour. 
 
3.3.3 Protein transfer to PVDF membrane 
Once gel electrophoresis was complete, protein was transferred from this gel to a PVDF 
membrane (Thermofisher Scientific) for detection. The gel was equilibrated in 1x transfer 
buffer for approximately 10 minutes. (10 x transfer buffer is composed of 30.3g of Trizma 
base, 144g of glysine and 2g of SDS (All obtained as powder form from Sigma-Aldrich). This 
is made up to 1 litre with nanopure water. 1x transfer buffer is created by diluting 150 ml 10x 
transfer buffer in 225 ml of methanol (Sigma-Aldrich) making this up to 1.5L with nanopure 
water.  
The PVDF membrane (ThermoFisher Scientific) is activated with absolute methanol and 
washed in 1x transfer buffer. The gel and membrane are then assembled in a cassette with 
blotting paper and sponges soaked in transfer buffer. Protein transfer was conducted in 1x 
transfer buffer at 4 degrees Celsius with 400 mA for 1.5 hours. An ice block was added to the 
transfer buffer of this apparatus to reduce heat produced by the transfer process and increase 
the efficiency of transfer. 
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3.3.4 Densitometry and statistical analysis 
Analysis of all Western blot membranes was conducted with VisionworksLS Version 7.0.2, 
ImageJ statistical software and Microsoft windows excel 2007. Each western blot membrane 
was visualised through chemiluminescense by using an ECL kit (Biorad) to treat each 
membrane according to the manufacturer’s instructions. Each membrane was left for five 
minutes in the dark room to allow the ECL solution to be absorbed by the membrane. These 
membranes were then exposes to UV light for a set period by using the 500 biospectrum 
imaging system to detect the relevant protein bands. Once detected these images were 
digitalised by using the VisionworksSL software which allow adjustments of these images for 
brightness and contrast. The files were converted to .tiff and .mpeg files. The files were 
analysed using ImageJ. ImageJ quantified these bands through densitometry by detecting the 
relative intensity of each band. To normalise each of these bands, the housekeeping gene 
GAPDH was used in each protein and control sample.  
 
3.4 ATP Levels from cultured DOA Fibroblasts 
3.4.1 Fibroblast seeding and drug treatment  
Primary fibroblast lines were harvested from two T75 flasks as described in Section 3.1.2. 
These cells were then counted as described in Section 3.1.6 and 30,000 cells were seeded into 
each well of a 96-well cell line plate (Greiner). These cells were left to incubate in 200µl cell 
line media for 24 hours. On the second day, media was aspirated from each well and washed 
2x with 200µl PBS (Oxoid) before being treated with the drug of interest. Each primary line 
was treated under four different drug conditions measured in ATP measuring buffer ( 156mM 
NaCl, 3mM KCl, 2mM MgSO4, 1.25Mm KH2PO4, 2mM CaCl2 and 20mM Hepes- All 
obtained from Sigma-Aldrich). These conditions include 1) 5mM Glucose with 1% pyruvate, 
2) 5mM D-deoxyglucose with 1% pyruvate, 3) 5mM glucose, 1% pyruvate and 20uM 
oligomycin and 4) 5mM d-deoxyglucose, 1% pyruvate and 20uM oligomycin (All obtained 
from Sigma-Aldrich).  
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3.4.2 Quantification of ATP levels  
Primary cell lines were left to incubate at 37˚C and 5% CO2. After 1.5 hours, 90µl of media 
was aspirated from each well and 100µl of CellTiter-Glo substrate solution (Cell Titer-Glo® 
Luminescent Cell Viability Assay, Promega) was added to each well. The plate was left to 
incubate in the dark at room temperature for 15 minutes before the luminescent signal from 
each well was detected and quantified using a Fluroskan Ascent (Thermo Scientific, Paisley, 
U.K.).  Each experiment was quantified in triplicate and further statistical analysis was 
conducted with excel (Microsoft, Reading, UK) and GraphpadTM V. 5 (Graphpad software).  
 
3.5 DNA Extraction 
3.5.1 Genomic DNA extraction from blood 
DNA was extracted from blood using Whole Blood Genomic Extraction kit (Nucleon) 
according to the manufacters protocol. All centrifugation steps were performed at room 
temperature.  5 mL of patient blood was added to a 50mL polypeptide centrifuge tube 
(Scientific Laboratory Supplies, Life Science). 4 volumes of reagent A were added and each 
sample was inverted and centrifuged at 3500g for 5 minutes to generate a cell pellet. 
The supernatant was discarded and a further 5mL of reagent A was added to suspend 
this pellet. The sample was vortexed and allowed to stand for 1 minute. The samples were 
centrifuged again at 3500g for five minutes and the supernatant discarded. 1mL Reagent B 
was added to lyse this cell pellet. 350uL of reagent C and 300µl Nucleon Resin were then 
added to each sample to achieve protein degradation and this sample was centrifuged at 3500g 
for 4 minutes.  
The DNA was then precipitated by transferring the supernatant to a clean 
polypropylene centrifuge tube (Scientific Laboratory Supplies, Life Science) and adding 1 
volume of absolute propan-2-ol. The tube was inverted several times and centrifuged at 4000g 
to pellet the precipitated DNA. Supernatant was removed and the DNA washed by adding 
1mL of 70% ethanol. The DNA was repelleted by centrifuging at 4000g and allowed to air 
dry for 10 minutes. The DNA was finally resuspended in TE buffer. These DNA samples 
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were measured using a NanoDropTM ND-1000 (NanoDrop Technologies, Wilmington, USA) 
.DNA samples were stored at -20˚C. 
 
3.5.2 Genomic DNA extraction from tissue 
To extract DNA from patient muscle, approximately 10-20 µg of muscle tissue from each 
patient was added to a glass test-tube and each sample was homogenised and treated with 
reagents from a blood and tissue kit (Qiagen) according to the manufacterers instructions. 
Briefy, 180µls of buffer ATL was added to each sample and the muscle was homogenised 
with tissueruptor (Qiagen). Once homogenised, each sample was transferred to a 1.5ml 
Eppendorf tube and 20 uls of proteinase K (Life Technologies) was added. The samples were 
heated to 56ºC overnight on a thermomixer (Sigma-Aldrich) to ensure maximum lysis of 
tissue. The following day, 200µls of buffer AL and 200µls of absolute ethanol (Sigma-
Aldrich) were added to each sample after brief vortexing and the samples were transferred to 
a 2ml collection tube within a DNeasy spin-column. The samples were centrifuged at 6000g 
for 1 minute, flo-through was discarded and the filter was placed in a new collection tube. 
500µls buffer AW1 was added to this new spin-column. After an additional centrifugation at 
6000g for 1 minute, flo-through was again discarded and 500µls of buffer AW2 was added. 
The samples were then centrifuged at 20,000g for 3 minutes and the filters of each spin 
column added to a 1.5ml Eppendorf tube. 100uls elution buffer was added to each filter and 
left at room temperature for 1 minute. The tubes were then centrifuged again at 6000g for 1 
minute to obtain purified DNA from each sample.  
 
3.5.3 Genomic DNA extraction from fibroblast line 
DNA was extracted from patient cell lines using the DNeasy® blood and tissue extraction kit 
(Quigen). Centrifugation steps for this protocol were performed at 21-25°C at 10,000 rpm. A 
cell pellet from each patient line (maximum 5 x 106) cells was homogenised in 200µl PBS 
(Oxoid). Protinase K (20 µl) (Life Technologies( and Buffer AL (200ul) were used to lyse the 
cells at 56°C for 10 minutes. Subsequently absolute ethanol (200 µl)(Sigma-Aldrich) was 
added to each of the patient samples to precipitate the DNA from the pellet. Each sample was 
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vortexed and transferred to a DNeasy® Mini spin-column which was placed in a 2ml 
collection tube. Each sample was centrifuged for 1 minute and then each sample spin column 
was transferred to a new collection tube. The previous tube containing sample supernatant 
was discarded. 500 µl of buffer AW1 was added to each spin column and these columns were 
centrifuged for one minute to wash the sample. The flow through was collected and discarded 
with the collection tube. A fresh tube was added to each spin column and 500 µl of buffer 
AW2 was used in the last washing stage of the protocol. These columns were centrifuged for 
3 minutes at 14,000 rpm to dry the DNeasy® membrane containing the DNA. This DNA was 
then eluted into a 1.5ml eppendorf tube by adding 100ul of elution buffer which was allowed 
to incubate on the membrane for 1 minute at room temperature. The spin column was 
centrifuged for 1 minute and the eluted DNA was collected in the eppendorf tube. The 
concentration of this DNA was determined by using a NanoDropTM ND-1000 (NanoDrop 
Technologies, Wilmington, USA) and these DNA samples were transferred to -20 for short 
term storage. 
 
3.6 Polymerase chain reaction  
A polymerase chain reaction (PCR) was achieved with a Veriti® 96-well thermal cycler 
(Applied Biosystems, Life Technologies, Paisley, UK) in 0.2 ml PCR strip-tubes (STARLAB, 
Hanburg Germany). Approximately 50ng of DNA from each sample was amplified in a 25µl 
mastermix reaction containing 5µls GoTaq buffer (Promega, Southhampton, UK)., 2.5uls 
dNTPs (dATP,dTTP,dCTP,dGTP (VH Bio, Gateshead, UK), 0.13 uls G2Taq polymerase 
(Promega, Southhampton, UK), 14.4 uls dH2O and 0.5uls 10uM forward and reverse primers 
(Integrated DNA Technologies, Interleuvenlaan, Belgium). DNA amplification was achieved 
under the following thermal cycler parameters: 95˚C for 7 minutes (denaturation); x30-x35 
cycles further denaturation with 95˚C for 1 minute, 58˚C for 1 minute and 72˚C for 1 minute; 
an extension step at 72˚C for 10 minutes and cooling to 4˚C for sample storage and prevent 
degradation. The amplicons genereated from these PCR reactions were stored at -20˚C. 
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3.7 Gel extraction of DNA amplicons 
To assess the efficiency and accuracy of mtDNA copy number quantification, three different 
templates were created using standard PCR protocols described in Section 3.6. These 
amplicons were run through and separated on a 1% (w/v) TAE agarose gel (BioRad) (Figures 
3-1 and 3-2). Once separated, these templates were cut from the gel and placed into separate 
2 ml eppendorf tubes (Cell Star). The tubes were weighed and each tube was allowed to hold 
a maximum of 200mg of gel fragment. 
The DNA from these gels was extracted using the QIAquick® Gel Extraction Kit  (Qiagen). 
All centrifuge steps in this protocol were performed at 20-25°C at 13,000 rpm. The gel 
fragments were treated with Buffer QG (600ul) and incubated for 10 minutes at 50°C. The 
tubes were vortexed every two minutes to dissolve the agarose gel. 200 ul of isopropanol was 
added to precipitate the DNA. This solution was added to a QIAquick® spin column placed in 
a 2ml collection tube and centrifuged for 1 minute. The supernatant in the collection tube was 
discarded. 750 µl of buffer PE was added to the spin column and the tube was centrifuged 
again for 1 minute. The spin column was then transferred to a fresh 2ml Eppendorf tube and 
centrifuged for 1 minute to dry the spin column membrane. This was then placed in a 1.5ml 
Eppendorf tube and 30μl of elution buffer applied to the membrane. 1 minute after the 
addition of the elution buffer, the column was centrifuged for 1 minute and the supernatant 
containing the DNA collected in the eppendorf tube. The concentration of DNA was 
quantified using a nanodrop ND-1000 (NanoDrop Technologies) and these tubes were stored 
at -20 °C. 
The number of mtDNA copies per ul of control DNA template were calculated by 
using the following equation where C = template concentration, Mw is the molecular weight 
(bp Product length x 2 x 330) and A is Avogadro’s constant (6.02 x 1023mol-1). 
                                   Copies/µl =  
A standard curve was generated from ctDNA template. The number of mtDNA copies in 
these templates was determined by measuring DNA concentration and using the mtDNA copy 
number calculation mentioned previously to quantify copy number in each of the control 
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templates. Each of these templates was then tested for efficiency before the experiment by 
performing a serial dilution and quantifying the PCR amplification as described in Section 
3.10.2.  
 
 
 
 
 
 
 
Figure 3-1 Representative image of ND1 amplicons generated through PCR and separated 
using a TAE agarose gel. 
 
 
 
 
 
 
Figure 3-2 Representative image of B2M amplicons generated through PCR and separated 
using a TAE agarose gel. 
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3.8 RNA Extraction 
3.8.1 RNA extraction from fibroblast lines 
RNA was isolated from patient and control cell pellets by following the manufacturer’s 
instructions (RNeasy minikit, Qiagen). All centrifugation was performed at room temperature.  
RNA concentration from each sample was quantified using NanoDropTM ND-1000 
(NanoDrop Technologies, USA). These samples were then stored at -80 degrees in cold 
storage. 
 
3.9 Reverse Transcription PCR of RNA Isolates 
3.9.1 cDNA synthesis 
To prepare the samples for quantitative PCR analysis, a superscript III first strand synthesis 
system (Invitrogen) was used to create cDNA from patient and control RNA isolates. This 
cDNA was created with a reverse transcription PCR method as outlined in the manufacturer’s 
instructions using the random hexamer protocol. 
 The first stage was to prepare the RNA/Primer mix for the reverse-transcription PCR 
(RT-PCR) reaction. The RNA of interest was mixed with 1 µl 10mm dNTPs, 1 ul random 
hexamers AND DEPC water to a final volume of 10 µl. Each sample was then incubated at 
65˚C for five minutes and placed on ice for a minimum time of 1 minute. 
A 10 µl synthesis mix was added which contained 2 ul 10x RT buffer, 4 ul 25 mM 
MgCl2, 2 ul 0.1M DTT, 1 ul RNaseOUT recombinant nuclease inhibitor and 1 ul Supercript 
III RT. This 20 ul mixture was then run with the following PCR protocol: 10 minutes at 25ºC, 
50 minutes at 50ºC, 5 minutes at 85ºC and cool to 4ºC. This PCR protocol results in the 
generation of cDNA. Each sample is then briefly centrifuged and 1 µl of RNase H is added. 
The sample is heated to 37ºC for 20 minutes to degrade any contaminating RNA. It can then 
be stored at -20ºC for future PCR reactions. 
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3.10 Real-Time PCR 
3.10.1  Principles of real-time PCR 
Real time quantitative PCR (RTqPCR) is a reliable method which has greater sensitivity than 
standard PCR reactions at detecting product produced from amplification of sample DNA. 
The principle of RTqPCR involves the non-specific fluorescent dye iQ™ SYBR® green 
(BioRad) which is designed to integrate into the DNA structure and provide a fluorescent 
signal. This signal is detected and quantified by a detector within the IQ5 thermocycler. 
During the DNA amplification process by the iTaq polymerase, the iQ5™ optical 
system software v.2.0 (BioRad) detects the level of sybergreen fluorescence which exceeds 
the background fluorescence and leads to a linear increase in the amplification curve. This 
linear increase should directly correspond to the amount of DNA being amplified 
exponentially during each cycle. The number of cycles in which fluorescence exceeds 
background noise is known as the threshold cycle (Ct). Preparations of reagents for RTqPCR 
analysis were performed in a UV-sterilised Aura PCR workstation (Bioair Instruments, Milan, 
Italy) to prevent contamination. 
 
3.10.2 Quantification of mtDNA copy number 
RTqPCR was used to quantify the levels of mtDNA copy number in each of the templates and 
patient lines. The real-time PCR analysis was performed on a 96 well plate (BioRad). The 
mtDNA copy number was assessed by amplifying two reference genes in each patient sample, 
the mitochondrial ND1 gene and the nuclear B2M gene (Figures 3-3 to 3-6). The relative 
number of ND1 copies amplified in each patient with respect to B2M is an indication of 
mtDNA copy number. These samples were analysed in biological triplicates. The protocol for 
RTqPCR amplification included denaturation at 95°C for 3 minutes, denaturation for 40, 10 
second cycles at 95 °C and annealing/extension for 1 minute at 62.5°C. The samples then 
underwent denaturation at 95 °C for 1 minute to ensure contamination did not take place. 
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Figure 3-3 Example of a ND1 amplicon serial dilution standard curve demonstrating 
efficiency (E), linearity (R^2) and slope.  
Generated by Bio-Rad IQ5TM software V.2.0. 
 
 
 
 
 
 
 
 
Figure 3-4 ND1 melt-curve. 
 This was generated through serial dilution of the ND1 amplicon and by measurement of the 
SYBRgreen fluorescent signal at each respective PCR amplication step.  
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Figure 3-5 Example of a B2M amplicon serial dilution standard curve demonstrating 
efficiency (E), linearity (R^2) and slope. 
 Generated by Bio-Rad IQ5TM software V.2.0. 
 
 
 
 
 
 
 
Figure 3-6 B2M melt curve.  
This was generated through serial dilution of the B2M amplicon and by measurement of the 
fluorescent signal at each respective PCR amplification step.  
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3.10.3 Quantification of gene expression using real-time PCR 
Similar to the quantification of mtDNA copy number using RTqPCR in Section 3.10.2, the 
relative mRNA expression of a specified gene was quantified by measuring the levels of 
cDNA in each patient and control line relative to a standard amplification curve. cDNA levels 
in each sample were also internally corrected against 2 reference genes B2M and B-Actin as 
described in Table 4-4. The protocol for RTqPCR includes denaturation at 95°C for 3 
minutes, denaturation for 40 10 second cycles at 95 °C and annealing/extension for 1 minute 
at 62.5°C. The samples then underwent denaturation at 95 °C for 1 minute to ensure 
contamination did not take place. 
 
3.11 Statistical Analysis of real-time PCR Data 
Analysis of gene expression was assessed using the ΔΔCt method. Following the 
amplification of DNA using the IQ5 thermocycler, a Ct value was generated for each of the 
patient samples. The fluorescent threshold for these samples was set at 500 RFU for mtDNA 
copy number and 200 RFU for relative gene expression. Each patient sample for each gene 
was repeated in triplicate per plate. The experiment was repeated three times to ensure 
accuracy of the results. The final value used in the analysis of mRNA expression levels in 
each patient was calculated by using the equation 2^-ΔΔct. 
 
3.12 Long-Range PCR 
Determination of multiple mtDNA deletions in patient sample was determined using the 
TaKara LA TaqTM PCR system (Takara Bio, Otsu, Japan). This system is capable of 
amplifying a DNA fragment thousands of bps long. The mitochondrial genome is 
approximately 16 kbs in length which makes it an ideal candidate for targeted long range PCR 
amplification. All long range PCR reactions were performed in a Veriti® thermal cycler 
(Applied Biosystems, Life Technologies) in 0.2ml strip tubes ( STARLAB, Hamburg, 
Germany). DNA extracted from patient muscle was used in a 25 µl long-range PCR 
mastermix used to amplify a 11kb DNA region. This mastermix contained 2.5µls 10x LA Taq 
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buffer (Takara, Bio), 4µls dNTPs (VH Bio), 0.25 µls TaKara LA Taq polymerase (Takara, 
Bio), 16.75 µls dH2O, 0.25 µls of 20µM forward and reverse primers and 1µl of patient DNA 
template per sample. Each sample was to amplify approximately 1-2ng of DNA. 
Amplification was carried out under the following conditions: denaturation occurred at 94˚C 
for 1 minute, x28 cycles of 94˚C for 30 seconds (further denaturation), 58˚C for 45 seconds 
(annealing step) and 68˚C for 11 minutes (extension step). The final step post-cycle is 72˚C 
for 12 minutes.  
After the successful amplification of the targeted 11kb region of mtDNA, these 
amplicons underwent gel electrophoresis on a 0.7% (w/v) TAE agarose gel (BioRad) as 
described in Section 3.13.1. 6 µl PCR amplicon was added to 6ul of Orange G (Sigma-
Aldrich) ( (Section 3.13.2) and 10ul of sample was added to each well of the agarose gel 
(BioRad). Gel electrophoresis was conducted with 1x TAE running buffer (Sigma-Aldrich) at 
a constant voltage of 30V for 4 hours. To confirm that the amplified PCR product was 
approximately 11kbs, GenerulerTM 1kb Plus DNA ladder (75-20,000 bps) (Fermentas, St 
Leon-Rot Germany) was run in parallel. The ladder and the PCR amplicons were visualised 
using a UV light source from an AlphaImager® 2200 system (Aalpha Innotech). 
 
3.13 Sanger Sequencing of Nuclear Genes 
3.13.1 Agarose gel electrophoresis 
Amplicons of genomic DNA generated through PCR were observed by running these PCR 
products through a 2% (w/v) 1x TAE agarose gel (BioRad) using electrophoresis. Agarose gel 
was created using 1x TAE buffer (0.04M Tris-acetate, 0.001M EDTA, pH: 8.3 (Helena 
Biosciences)) which was added to a conical flask and heated in a microwave for 2-5 minutes. 
This mixture was allowed to cool and EtBr was added (0.4ug/ml (Sigma-Aldrich)) to 
intercalate DNA. This mixture was then added to an electrophoresis tray with gel combs and 
allowed to polymerise.  
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3.13.2 PCR Amplification 
PCR amplification was achieved using 50ng genomic DNA as described in Section 3.6. The 
approximate concentration of these amplicons was compared by first mixing 6µl of each PCR 
product with 6µl of Orange G solution (Sigma-Aldrich), 70% nanopure dH2o (v/v) and 30% 
glyverol (Sigma-Aldrich). 10 µl of this mixture was then added to wells in a 2% w/v agarose 
gel with ethidium bromide as previously described in Section 3.13.1. Hyperladder IV was 
also added (5ul) to a well of the agarose gel to visualise PCR product size. These samples 
then underwent gel electrophoresis using 1xTAE as running buffer and a constant voltage of 
80V for approximately 40 minutes-1 hour. PCR amplicon bands were visualised under UV 
light generated by an AlphaImager ® 2200 system (Alpha Innotech, Kasendorf, Germany). 
 
3.13.3 ExoFap methodology 
The ExoFap reaction is a fast and efficient PCR clean-up step which degrades unwanted 
deoxynucleotides and primers left over from genomic amplification. ExoFap consists of 
FastAP Thermosensitive Alkaline Phsophatase (FAP) (Thermo Scientific) and Exonuclease 1 
(Exo 1) (Thermo Scientific). Volumes of 0.5 µl of Exo 1 and 1 ul of FAP were added to each 
3/5µl PCR reaction in a 96-well sequence reation plate (Greiner) on ice. The plate was sealed 
with a rubber met and pulse spun in a centrifuge before the mixture was incubated at 37°C for 
15 minutes.  These enzymes was subsequenctly inactivated by incubating the mixture at 80°C 
for a further 15 minutes. 
 
3.13.4 Big-DyeTM sequencing  
BigDyeTM Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Life Technologies) is 
used for preparing a fluorescent-based cycle sequencing reaction in a standard PCR 
thermocycler.  A mixture of 2µl  BigDye Terminator v3.1 Sequencing Buffer (x5), 11µl 
nanopure water, 1µl Primer and 1 µl Big Dye was added to the 3/5 µl PCR reactant. This 
mixture was then run using the Big Dye thermocycler protocol which includes 1 minute at 
96°C, x25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes.  
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3.13.5 Ethanol precipitation 
In order to remove non-incorporated nucleotides and excess salts, each sample underwent an 
ethanol precipitation step. 2 µls of 125mM EDTA, 2 uls of sodium acetate (3M) and 70 µls of 
absolute ethanol were added to each sample well in a 96 well sequencing reaction plate (All 
obtained from Sigma-Aldrich). These samples were incubated at room temperature for 15 
minutes before they were centrifuged at 2000g for 30 minutes. The supernatant was removed 
and 70 µls of 70% ethanol (Sigma-Aldrich) was added to each sample. The plate was 
centrifuged at 1650g for a further 15 minutes before this supernatant was also removed and 
the plate was allowed to air dry for 10 minutes. Samples were suspended in 10uls Hi-Di 
(Applied Biosystems, Life Technologies).  
 
3.13.6 Genomic sequencing  
After resuspension of samples in Hi-Di, samples were denatured at 95˚C for 2 minutes before 
loading onto the ABI 3130xl genetic analyser (Applied Biosystems, Life Technologies). 
Sequence chromatograms generated which were compared against reference sequence 
reproduced from Genbank (http://www.ncbi.nlm.nih.gov/RefSeq/) by using Seqscape v. 2.6 
(Applied Biosystems). 
 
3.14 Live Cell Imaging with Confocal Microscopy 
3.14.1 Cell seeding 
Primary fibroblasts were seeded on a glass bottomed confocal dish (Wilco) at a density of 
100-150,000 cells and incubated with Minimum Essential growth media (as described in 
Section 3.1.6) at 37˚C for 24 hours. Primary fibroblasts which were incubated in an oxidative 
media (galactose) containing MeM glucose-free media with 5mM galactose (Sigma-Aldrich) 
and supplemented with 1% L-glutamine, 1% sodium pyruvate, 1% non-essential amino acids , 
1% Penicillin-streptomycin and 1% Vitamins for 48 hours ( All obtained from Gibco, Life 
Technologies, Paisley, UK).  
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Primary myotubes were seeded at a density of 70,000 cells in a glass bottomed 
confocal dish (Wilco) and incubated in Skeletal Muscle Cell Differention Media (Promocell) 
with 2% FBS and 1% Penecillin-Streptomycin (All obtained fro, Gibco, Life Technologies, 
Paisley, UK) for 24 hours at 37˚C.  
 
3.14.2 MitoTracker® Red CMXRos incubation 
On the day of imaging, growth media was aspirated from each dish and primary cells were 
incubated with fresh media containing 75nM MitoTracker® CMXRos (Life Technologies) for 
30 minutes. These cells were then washed twice with PBS (Oxoid) and incubated in fresh 
media without phenol red and containing 25mM Hepes (Sigma-Aldrich). A similar protocol 
was used for the dual-staining of patient primary myotubes with MitoTracker® Red 
CMXROS and Quant-iT™ PicoGreen® (Life Technologies). This protocol can be found in 
Section 5.2.4. 
 
3.14.3 Mitochondrial fragmentation in fibroblasts  
Images of the primary fibroblast and myotube mitochondrial network were captured with an  
A1r inverted confocal microscope (Nikon) using a 63x 1.4 NA objective unless otherwise 
stated. 
 
3.14.4 Image analysis 
 The excitation wavelength for MitoTracker® Red CMXRos (Life Technologies) was 561nm, 
respectively. Primary fibroblasts were z-stacked with section interval at 0.1µm for 69 slices. 
Approximately 50 cells were captured for each primary fibroblast cell line. 
 
3.14.5 Statistical analysis 
Quantitative Analysis was analysed using excel (Microsoft, Reading, UK) and GraphpadTM 
V.5 (Graphpad software) 
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Genotype-Phenotype Characterisation in Autosomal 
Dominant Optic Atrophy 
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4.1 Introduction 
Autosomal dominant optic atrophy (DOA) is the most common congenital optic neuropathy 
with a global prevalence of 3 in 100,000 individuals (Thiselton et al., 2002). It is 
characterised by the selective degeneration of the retinal ganglion cell layer leading to the 
deterioration of the optic nerve. The syndrome presents as a gradual and severe visual deficit 
until virtually all patients diagnosed with this condition fulfill the requirements for registered 
legal blindness (Lenaers et al., 2012). It was originally clinically identified by Batten in 1896 
but adopted the name Kjer’s Optic Neuropathy due to additional studies performed by Poul 
Kjer in 1959 who described 19 families with the condition (Kjer, 1959). Most patients present 
with isolated optic atrophy (OA), although, some patients with similar age of onset of 
progressive visual loss also develop with extra-ocular multi-systemic symptoms, a subgroup 
often refered as DOA ‘plus’ (DOA+). In some instances, members of the same family 
carrying the same pathogenic Opa1 mutation may present with different severity of the 
disease (Yu-Wai-Man et al., 2010b). Transmission of DOA+ to succeeding generations is, 
however, typically more severe with incomplete penetrance (Yu-Wai-Man et al., 2010b; 
Amamti-Bonneau et al., 2008; Hudson et al., 2008).  
Until the last few decades, clinical research on DOA was hampered by the lack of 
longitudinal and follow-up studies of patients due in part to the lack of knowledge of the 
underlying genetic aetiology of the disease. In clinical practice, patients were phenotypically 
categorised which may have excluded individuals with underlying OPA1 mutations (Votruba 
et al.1998b).  
Genetic and biochemical analyses have frequently treated DOA as a single clinical 
manifestation grouping both OA and DOA+ together in order to determine common threads 
between DOA and other mitochondrial related optic neuropathies (Zanna et al., 2008; Agier et 
al., 2012), in part due to the lack of sufficient biobank material from either DOA+ or OA 
patients. A rigorous investigation of the underlying complex biochemical parameters which 
are distinct between these two groups has yet to be investigated. Preliminary investigation 
suggests that OA usually results from deletions, nonsense mutations and splice site defects 
which normally result in OPA1 haploinsufficency (Olichon et al., 2003; Marchbank et al., 
2002). On the other hand, missense mutations found in the OPA1 GTPase domain tend to be 
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more associated with a dominant-negative effect which may have a role in the increased 
severity of the disease (Olichon et al., 2007).  
Previous investigations of the molecular mechanisms governed by OPA1 have been 
carried out in a range of in vivo and in vitro models which include Drosophila melanogaster, 
Rattus norvegicus, Danio rerio and primary human tissues (Zanna et al., 2008; Chen et al., 
2007; Yarosh et al., 2008; Rahn et al., 2013). Fibroblasts are easily accessible from skin 
tissue derived from patients which can be obtained through non-invasive means. In the 
present project, primary human fibroblasts were then selected as a model to investigate the 
biochemical mechanisms which underpin DOA pathogenesis.  
The aim of this study was then to investigate and compare biochemical parameters 
between OA and the more severe DOA+ syndromes to identify both common and divergent 
factors which may explain why a subgroup of patients diagnosed with DOA develops a more 
severe visual deficit in addition to secondary multi-systemic features. 
 
 
 101 
    
4.2 Materials and Methods  
4.2.1 OPA1 patient cohort  
The investigation of the disease mechanisms between DOA+ and OA was conducted in 
primary fibroblasts derived from eight patients described in Table 4-1. Four of these patients 
harbour missense mutations found in the GTPase domain of OPA1 (exons 8-15) and were 
diagnosed with an optic atrophy with additional multi-systemic symptoms. The remaining 
four patients presented with an isolated optic nerve involvement and harboured either 
deletions or splice-site OPA1 mutations. This study had the relevant institutional approval and 
written informed consent was obtained from all patients.   
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Table 4-1. Clinical features and OPA1 mutations of the patients included in this study.
            
Pedigree 
Age 
Gender 
Optic 
atrophy 
Deafness Ataxia Myopathy Neuropathy PEO Others 
OPA1 
mutations 
Exon / Intron 
(Years) 
DOA+(1) 69 M +   + +     Spasticity 
c.768C>G, 
c.854A>G 
5b ,8 
DOA+(2) 50 M + +       +   c.1198C>T 12 
DOA+(3) 57 M + +   +   +   c.1334G>A 14 
DOA+(4) 57 M +   + + + +   c.34521294A>G 13 
OA(1) 44 M +             c.1516+1G>T Intron 15 
OA(2) 64 M +             Exon 1-5 del. 1-5 del. 
OA(3) 48 M +             
c.2708_2711 
del(TTAG) 
27 
OA(4) 46 M +             
c.876-878 del 
(TGT) 
9 
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4.2.2 Cell culture 
Cell lines were maintained according to the protocol mentioned in Section 3.1. Each line was 
routinely checked for the presence of mycoplasma and all lines were found to be consistently 
mycoplasma negative for all experimental investigations. 
 
4.2.3 MitoTracker® Red CMXRos staining 
Cell seeding and MitoTracker® Red CMXRos (Life Technologies) staining of the 
mitochondrial network was performed according to the protocol in Section 3.14. Two glass-
bottomed confocal dishes (Wilco) containing primary Opa1 primary fibroblasts were stained 
simultaneously and washed twice with PBS (Oxoid) and left to incubate in imaging media 
containing 25mM HEPES (Sigma-Aldrich). One dish was used for imaging while the second 
dish was kept at 37ºC in an incubator without a CO2 regulator one hour prior to imaging on 
each day. A total of 24 glass bottomed dishes were prepared (4 control and 8 primary patient 
fibroblast lines). 
 
4.2.4 Mitochondrial network image capture and quantification 
Mitochondrial network image capture was performed using an A1r confocal microscope 
(Nikon) with a x63 oil-based objective lens. Imaging was performed at 3% laser power at 
561nm with a 512x512 voxel frame. A total of 69 slices (8µm) was captured along the z-axis 
for each fibroblast analysed. Approximately 50 cells were captured (25 cells per confocal 
dish) for each patient and control primary line analysed. 
Five parameters were measured under each condition: (1) Total Mitochondrial Length; 
(2) Total Mitochondrial Volume; (3) Total Number of Fragments; (4) Average Mitochondrial 
Length (5) Average Mitochondrial Volume; Average Mitochondrial Length and Volume were 
quantified by determining the Total Mitochondrial Length and Volume respectively and 
dividing by the number of mitochondrial fragments in each fibroblast to determine the ‘total 
length’ of each mitochondrial structure.  
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4.2.5 Protein expression in cultured fibroblasts 
Protein expression levels were analysed using western blot analysis to measure the expression 
in both OPA1 and individual constituent subunits of the respiratory complexes in DOA+ and 
OA primary fibroblasts. Protein levels were corrected to GAPDH protein levels and 
investigated using the method described in Section 3.3. Primary antibodies used to detect 
these proteins can be found in Table 4-2. 
 
4.2.6 OPA1 and mtDNA maintenance gene expression  
Quantification of mtDNA copy number in primary Opa1 fibroblasts was conducted with an 
iQTM SYBR® Green (Bio-Rad) methodology and a RTqPCR detection system (Bio-Rad). The 
relative number of mtDNA copies was determined by quantifying the number of mtND1 
copies relative to the number of nuclear B2M copies using the ΔΔCT method (described in 
Section 3.10.2). MtDNA copy number was quantified in four primary controls and eight 
primary DOA patient fibroblasts. 
Investigation of mtDNA copy number maintenance was also conducted by quantifying 
the mRNA expression level of TFAM using a reverse transcription qPCR protocol as 
described in Section 3.10.3. Details of RTqPCR primers used have been provided in Table 4-
3 and 4-4. 
 
4.2.7 Cell Titer-Glo luminescent cellular ATP assay 
Investigation of ATP levels was achieved by seeding primary fibroblasts onto 96-well cell 
line plates (Greiner) and treating them with drugs to inhibit either the glycolytic or the 
OXPHOS ATP synthesis as described in Section 3.4. The levels of ATP were quantified 
using a CellTiter-Glo Bioluminescent Cell Viability Assay (Promega) according to the 
manufacters protocol.  
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      Primary antibody 
target 
Product number 
Concentration 
used 
Protein molecular weight Species 
Incubation 
period/time 
OPA1 ab119685 1:1000 80-100 kDa 
mouse 
monoclonal 
1h room temperature 
NDUFB8 ab110242 1:4000 17kDa 
mouse mo 
noclonal 
1h room temperature 
SDHA ab14715 1:1000 70kDa 
mouse 
monoclonal 
1h room temperature 
COXII ab110258 1:1000 24kDa 
mouse 
monoclonal 
1h room temperature 
ATP5A ab14748 1:4000 55kDa 
mouse 
monoclonal 
1h room temperature 
GAPDH sc-25778 1:1000 37kDa rabbit polyconal 1h room temperature 
      
Table 4-2 List of primary antibodies and dilutions used to perform western blot analysis of OPA1 and mitochondrial repiratory subunits. 
OPA1: Optic atrophy 1 protein; NDUFB8: Nuclear encoded complex I subunit; SDHA: Nuclear encoded complex II subunit; COXII: mitochondria 
encoded complex IV subunit; ATPA5: nuclear encoded complex V subunit; GAPDH: glyceraldehyde-3-phosphate.  
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Template Base Pairs Forward Primer (5’-3’) Reverse Primer (3’-5’) 
B2M 1092 CGCAATCTCCAGTGACAGAA GCAGAATAGGCTGCTGTTCC 
MTND1 1041 AGGAACTCGGCAAATCTTACC GTCATGTGAGAAGAAGCAGG 
RTqPCR 
      
B2M 231 CACTGAAAAAGATGAGTATGCC AACATTCCCTGACAATCCC 
MTND1 111 ACGCCATAAAACTCTTCACCAAAG GGGTTCATAGTAGAAGAGCGATGG 
    
Table 4-3 List of primers for mtDNA copy number quantification. 
Templates were designed to produce standard curves with known DNA copy number. qPCR primers were used for the real-time PCR assay.Genbank 
accession numbers: B2M: NM_004048.2; mtND1: NC_012920.1. RTqPCR conditions used to quantify mtDNA copy number is described in Section 
3.10.2. 
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Template Base Pairs Forward Primer (5’-3’) Reverse Primer (3’-5’) 
TFAM 139 GCTCCCCTTCAGTTTTGTGT TTTTGCATCTGGGTTCTGAGCT 
OPA1 117 GTTCAACTGGCGGAAGACC TGCAGAGCTGATTATGAGTACGA 
Reference Genes bp 
    
B2M 231 CACTGAAAAAGATGAGTATGCC AACATTCCCTGACAATCCC 
B-ACTIN 131 GATGCAGAAGGAGATCACTGC ACATCTGCTGGAAGGTGGAC 
    
Table 4-4 List of primers for relative mRNA gene expression of mitochondrial maintenance markers.  
TFAM: transcription factor A, mitochondrial;OPA1: Optic atrophy 1; B2M: beta-2-microglobulin. 
Gen bank accession numbers: TFAM: NM_003201.2; OPA1: NM_015560.2; B2M: NM_004048.2; B-Actin: NM_001199954.1. The RTqPCR 
conditions used to quantify gene expression are described in Section 3.10.3. 
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4.3 Results 
4.3.1 OPA1 protein and gene expression in fibroblasts from DOA patients 
OPA1 protein levels were assessed in fibroblasts from the cohort of patients described in 
Table 4-1 using western blot analysis. Fibroblasts from DOA+ and OA patients were directly 
compared with fibroblasts from healthy donors. 
Overall, DOA+ primary fibroblasts had similar OPA1 protein levels compared with 
healthy controls (Figure 4-1). However, when studying patients separately, the four different 
patients showed varying levels (Appendix Figure A-1). Interestingly, DOA+(1) fibroblasts, 
presenting as a compound heterozygote (Table 4-1) had significant lower OPA1 protein 
levels, probably a direct result of two mutated versions of the protein.   
OA primary fibroblasts consistently had lower OPA1 protein levels compared with 
controls (Appendix Figure A-1; A-2). Overall, OPA1 levels were statistically decreased by 
less than 50% (Figure 4-1), consistent with the expression of one wild-type (WT) allele and a 
deleted one. 
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Figure 4-1 OPA1 protein densitometric analysis from primary fibroblasts from DOA+ and OA patients  
Representative images of western blots measuring OPA1 and GAPDH levels from controls, DOA+ and OA patient fibroblast (A). Densitometric 
analysis was performed using ImageJ and OPA1 densitometry normalised to GAPDH. OPA1/GAPDH ratios were expressed compared to mean of 
three different control cell lines (n=4) (B). Error bars represent standard error of the mean (SEM) **** p≤ 0.0001 using a Student’s unpaired t-test 
against controls. Refer to appendix A for representative raw images of immunoblots. 
(A) (B) 
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OPA1 mRNA expression was also assessed in fibroblasts from the cohort of patients 
described in Table 4-1 using real-time PCR anaysis. Fibroblasts from DOA+ and OA patients 
were directly compared with fibroblasts from healthy donors.  
Overall, DOA+ primary fibroblasts showed a statistically significant decrease in 
OPA1 gene expression by ~50% compared with controls (Figure 4-2). 
The OA group also showed a similar low trend, however, this was not significant 
(Figure 4-2). This is due to the variability in gene expression in individual patients. Indeed 
OA(1) and OA(3) had decreased OPA1 gene expression, whilst OA(4) did not (Appendix 
Figure B-1), suggesting different mechanisms regulating the gene expression of the different 
mutated OPA1 alleles in the different patients. 
 
 
 
 
 
 
 
 
Figure 4-2 OPA1 gene expression of primary fibroblasts from DOA+ and OA patients.   
Relative OPA1 gene expression was measured using real-time PCR and standardised against 
mean B-actin and B2M gene expression. OPA1/mean housekeeping genes was expressed 
compared to mean of three different control cell lines (n=3). Error bars represent Standard 
Error of the Mean (SEM). * p≤ 0.05 using a Student’s unpaired t-test against controls. 
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4.3.2 Mitochondrial network in primary fibroblasts from DOA+ and OA patients 
Mitochondrial networks from fibroblast cell lines were visualised using the mitochondrial-
specific MitoTracker® Red CMXRos stain. Images were capture along the z-axis for each 
fibroblast analysed allowing 3D-representation for further analysis. Images were then 
processed and filtered using the Huygens deconvolution algorithm (part of Huygens Essential 
software) (Figure 4-3). The Object analyser wizard (Hugens Essential) allowed detection and 
measurement of mitochondrial fragments in each cell.  
 
 
 
Figure 4-3 Mitochondrial staining of fibroblast cells and image processing 
Staining of the mitochondrial network was performed with MitoTracker® Red CMXRos 
(Molecular Probes, Life technologies). Raw image of control primary fibroblast was captured 
using Nikon Ti confocal microscope objective x63 assisted with Nyquist sampling (A). 
Computerised Image deconvolution of the same control primary fibroblast obtained using 
Huygens Essential deconvolution wizard (B). Scale bars represent 10μm.  
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Fibroblast mitochondrial network was visualised under two different bioenergetics conditions. 
Cell lines were grown in basal condition consisting of glucose suplemented medium, 
favorising glycolytic-driven energy production alongside basal OXPHOS-driven energy 
production. Fibroblast mitochondrial network was also visualised following specific 
OXPHOS-driven energy production, consisting of a medium supplemented with galactose but 
lacking glucose. Fibroblasts from all patients in the study cohort were then visualised and 
mitochondrial network quantified.(Figure 4-4). 
Total mitochondrial network length was expanded in all DOA+ patients and half of 
the OA patients (Appendix Figure C-1). Consequently, total mitochondrial length was 
statistically increased in both DOA+ and OA patients but with an exagerated effect in DOA+  
(Figure 4-5A). Total volume was also increased in most patients of the two groups 
(Appendix Figure C-1) leading to a mild significant increased average of total volume in 
both DOA+ and OA patient groups (Figure 4-5B). 
Following galactose treatment in control fibroblasts, total mitochondrial network 
length was retracted alongside with an increased total volume, suggesting a swollen total 
mitochondrial network. A similar effect was observed in both DOA+ and OA groups, 
although more intense in the OA group (Figure 4-5). 
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Figure 4-4 Mitochondrial network staining in fibroblast patients and controls under different bioenergetics conditions 
Staining of the mitochondrial network was performed with MitoTracker® Red CMXRos (Molecular Probes, Life technologies). Images of primary 
fibroblasts were captured using Nikon Ti confocal microscope objective x63 assisted with Nyquist sampling followed by Computerised Image 
deconvolution using Huygens Essential deconvolution wizard. Representative images of Fibroblast controls (A,D), Fibroblasts from DOA+ (B,E) and 
OA patients (C,F). All fibroblasts were treated to two different bioenergetics conditions: glucose treatment for 24 hours (A-C) or galactose treatment 
for 48 hours (D-F). Scale bars represent 10μm. .
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Figure 4-5 Total length and Volume measurements of the Mitochondrial Network patient and control Primary Fibroblasts 
Total mitochondrial length (A) and total volume (B) were measured using Huygens Object analyser module in fibroblasts imaged following either 24 
hour incubation with 5mM glucose (blue) or 48 hour incubation with 5mM galactose (red). Error bars represent the standard error of the mean (SEM). 
*** p  0.001 and **** p  0.0001 using a Student unpaired t-test against controls (n=200).  
A B 
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Under glucose conditions, the total number of mitochondrial fragments was 
significantly increased virtually in all patient fibroblasts (Appendix Figure C-2), with higher 
numbers in the DOA+ group (Figure 4-6A). Average length of mitochondrial fragments was 
also significantly decreased in both groups with shorter fragments measured in DOA+ 
patients (Figure 4-6B, Appendix Figure C-3A). Both these obsevations suggest a higher 
level of fragmentation in DOA+ patient fibroblasts under basal conditions than in OA patient 
fibroblasts, both groups showing fragmentation compared with controls. In parallel, the 
average volume was only midly decreased in DOA+ patients but not in OA patients compared 
with controls (Figure 4-6C, Appendix Figure C3B).  
Galactose treatment had the overall effect of decreasing the number of mitochondrial 
fragments, increasing the average fragment length and increasing the average fragment 
volume, consistent with mitochondrial elongation and mitochondrial swelling. A similar trend 
was observed in patient fibroblasts in both groups. However, this elongation effect 
(represented by a decreased mitochondrial fragment number and an increased fragment 
length) was exagerated in OA patient fibroblasts (Figure 4-6A-B and Appendix Figure C2C  
C3B and C5A). Strikingly, fibroblasts from OA patients had bigger fragment average 
volumes than from DOA+ patients, suggesting a high level of swelling. However, both DOA+ 
and OA groups had swollen mitochondria compared to control fibroblasts.   
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Figure 4-6 Mitochondrial fragmentation of the Network in patient and control primary fibroblasts  
Average number of mitochondrial fragments (A) were measured using Hugens Object analyser software in fibroblasts imaged following either 24 hour 
incubation with 5mM glucose (blue) or 48 hour incubation with 5mM galactose (red). Average fragment length (B) and average fragment volume (C) 
were calculated as described in section 4.2.4. Error bars represent the standard error of the mean (SEM). * p  0.05, ** p  0.01, *** p 0.001, and 
**** p  0.0001 using a Student’s unpaired t-test against controls (n=200). 
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4.3.3 MtDNA maintenance 
Mitochondrial DNA (mtDNA) copy number was measured using a RTqPCR assay designed 
to compare the relative levels of mitochondrial gene ND1 with respect to nuclear-encoded β-
2-microglobulin (B2M) in fibroblasts from healthy controls, DOA+ and OA patients. 
Compared with fibroblast from controls, fibroblasts from patients, whether from DOA+ or 
OA groups, did not reveal major variations in mtDNA copy number (Figure 4-7A, Appendix 
Figure D-1A). 
Mitochondrial transcription factor A (TFAM) mRNA expression was also measured 
using RTqPCR. TFAM mRNA levels seemed slightly decreased in most DOA+ and OA 
patient fibroblasts (Figure 4-7B, Appendix Figure D-1B). Due to high variability between 
patients, this decrease was only significant in the DOA+ group but not in the OA group. 
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Figure 4-7 MtDNA maintenance markers in primary fibroblasts from DOA+ and OA 
patients.   
MtDNA copy number was measured using real-time PCR and normalised to nuclear encoded 
B2M copy number (A). TFAM was measured using real-time PCR and standardised against 
mean B-actin and B2M gene expression (B). Both mitochondrial maintenance markers were 
expressed compared to mean of three different control cell lines (n=3). Error bars represent 
Standard Error of the Mean (SEM). * p ≤ 0.05 using a Student’s unpaired t-test against 
controls. 
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4.3.4 OXPHOS protein levels and ATP levels 
Several OXPHOS complex subunit protein levels were assessed using western blot analysis in 
fibroblasts from DOA+ and OA patients and compared with fibroblasts from healthy donors 
(Figure 4-8). Overall, subunit protein levels were variable between the different DOA 
patients (Appendix Figures E-1; E-2;E-3;E-4). 
Complex I subunit NDUFB8 had overall increased levels in both DOA+ and OA 
groups (Figure 4-9A). The nuclear-encoded complex II SDHA had significant increased 
levels in the DOA+ group, mainly due to one patient DOA+(1), whilst OA patients had 
consistently similar levels to controls (Figure 4-9B and Appendix Figure E-1B). The 
mitochondria-encoded complex IV subunit COXII had similar levels in DOA+ patient 
fibroblasts compared with controls. The OA group showed a mild increase mainly due to one 
of the patients (Figure 4-9C and Appendix E2-C). Overall, complex V subunit ATP5A 
showed no gross variation in protein level in both DOA+ and OA groups compared with 
controls (Figure 4-9D). 
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Figure 4-8 Montage of OXPHOS complex subunits western blot images from primary fibroblasts from DOA+ and OA patients.  
Representative images of western blots measuring OXPHOS complex subunits and GAPDH levels from controls (A), DOA+ (B) and OA (C) patient 
fibroblasts. COX II: mitochondria encoded complex IV subunit (17kDa); SDHA: Nuclear encoded complex II subunit (70kDa); NDUFB8: Nuclear 
encoded complex I subunit(14kDa); ATP5A: nuclear encoded complex V subunit (55kDa) and GAPDH: housekeeping protein (37kDa). Refer to 
Appendix E for representative raw images of immunoblots. 
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Figure 4-9 OXPHOS complex subunits protein levels from primary fibroblasts from 
DOA+ and OA patients  
Densitometric analysis of NDUFB8 (A), SDHA (B), COXII (C) and ATP5A (D). OXPHOS 
subunit immunoblots was performed using ImageJ and each subunit densitometry normalised 
to GAPDH. Ratios were expressed compared to mean of three different control cell lines 
(n=3). Error bars represent standard error of the mean (SEM). * p  0.05, ** p  0.01 and *** 
p  0.001 using a Student’s unpaired t-test against controls. 
(A) (B) 
(C) (D) 
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Following the observed disturbances in OXPHOS subunit levels, ATP levels were measured 
using a luminescent assay under different biogenesis conditions (Figure 4-11 and Appendix 
Figure E-4). 
Under basal glucose conditions, total ATP levels were not statistically different 
between the DOA+, OA and control groups. Under glycolysis-driven conditions, with 
oligomycin treatment, ATP levels were lower than under glucose conditions in all groups. 
Similarly, under basal conditions, ATP levels in the DOA+ group were slightly lower than the 
other two groups, although not significant. 
Under OXPHOS-driven conditions, with D-deoxyglucose treatment, ATP levels were 
approximately three times lower than in glucose conditions and twice lower than under 
oligomycin treatment in all groups. There was no difference in ATP levels in both DOA+ and 
OA groups compared with controls. 
Under minimal bioenergesis, treated with a combination of oligomycin and D-
deoxyglucose, ATP levels were very low showing minimal ATP production. 
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Figure 4-10 ATP levels measured in primary fibroblasts from DOA+ and OA patients  
Fibroblasts from patients and controls were treated with a range of bioenergetics conditions: glucose (Glucose), glucose and oligomycin (oligomycin), 
glucose and d-deoxyglucose (D-Deoxyglucose) and glucose with d-deoxyglucose and oligomycin (D-D+oligo). Error bars represent standard error of 
the mean (SEM). **** p≤0.0001 using a Student’s unpaired t-test against controls (n=3).
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4.4 Discussion  
4.4.1 Different mechanisms of OPA1 allelic expression in OA and DOA+ patients  
The effects of different types of mutations on OPA1 expression at the mRNA and protein 
levels were very different and potentially pinpoint different types of pathogenetic 
mechanisms within the same disease, DOA. 
OA syndrome is characterised with isolated optic nerve involvement and accounts 
for approximately 80% of all DOA cases (Lenears et al., 2012). Except for OA(4) patient, 
all other OA patients had lower protein levels, due to a decrease in gene expression as 
shown by the RTqPCR assay. Of note, gene expression was not statistically significant and 
as low as for protein levels in the OA group compared with controls because it was 
missing OA(2) patient in the group analysis, however all three remaining patients showed 
consistency between protein and gene expression. A decrease of 50% in gene expression is 
consistent with the expression of only one WT allele and silencing of the mutant allele. 
This effect is described as loss of function also refered as haploinsufficiency. 
Haploinsufficiency in DOA was first hypothesised by Alexander and colleagues (2000) 
and the first evidence in different types of OPA1 mutations was described soon afterwards 
(Pesch et al., 2001; Marchbank et al., 2002). For OPA1 mutations leading to loss of 
transcription of the mutated allele, Schimpf and colleagues (2008) were able to 
demonstrate a nonsense-mediated decay mechanism. However, they also observed that for 
some of the mutations, particularly those not leading to premature termination codon, such 
as missense and in-frame mutations, a nonsense-mediated decay did not occur and OPA1 
mRNA and protein levels were normal.  
OA(4) patient harbours an 876-878 (TGT) deletion in exon 9 which results in an 
in-frame deletion of a single amino acid at the C-terminus of the protein (termination at 
codon 960) which may go undetected by nonsense-mediated decay quality control. Gene 
and protein levels in OA(4) were found to be consistently normal, which may indicate that 
OA(4) is not subject to nonsense mediated quality control. 
One limitation of quantifying OPA1 OA protein level in this study is that the 
commercial antibody used in the western blot analysis to determine protein level is 
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targeted to an epitope on the C-terminus of the OPA1 protein. If the mutated OPA1 allele 
were to express a truncated protein in a dominant negative fashion as hypothesised by 
Kushnareva and colleagues, 2016, it would be undetectable by this assay because the 
truncation is upsteam of the antibody epitope. However Kunshnareva’s study which used 
an N-terminus targeted antibody reaffirmed a model of haploinsufficiency and it is likely 
that the same mechanism is operating in primary fibroblasts.  
On the other hand, DOA+ subgroup, presenting with extra-ocular symptoms in 
addition to the optic neurodegeneration defining DOA, account for approximately 20% of 
all cases (Lenaers et al., 2012; Yu-Wai-Man et al., 2010b). Most of these patients harbour 
pathological missense variants in the GTPase domain of OPA1 (Yu-Wai Manet al., 
2010b).  
OPA1 expression analysis showed higher variability within DOA+ patients. In the 
case of missense or in-frame mutations, as the resultant transcript would not be truncated 
but instead modified, such mutation would not be detected by non-sense mediated decay 
(Schimpf et al., 2008). However, mutated proteins could post-transcriptionally be 
degraded or, if not detected by a cellular chaperone system (Kriegenburg et al., 2012), 
result in the production of misfolded protein in the cell. In the case of DOA+(2), DOA+(3) 
and DOA+(4), OPA1 protein levels were not decreased indicating that both alleles should 
be expressed. The resulting overexpressed or normal levels of OPA1 protein suggest a 
potential dominant-negative effect in the DOA+ group, as previously hypothesised 
(Olichon et al., 2007).  
Decreased OPA1 protein levels with normal gene expression in DOA+(1) patient 
could be explained by the presence of the two heterozygous missense mutations (c.768 
C>G (exon 5b) and c.854A>G (exon 8) in trans). It is very likely that one or the two alleles 
are fully expressed but the two resulting mutated proteins have a dominant-negative effect 
resulting in destabilsation of the protein and a lower level than expected. Further study of 
allelic expression and OPA1 complex structure would be required. Interestingly, this 
patient presents with one of the most clinically severe cases of DOA in this cohort with 
optic atrophy, ataxia, myopathy and spasticity. 
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OA and DOA+ syndromes are characterised by two different types of mutations 
leading to two very different pathogenetic mechanisms: haploinsufficiency in most OA 
patients and dominant-negative mechanism in most DOA+ patients with mutations in the 
GTPase domain. These two different mechanisms could result in the involvement of 
different cellular and mitochondrial pathways between the two groups, potentially 
explaining different levels of severity between the two syndromes. Due to the 
multifunctional roles of OPA1 protein in mitochondrial dynamics, mitochondrial cristae 
structure, apoptosis, calcium signalling, OXPHOS complex stabilisation and mtDNA 
maintenance (Chevrollier et al., 2012; Zanna et al., 2008; Hudson et al., 2008; Amati-
Bonneau et al., 2008; Agier et al., 2012; Fueloep et al., 2011), it is difficult to predict how 
the different types of mutations can affect mitochondrial and cellular function.  
 
4.4.2 Mitochondrial network fragmentation and morphological differences in 
DOA+ and OA patients  
Analysis of mitochondrial fragmentation patterns was performed by confocal microscopy 
followed by semi-quantitative 3D image analysis allowing the measurement of three 
separate parameters: total mitochondrial length, total mitochondrial volume and number of 
total fragments per cell. These three parameters were then used to calculate two further 
metrics: average mitochondrial length and average mitochondrial volume. This image 
analysis method has great quantitative sensitivity in detecting mitochondrial morphological 
differences compared to previous qualitative (Zanna et al., 2008; Olichon et al., 2007; 
Chevrollier et al.,2008) and semi-quantitative (Agier et al.,2012; Chevrollier et al., 2012) 
analyses some of which are described below.  
Investigating morphological differences between DOA+ and OA primary 
fibroblasts under basal conditions in which cells use both OXPHOS and primarily 
glycolytic systems to derive chemical energy, highlighted two relevant observations. The 
first was a significant increase in total length in all DOA+ and half OA fibroblast lines 
(Table 4-5) and there are a number of possible reasons for this observation. The simplest 
explanation was that the total number of mitochondrial fragments found in DOA primary 
lines was significantly greater than control. This appears to correlate with a significant 
increase in total mitochondrial length (Appendix C1 and C2). So therefore this significant 
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increase in total length is a cumulative effect of the length of a much greater number of 
mitochondrial fragments. Agier and colleagues who observed a similar increase in total 
length of OPA1 primary lines also found a significant decrease in DRP1 steady-state which 
occurred at the post-transcriptional level (Agier et al., 2012).  This may also indicate that 
DRP1 may have a role in modulating total length although further evidence is required to 
make this assertion. The second observation was an increased fragmentation of average 
length and volume in DOA primary fibroblasts. This was reported in previous reports by 
Zanna et al. (2008); Olichon et al. (2007) and Chevrollier et al. (2008). However, DOA+ 
was found to be particularly susceptible to fragmentation under these basal conditions 
which has not been reported previously. This observation was reinforced by quantification 
of average volume which also demonstrated significant fragmentation in DOA+ compared 
with control. Severe fragmentation in DOA+ with milder fragmentation in OA would 
appear to be a basic pathophysiological observation. 
Investigation of morphological differences under forced oxidative conditions 
(5mM galactose) in which chemical energy is reliant on the OXPHOS system rather than 
glycolytic ATP (Rossignol et al., 2004; Bustamante and Pedersen, 1977), highlighted three 
relevant observations. The first was a general increase in both average length and volume 
of mitochondria in control, DOA+ and OA primary fibroblasts. This is reminiscent of 
Tondera and colleagues (2009) stress-induced mitochondrial hyperfusion (SIMH). SIMH 
is a normal acute physiological adaptation to a stress to promote cell survival through 
mitochondrial morphology modulation (Tondera et al., 2009). However, this increase in 
average length and volume was particularly intensified for OA primary fibroblasts with 
both excessive length and disproportionate swelling observed. 
Variations in mitochondrial morphology between both OA and DOA+ groups 
might be a direct consequence of OPA1 allelic expression.OPA1 is expressed as different 
spliced isoforms that form oligomeric complexes to direct its fusion and cristae 
remodelling roles (Frezza et al., 2006; Ramonet et al., 2012). The presence of mutated 
OPA1 protein due to missense mutations in the GTPase domain detected in DOA+ patients 
may interfere with oligomeric complex stabilisation, in turn impinging on OPA1 
functional and structural roles under basal conditions and lead to excessive fragmentation 
of mitochondrial network.  
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Under SIMH conditions induced by galactose treatment, ATP is specifically 
produced via OXPHOS and mitochondrial production is increased. The exaggerated SIMH 
and disproportionate swelling found in OA may be directly linked to OPA1 
haploinsufficiency. Deletions found in OA OPA1 lead to the degradation of truncated 
OPA1 mRNA and the translation of only wild-type OPA1 isoforms. With the absence of a 
modified protein, the resulting oligomerisation would lead to the formation of wild-type 
stable complexes and normal function, explaining the lesser impact on mitochondrial 
network morphology observed under normal conditions compared to DOA+ cases. 
However, the severe defect mainly observed under SIMH induced by OXPHOS-driven 
conditions might be more associated by the low levels of OPA1 protein available 
suggesting a higher demand of the protein during intense cristae remodelling required to 
maintain the mitochondrial network. This phenomenon implies a threshold of OPA1 
molecules needed beyond which disturbance of mitochondrial morphology can be 
detected. The mechanism of this mitochondrial swelling merits further investigation but 
one could hypothesize that this increase in mitochondrial volume may be due to a 
dysregulation of calcium/ potassium flux, resulting in the efflux of calcium and 
subsequenct swelling of the mitochondrial network due to a loss in cristae structure 
(Kushnareva et al., 2013).  
The different morphologies found in DOA+ and OA primary fibroblasts under 
basal and oxidative conditions imply alternative biochemical dysfunctions within 
mitochondria of OA and DOA+ patients. Variations in morphological parameters which 
occur within DOA+ and OA groups are likely reflective of either the underlying OPA1 
mutation or relative number of passages on each line. However, similar fragmentation 
patterns were also quantified in Chapter 5 reaffirming the different morphologies between 
these two groups.  Further understanding the nature of these alternative dysfunctions may 
explain clinical differences observed between these two groups in future studies. This is 
particularly pertinent given that optic and auditory systems, the central and peripheral 
nervous system, heart, muscle, pancreas, kidney and liver are all susceptible to 
mitochondrial dysfunction (Chinnery et al., 2015). 
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4.4.3 mtDNA maintenance is mildly dysregulated in DOA+ patients with no 
steady-state consequence on mtDNA copy number 
To assess the effects of OPA1 mutations on mtDNA maintenance, mtDNA copy number 
was measured using a real-time PCR. No variation in mtDNA copy number between 
controls, DOA+ and OA primary fibroblasts were detected. This observation is consistent 
with a previous report by Agier and colleagues who also demonstrated no significant 
difference in their cohort of four DOA patients implying that at least in these primary 
fibroblasts, pathological mutations in OPA1 do not appear to impact on gross mtDNA 
maintenance (Agier et al., 2012). However, this observation was contradicting Zanna and 
colleagues work who demonstrated a significant increase in mtDNA copy number in 
primary fibroblasts derived from a cohort of ten patients (Zanna et al., 2008).  
The maintenance of mtDNA was further assessed by analysing the relative gene 
expression of TFAM, a component of the mitochondrial nucleoid involved in mtDNA 
coiling and transcription. TFAM gene expression was significantly decreased in DOA+ but 
not in OA when compared against control.A slight decrease in TFAM levels with normal 
mtDNA copy number suggests a mild impairment in mtDNA maintenance with no overall 
effect in steady-state mtDNA copy number in normal conditions. This is consistent with 
previous in-house analyses which demonstrate a defect in mtDNA replication rate under 
stress conditions (driven repopulation of mtDNA after treatment with ethidium bromide).  
Currently there is much controversy in the field as to how pathological OPA1 
mutations may impact mtDNA maintenance. In addition to mtDNA levels quantified in 
primary fibroblasts, investigation of primary leukocytes using RTqPCR have indicated 
both a slight mtDNA depletion or a significant mtDNA proliferation in different studies 
(Kim et al., 2005; Sitarz et al., 2012). Additional investigation in single skeletal muscle 
fibres also demonstrates a mechanism of significant mtDNA proliferation, especially in 
COX-negative tissue (Yu-Wai-Man et al., 2010b). This may indicate that pathological 
disruption of OPA1 may result in a gross disruption of mtDNA maintenance although 
there may not be a different level of susceptibility of mtDNA maintenance in the different 
tissues. 
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4.4.4 OXPHOS subunit protein level variations in DOA do not have direct effect 
on overall ATP cellular levels 
OPA1 performs a variety of functions, which include maintance of cristae morphology, 
regulation of the IMM fusion and stabilisation of OXPHOS complex assembly (Zanna et 
al., 2008). Given these functions, it is plausible that OPA1 mutations may disturb 
OXPHOS function. Relative protein expression levels of individual subunits of OXPHOS 
complexes I, II, IV and V were semi-quantitatively analysed using western blot. Previous 
reports have found an abnormal steady-state of subunits associated with complex I (Zanna 
et al., 2008) which was potentially associated with an OXPHOS enzymatic defect. 
Analysis of these OXPHOS subunits corrected against GAPDH demonstrated a significant 
increase in NDUFB8 in both DOA+ and OA. However a significant increase of nuclear 
encoded SDHA was also detected in DOA+ which may indicate an excess of 
mitochondrial organelles. Further investigation is needed to detect a potential OXPHOS 
complex assembly defect (using blue-native gel electrophoresis) and analysis of enzymatic 
activity of complexes I. Abnormal steady-state levels of complex I subunits in OA may be 
preliminarily indicative of an underlying OXPHOS system defect.  
To further investigate the effects of varying OXPHOS subunit protein levels, 
cellular ATP production was measured. Total cellular, glycolysis-driven and OXPHOS-
driven ATP production were independently analysed and compared. No major ATP 
production disturbances were observed in any conditions between the three groups. This 
observation in consistent with previous measurements of ATP performed by Zanna and 
colleagues  who also reported no gross differences in ATP level in DMEM glucose (Zanna 
et al., 2008).  
D-deoxyglucose specifically inhibits the glycolytic pathway by competitive 
inhibition. D-deoxyglucose contains a hydrogen in place of two hydroxyl groups which 
prevents glucose molecules from being further processed to glucose-6-phosphate. This 
inhibition decreases the efficiency of glycolysis to generate ATP and increases the reliance 
of the primary fibroblasts to generate ATP through the OXPHOS system. In contrast, 
instead of inhibiting the glycolytic pathway, galactose is broken down to generate ATP via 
glycolysis but with a much lower ATP net yield. As the medium is supplemented by 
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glutamine, the cell mainly relies on the OXPHOS system for ATP generation via amino 
acid metabloism.  
The alternative mechanisms which these drugs use to enhance ATP production 
through OXPHOS may partially explain why there is no significant defect detected in 
DOA+ and OA groups under d-deoxyglucose treatment while primary fibroblasts treated 
under galactose exhibit abnormal mitochondrial morphology. Furthermore, mitochondrial 
morphology was quantified after 48 hours incubation with galactose while ATP generation 
was quantified under 1.5 hours incubation with d-deoxyglucose. It could be that any defect 
in OXPHOS may not be detectable until a later time point when mitochondrial 
morphology remodelling may exacerberate a defect in OXPHOS. Evidence for altered 
mitochondrial bioenergetics was demonstrated in Zanna et al., (2008) in which they 
observed increased mitochondrial ATP following 24 hour galactose treatment in both 
control and DOA primary fibroblasts, pointing to an underlying biochemical defect. 
Further investigation of how mitochondrial morphology in DOA under galactose treatment 
is linked to OXPHOS is required, particularly in OA patients. 
4.4.5 Conclusion  
The present study presented two very distinct syndromes of DOA with two different 
mutational effects. On one hand, primary fibroblast lines from DOA+ patients with 
missense muations showed normal levels of OPA1 gene and protein, with propensity to 
escape cellular quality control mechanisms such as nonsense-mediated decay. Such 
mutations led to a clear fragmentation of the mitochondrial network suggesting an 
impairment of OPA1 mediated maintenance of the mitochondrial structure and potentially 
an impairment of fusion under normal conditions. Pathological missense variants may then 
impact on normal OPA1 function, indicative of dominant–negative effect. Mitochondrial 
respiration and mtDNA copy number did not seem to be directly affected; however, the 
decrease in TFAM gene expression implicated a wider effect on mtDNA maintenance. In 
conclusion, dysfunction in DOA+ primary fibroblasts may be due to impaired 
mitochondrial fusion/structure and mtDNA replication rate (Table 4-5). 
On the other hand, investigation of OA primary fibroblasts showed a significant 
decrease in OPA1 steady state which occurred at the post transcriptional level probably 
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due to nonsense mediated decay. Haploinsufficiency led to a mildly significant 
fragmentation of the mitochondrial network under basal conditions. There was also no 
gross defect in mitochondrial respiration and mtDNA maintenance detected. Under 
oxidative conditions, OA primary fibroblasts showed a clear effect on mitochondrial 
morphology, represented by excessive SIMH and excessive swelling of mitochondria. This 
may indicate that under oxidative conditions, where a greater threshold of OPA1 is 
required for adaptation to stress, OPA1 function is severely compromised. In conclusion, 
as a consequence of OPA1 haploinsufficiency, OA primary fibroblasts may have a greater 
impact under stressful conditions and this defect may be due to a dysregulation of 
mitochondrial structure (Table 4-5). 
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Table 4-5 Summary of data obtained from analysis of DOA+ and OA primary fibroblasts. 
SIMH: Stress-induced Mitochondrial Hyperfusion; CI: complex I from the OXPHOS system, represented by NDUFB8A subunit; CII: complex II from 
the OXPHOS system represented by SDHA subunit 
 
 DOA+ OA 
OPA1 levels Normal levels  < 50% lower levels 
Mitochondrial Network under 
basal conditions 
Expansion of total 
mitochondrial network 
Acute fragmentation 
Mild expansion of total 
mitochondrial network 
Mild fragmentation 
Mitochondrial Network under 
OXPHOS-driven conditions 
Normal retraction of total 
mitochondrial network 
 SIMH 
Intensisfied retraction of total 
mitochondrial network 
Exagerated SIMH accompanied 
by intensified swelling 
mtDNA maintenance and 
replication 
Normal mtDNA copy number 
lower TFAM levels 
 
Normal mtDNA copy number but 
40% lower TFAM levels 
OXPHOS function 
Increased protein levels of CI 
subunit  
No overall significant ATP 
production changes 
Increased CI subunit protein level  
No overall significant ATP 
production changes 
 Dominant negative effect Haploinsufficiency 
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Chapter 5  
 
 
 
     Mitochondrial Network and Nucleoid Distribution in    
……..OPA1-Mutant Myotubes 
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5.1 Introduction 
Mitochondrial nucleoids are essential structures that play numerous roles including regulating 
mtDNA maintenance and copy number, segregation of mtDNA in daughter mitochondria following 
fission, manipulating mtDNA transcription and acting as an interface between mtDNA function and 
global cellular signalling pathways (Alam et al., 2003; Moraes et al., 2001; Tyynismaa and 
Suomalainen, 2009).  
Case series investigating key pathological mechanisms underpinning OPA1 mutations and 
mitochondrial dysfunction originally identified a disruption of mtDNA maintenance illustrated by 
the presense of multiple mtDNA deletions in patients diagnosed with optic atrophy and 
mitochondrial myopathy using histopathological staining (Amati-Bonneau et al., 2008).  
This observation was also confirmed in a pedigree of optic atrophy with progressive external 
ophthalmoplegia, ataxia, deafness, visual failure and sensory-motor neuropathy due to a 
pathological missense variant identified in Opa1 (Hudson et al., 2008). Hudson and colleagues then 
proposed that OPA1 may be a component of the mitochondrial nucleoid which may explain its 
involvement in mtDNA instability (Hudson et al., 2008).  
This initial set of observations combined with more recent investigations suggesting a 
relationship between OPA1 dysfunction and mtDNA proliferation (Sitarz et al., 2012; Yu-Wai-Man 
et al., 2010b), led to an investigation by Elachouri and colleagues to identify this mechanistic link 
between OPA1 and mtDNA maintenance (Elachouri et al., 2011). Their work highlighted a physical 
interaction of a 10kDa N-terminus OPA1 isoform with mtDNA, implicating OPA1 protein in 
mtDNA maintenance within HeLa cells. Similar to ATAD3, this 10kDa isoform was responsible for 
anchoring the mitochondrial nucleoid to the IMM, a necessary step for mtDNA replication, fidelity 
and nucleoid distribution within the mitochondrial network (Figure 5-1). 
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Figure 5-1 Mitochondrial nucleoid anchoring to the inner mitochondrial membrane via 
binding with OPA1 
OPA1 is alternatively spliced to produce pre-mature isoforms containing exon 4b. These isoforms 
are further processed by OPA1 protease YME1L and the mature protein isoform acts to bind 
mitochondrial nucleoids to the IMM to facilitate mtDNA replication and nucleoid distribution 
(Reproduced from Elachouri et al., 2011) 
 
 In addition, disruption of mitochondrial dynamics has been identified as a common hallmark 
of neurodegenerative disorders (Santel et al., 2006; Kijima et al., 2005; Zuchner et al., 2004; 
Waterham et al., 2007; Olichon et al., 2003). This is particularly pertinent for DOA because 
mutations in Opa1 may lead to a generalised disruption of mitochondrial fusion and increased 
fragmentation of the mitochondrial network (Zanna et al., 2008). This disruption may impinge on 
quality control, inhibiting both mitochondrial content mixing and the distribution of nucleoids 
(Meeusen et al., 2006; Detmer and Chan, 2007; Chen et al., 2007). This hypothesis is based upon 
experimental observation that mitochondrial fusion results in the repopulation of ρ0 cells through 
the slow migration of mtDNA/nucleoids in these fusion events (Legros et al., 2004). Moreover, 
mitochondrial networks with excessive fragmentation have been found to contain at least one 
mtDNA/nucleoid per mitochondrial fragment. These observations imply that mtDNA/nucleoid 
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distribution may be a regulated process and that potential disruption of this process, perhaps 
through excessive mitochondrial fragmentation, may impact mtDNA number and distribution 
(Margineantu et al., 2002). Strikingly, MFN2 dysfunction was shown to inhibit outer membrane 
fusion and lead to a decrease in mtDNA copy number further validating this hypothesis (Chen et al., 
2010; Vielhaber et al., 2013). These observations imply a relationship between mitochondrial 
dynamics and mtDNA/ nucleoid maintenance, number and distribution which has yet to be 
investigated in primary DOA patient tissue. 
To investigate this mechanistic relationship, we employed both Quant-iT™ PicoGreen® 
cytochemical and MitoTracker® Red CMXRos staining. The use of Quant-iT™ PicoGreen® has 
been used previously by Ashley et al. (2008) and Ylikallio et al. (2010) to determine both the 
relative number and size distribution of mtDNA/nucleoid molecules in primary cell models of 
mtDNA depletion due to pathological POLG1 mutations in Alpers syndrome and a bitransgenic 
Twinkle/TFAM mouse model, respectively. Both studies presented a detrimental decrease in 
mtDNA molecule number, respectively. 
Although Quant-iT™ PicoGreen® staining of live cells is less sensitive than anti-dsDNA 
antibodies, its advantages include a greater accuracy in quantifying nucleoid/mtDNA level (Ashley 
et al., 2008). Live cell cytochemical staining also provides additional data on the distribution and 
morphology of these mtDNA molecules and bypass the necessity to fix the cells. The use of 
mitotracker to analyse the fragmentation of the mitochondrial network in DOA primary tissue is 
also a well validated technique and ideal for in vitro analysis (Zanna et al., 2008; Agier et al., 2012; 
Chevrollier et al., 2012).  
The development of these confocal fluorescent assays has led us to investigate both 
mitochondrial fragmentation and the relative number and distribution of mitochondrial nucleoids. 
These parameters were measured in primary myotubes which are a tractable model system derived 
from quiescent satellite cells from patient muscle tissue. Advantages of this model include the 
ability to culture these satellite cells before myotube differentiation and to retain many of the 
biochemical traits of donor cells and mirror phenotypic traits which can be found in DOA+ and OA 
primary tissue (Thompson et al., 1996; Bell et al., 2010; Spinazzi et al., 2008). These differentiated 
myotubes are also more biochemically related to patient muscle fiber than primary fibroblasts and 
myoblasts. This is particularly pertinent given the observation of COX deficiency and bioenergetic 
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failure revealed through histochemical staining of DOA+ patient muscle biopsies as a consequence 
of the clonal proliferation of mtDNA molecules with multiple deletions (Hudson et al., 2008; 
Amati-Bonneau et al, 2008.) 
In parallel, primary differentiated myotubes with a pathological WFS1 mutations were also 
quantified using this in vitro live cell assay. The presentation of a pathological phenotype due to 
mutations of WFS1 is reminiscent of the many multi-systemic optic disorders normally associated 
with mitochondrial dysfunction such as DOA. However WFS1 is housed within the endoplasmic 
reticulum and is not primarily a mitochondrial disorder.  
The aim of this study was to quantify fragmentation of the mitochondrial reticulum in 
primary myotubes of patients diagnosed with DOA+ and OA and correlate these findings with the 
distribution of mtDNA molecules to detect a potential disturbed nucleoid distribution maintenance 
and number, which may play a role in the pathogenesis of DOA. 
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5.2 Materials and Methods 
5.2.1 Patient cohort 
Mitochondrial nucleoid distribution within the mitochondrial network was investigated using 
primary differentiated myoblasts, myotubes, derived from nine patients and three controls as 
described in Table 5-1. This study was supported by institutional approval and written informed 
consent was obtained from all patients. 
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Control Group Age Gender      OA Spastic Paraplegia Myopathy Deafness     Ataxia   
MyoControl(1) 47 M - - - - -   
MyoControl(2) 21 F - - - - -   
MyoControl(3) 29 F - - - - -   
DOA+ Group   
   
 
  
OPA1 Mutation 
MyoDOA+(1) 48 F + + - - - c.889C>T 
MyoDOA+(2) 59 M + + - - - c.876-878 del (TGT) 
MyoDOA+(3) 55 F + - + - - c.870+5g>a 
MyoDOA+(4) 36 F + - + - - c.870+5g>a 
OA Group   
      
  
MyoOA(1) 41 M + - - - - c.876-878 del (TGT) 
MyoOA(2) 59 M + - - - - Exon 1-5 Deletion 
MyoOA(3) 60 F + - - - - c.2713C>T 
MyoOA(4) 65 M + - - - - c.2818+5g>a 
WFS1 Group   
      
WFS1  Mutation 
WFS1(1) 36 F + - - + + c.409_424dup16 
         
Table 5-1 Clinical characteristics of controls and optic atrophy patients with known pathogenic mutations. 
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5.2.2 Seeding of patient myoblasts and differentiation into myotubes 
A 50 µg/ml collagen solution was prepared (Collagen: Life Technologies A10483-01) in 
filtered sterilised 20 mM acetic acid solution (Sigma-Aldrich). 1 ml of this collagen solution 
was added to a glass-bottomed confocal dish (Wilco) and left to incubate at room temperature 
overnight. The collagen solution was carefully aspirated and each dish was washed three 
times with autoclaved PBS solution (Oxoid) and used either immediately for myoblast cell 
seeding or left at 4oC. 
From a T25 flask, primary DOA and WFS1 myoblasts were seeded onto glass-bottomed 
confocal dishes (Wilco) as previously described (Section 3.14.1.) at a density of 75,000 cells/ 
dish. These cells were left to incubate overnight or until the cell density reached 50-70% 
confluence. Once this cell density threshold was achieved, the Skeletal Muscle Cell Growth 
Medium (Promocell) was aspirated from each dish and washed with PBS (Oxoid). Myoblasts 
were then incubated with Skeletal Muscle Differentiation Medium (Ready-to-use) (Promocell 
C-23061) for 24 hours before this media was aspirated and replaced with fresh differentiation 
medium. These cells were incubated in fresh differentiation medium every 2-3 days and 
primary myotubes were ready for imaging on day 6 of this protocol. Seeding and 
differentiation of myoblasts was performed by Dr. Florence Burté. 
5.2.3 MitoTracker® Red CMXRos and Quant-iT™ PicoGreen® staining  
On the day of imaging, cells were incubated with 1ml 3µl/ml stock Quant-iT™ PicoGreen®  
solution (Life Technologies) diluted in Skeletal Muscle Differentiation Medium (PromoCell: 
C-23061) for 1 hour at 37˚C. Thirty minutes mid-incubation of Quant-iT™ PicoGreen®  
stain, the staining medium was aspirated and 1ml of Skeletal Muscle Differentiation Medium 
containing 3µl/ml Quant-iT™ PicoGreen®  (Life Technologiesnologies) and an optimised 
concentration of MitoTracker® Red CMXRos  (50, 75 and 100nM) was added. Both Quant-
iT™ PicoGreen®  andMitoTracker® Red CMXRos were incubated for a further 30 minutes. 
This staining medium was aspirated and the cells were washed twice with PBS (oxoid) before 
they were added to DMEM (25mM glucose/phenol red free)(Gibco, Life Sciences) with 2% 
FBS ,1% Penicillin-Streptomycin and 25mM Hepes (All obtained from Sigma-Aldrich). 
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5.2.4 Optimisation of myotube image capture   
Optimisation of MitoTracker® Red CMXRos loading, Quant-iT™ PicoGreen® staining and 
confocal image acquisition settings were required before standardised mitochondrial network 
morphology and mtDNA/nucleoid capture of primary myotubes was achieved. Initial attempts 
to load 75nM MitoTracker® Red CMXRos (as in Section 4.2.3 for fibroblasts) and 3µl/ ml 
stock Quant-iT™ PicoGreen®  (Life Technologies) with a specific cutoff threshold for HV 
settings resulted in both low level and saturated signal variation in both channels preventing 
accurate image capture (Figure 5-2). To minimise this variation, two control myotubes 
(MyoControl (1) and MyoControl (3)) were analysed under twelve different conditions for 
MitoTracker® Red CMXRos and four different conditions for Quant-iT™ PicoGreen® . 
Briefly, to correct for signal variation using the Quant-iT™ PicoGreen® channel, 
myotubes were loaded with 3ul/ml stock Quant-iT™ PicoGreen® for 1 hour at 37ºC before 
confocal HV and laser power was adjusted and three myotubes were captured for analysis to 
determine the optimal acquisition settings as described in Table 5-2. 
To correct for MitoTracker® Red CMXRos, myotubes were loaded with 50, 75 or 100 
nM MitoTracker® Red CMXRos at 37ºC for 30 minutes before confocal HV and laser power 
was adjusted as described in Table 5-2 for each concentration. Both Quant-iT™ PicoGreen®  
and MitoTracker® Red CMXRos signals were analysed using Huygens Essential Analyser 
(Scientific Volume Imaging, Hilversum, the Netherlands) to determine  fluorescent signal 
intensity. 
This analysis highlighted a greater variation in MitoTracker® Red CMXRos which led 
to either a saturated or an extremely weak signal which was problematic for image capture. In 
order to correct for this variation, myotubes were incubated with 75nM MitoTracker® Red 
CMXRos as previously described and HV was manually adjusted. A linear relationship exists 
between HV and signal fluorescent intensity and so MitoTracker® Red CMXRossignal was 
adjusted both to saturation and to the lower threshold of signal intensity to determine signal 
range. The mitochondrial network in each primary myotube line was captured 20% below the 
signal saturation threshold (corrected condition) to acquire the mitochondrial network in 
these cells. This signal was subsequently analysed with Huygens Essential Analyser 
(Scientific Volume Imaging, Hilversum, the Netherlands) and statistically assessed through a 
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Student’s unpaired T-test of average mitochondrial length and volume to determine that there 
were no significant differences between control cells analysed (Figure 5-2) 
 
Table 5-2 Parameters used to analyse primary myotubes during image acquisition 
optimisation. 
 
5.2.5 Mitochondrial network and nucleoid distribution and image acquisition  
Excitation wavelength for MitoTracker® Red CMXRos and Quant-iT™ PicoGreen® were 
561nm and 488nm, respectively. Primary myotubes were z-stacked with a section interval of 
0.2um for 79 slices. Both the mitochondrial network (561nm excitation) and mtDNA/nucleoid 
(488nm excitation) were captured simultaneously. Laser power and PTM were carefully 
optimised to avoid both saturation and low level signal during image acquisition. 
5.2.6 Image deconvolution  
Following acquisition of live-cell images, the files were converted to TIFF format and each 
channel was stacked using ImageJ. ImageJ was also used to process these images by using the 
rolling-ball algorithm (Castle and Keller, 2007: Available at rsb.info.nih.gov/ij/plugins/rolling-
ball.html) to average background intensity variation before the files were imported to Huygens 
Essential Software ( Scientific Volume Imaging, Hilversum, the Netherlands) for 
deconvolution. Each channel was deconvolved independently with a standardised background 
threshold until confidence level approached 99% or the number of iterations approached 40.
     
  HV-Green 
488-Green 
Channel (%) 
HV-Red 561-Red Channel (%) 
Original 
Settings 
90 3 90 1 
Condition 1 80 3 90 2 
Condition 2 100 3 100 1 
Condition 3 90 2 80 1 
Condition 4 90 1 80 1 
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5.2.7 Image analysis 
Images were subsequently analysed with Huygens Essential Software (Scientific Volume Imaging, 
Hilversum, the Netherlands) using a standardised set of parameters for each channel (561nm 
channel (Mitotracker® Red CMXRos); Threshold 10%, Seed 11%, Garbage 40; 488nm channel 
(Quant-iT™ PicoGreen® ); Threshold 8%, Seed 6%, Garbage 4. A region of interest (ROI) was 
selected in each cell analysed for each channel. The final analysis was corrected for the size of this 
ROI as a mean of standardisation for each cell measured. 
A minimum of 12 myotubes were imaged for each primary myotube cell line (N ≤ 12). 
Three parameters were quantified while measuring the morphology of the mitochondrial network: 
(1) Average length/volume, (2) total length/volume and (3) the number of fragments detected in the 
network. The total length/volume is the sum total of the length and volume of all mitochondrial 
fragments within the network of each cell. The number of fragments is the number of objects 
detected by Huygens Essential Software Object Analyser (Scientific Volume Imaging, Hilversum, 
the Netherlands) using optimised thresholds for detecting mitochondrial organelles in each cell 
analysed. The average length/volume is a metric calculated from the ratio between the total 
length/volume and the number of fragments of each cell. Similarly, the number and distribution of 
mtDNA/nucloids was quantifed using Quant-iT™ PicoGreen® staining using an optimised signal 
threshold. 
The number, mean and standard error of the mean were generated from the analyses of these 
parameters calculated for each myotube disease group analysed. These parameters were corrected 
by there respective cell’s ROI. The number of objects was also corrected by the ROI and 
distribution was calculated by determining Log10 of the number of objects defined between an upper 
and lower threshold of object size.  
 
5.2.8 Statistical analysis 
Statistical analysis was performed with excel (Microsoft, Reading, UK) and GraphpadTM V. 5 
(Graphpad software). Comparison between groups was carried out using a Student’s unpaired t-test. 
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5.3 Results 
5.3.1 Optimisation of myotube image acquisition  
Two control myotube lines were analysed and their signal fluorescence quantified in either 
corrected (refer to Section 5.2.4) or uncorrected conditions. This analysis showed that there were no 
significant differences between quantifying each individual line under corrected or non-corrected 
conditions. There appeared to be a mildly greater variation along the Z-axis (volume) in uncorrected 
values. Therefore, it was decided to analyse all myotube lines under a corrected threshold to ensure 
no information loss due to signal variation (Figure 5-2). 
 
Figure 5-2 Optimisation of mitochondrial network capture in primary control myotubes. 
The mitochondrial network was captured and quantified in the same myotube control line manually 
adjusted 20% below the point of saturation. Average fragment length (A) and average fragment 
volume were calculated (B) for each cell (n ≥ 3) in two different control cell lines (Control1 and 
Control2). The signal of the mitochondrial network was captured and quantified in each myotube 
line using the same standardised settings throughout. Graphs were statistically compared using a 
Student’s unpaired t-test 
(A) (B) 
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5.3.2 Mitochondrial network analysis in myotubes from DOA patients.  
5.3.2.1 Mitochondrial network variation analysis between control cell lines 
Total mitochondrial length was determined in each of the three primary myoblast lines, 
myoControl(1), myoControl(2) and myoControl(3) (n = 33, Figure 5-3). The greatest total 
length was observed in line myoControl(1) (Mean = 432.11, SEM = 25.14) and the least total 
length was detected in line myoControl(2) (Mean = 278.97, SEM = 37.16). A statistically 
significant difference was noted between total length of these two myoblast lines (P = 0.0023; 
p < 0.01) using a Student’s unpaired t-test. No significant difference was detected between 
lines myoControl(1) and myoControl(3) (p = 0.1569) or lines myoControl(3) and 
myoControl(2) (p = 0.2372).  
Measurement of total mitochondrial volume indicated that the greatest total volume 
was found in primary line myoControl(1) (Mean = 409.13, SEM = 45.09) and the least total 
volume was found in myoControl(2) (Mean = 163.97, SEM = 40.01). Statistical comparison 
between these two lines was significant (p = 0.0006; p < 0.001) which is consistent with the 
previous data generated for total mitochondrial length. Again, no significant difference in 
total volume was detected between myoControl(2) and myoControl(3) (p = 0.5486), however 
a significant difference was detected between lines myoControl(1) and myoControl(3) (p = 
0.0059, p < 0.01).  
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Figure 5-3 Variability in total network morphology between control myotube lines 
Total mitochondrial length (A) and total volume (B) were measured using Huygens Object 
analyser module in control myotubes. Error bars represent the standard error of the mean 
(SEM). ns non-significant, ** p  0.01 and *** p  0.001 using a Student’s unpaired t-test 
against controls (n ≥ 10). 
 
Comparing the average mitochondrial length between myoControl(1), myoControl(2) 
and myoControl(3) (Figure 5-4B), primary line myoControl(1) had the greatest average value 
(Mean = 3.88, SEM = 0.24) while myoControl(3) was of least average length (Mean = 3.20, 
SEM = 0.18) with a statistical significance (p< 0.001). The average length of myoControl(3) 
however was not significantly different from myoControl(2) (P = 0.0794). This is consistent 
with previous measured parameters. 
Investigation of average mitochondrial volume reveals a similar trend (Figure 5-4C). 
The greatest average mitochondrial volume is found in line myoControl(1) (Mean = 3.96, 
SEM = 0.74) while myoControl(2) has the least mitochondrial volume (Mean = 1.86, SEM = 
0.41). This difference in average volume between myoControl(1) and myoControl(2) is 
statistically significant (P = 0.0247, p < 0.01) while the difference in average volume between 
myoControl(3) and myoControl(2) is not significant (P = 0.8133). 
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The total number of mitochondrial fragments was also determined in myoControl(1), 
myoControl(2) and myoControl(3) (Figure 5-4A). Again the same trend in variability was 
seen with myoControl(1) having the greatest number of mitochondrial fragments (Mean = 
115.79, SEM = 8.39) and myoControl(2) having the least number of fragments (Mean = 
81.63, SEM = 10.77). Statistical significance was noted between lines myoControl(1) and 
myoControl(2) (p = 0.0197; p < 0.05) while no statistical significance was found between 
lines myoControl(1) and myoControl(3) (p = 0.0695) and lines myoControl(2) and 
myoControl(3) (p = 0.5905). 
Overall, Variations between cell lines were more obvious when analysing volume 
parameters compared with length parameters. Also, total mitochondrial network was very 
similar between MyoControl(2) and MyoControl(3), whilst Myocontrol(1) appeared as an 
outlier compared to the other cell lines. This difference could be due to the older age or the 
gender of the healthy control and should be included to take in account the variations due to 
age and gender differences when comparing with the patient cell lines. 
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Figure 5-4 Variability in mitochondrial fragment morphology between control myotube lines 
Average number of mitochondrial fragments (A) were measured using Huygens Object analyser software in imaged control myotubes. Average 
fragment length (B) and average fragment volume (C) were calculated as described in section 5.2.6. Error bars represent the standard error of the 
mean (SEM). ns non-significant, * p  0.05 using a Student’s unpaired t-test against controls (n ≥ 10). 
 
(A) (B) (C) 
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5.3.2.2 Mitochondrial fragmentation analysis in patient primary myotubes 
Mitochondrial network analysis was visualised using the mitochondria specific stain 
MitoTracker® Red CMXRos in all the cell lines in the myotube cohort and morphology was 
compared between each disease group. Figure 5-5 shows representative images for each 
disease group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-5 Representative image of primary myotubes from control, DOA+, OA and WFS1 
patient-derived cell lines 
Staining of the mitochondrial network was performed with MitoTracker® Red CMXRos 
(Molecular Probes, Life technologies). Images of primary myotubes were captured using (Nikon) Ti 
confocal microscope objective (x63) followed by Computerised Image deconvolution using 
Huygens Essential deconvolution wizard. Representative images of a myotube from control (A), 
myotubes from DOA+ (B), OA (C) and WFS1 patients (D). Scale bars represent 10μm. 
 
A- Control 
B-DOA+ 
C- OA 
D- WFS1 
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Total network length was increased in all DOA+ patient myotubes from 1.5 to 2-fold 
(Appendix Figure F-1A). Consequently, the DOA+ patient group showed an overall total 
network extension compared to controls. In the OA group, three out of the four patients 
showed very mild total mitochondrial network length increase, with an average not 
significantly different to controls and significantly lower than in the DOA+ group. The WFS1 
patient cell line did not show gross changes in total mitochondrial network length compared 
with control and OA groups (Figure 5-6A). 
Among the cell lines derived from DOA+ patients, total network volume showed more 
variation leading to an overall mean similar to the control group (Appendix Figure F-1B). In 
the OA group, three out of four cell lines showed a very mild decrease or normal total 
mitochondrial network volume. Strikingly, MyoOA(4) showed an overly increased total 
mitochondrial network. WFS1 did not present any gross changes in total network volume 
(Figure 5-6B). 
Despite a significant increased number of fragment in all cell lines, mitochondria were 
not fragmented in all DOA+ myotube cell lines (Appendix Figure F-2A-B) as indicated by 
the average fragment length parameter. Despite an overall indication of no fragmentation in 
the OA group (Figure 5-7A-B), MyoOA(1) was very fragmented (Appendix Figure F-4B). 
Average mitochondrial volume did not show significant changes in each disease group 
when compared to controls (Figure 5-7C). This is mainly due to a high variation between 
myotubes derived from DOA+ patients for the DOA+ group (Appendix Figure F-2C) and 
for the OA group it is mainly due to the high increase in average volume in OA cell line, 
MyoOA(4), whilst the other cell lines did not show changes (Appendix Figure F-4C).
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Figure 5-6 Total length and volume measurements of the mitochondrial network in patients 
and control primary myotubes 
Total mitochondrial length (A) and total volume (B) were measured using Huygens Object analyser 
module in myotubes derived from different optic atrophy and control groups. Error bars represent 
Standard Error of the Mean (SEM). ns non-significant, **** p  0.0001 using a Student’s unpaired 
t-test against controls (n ≥ 12). 
 
(A) (B) 
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Figure 5-7 Mitochondrial fragmentation of the mitochondrial network in patient and control primary myotubes. 
Average number of mitochondrial fragments (A) were measured using Huygens Object analyser software in fibroblasts imaged. Average fragment 
length (B) and average fragment volume (C) were calculated as described in section 5.2.6. Error bars represent the standard error of the mean (SEM). 
** p  0.01, and **** p  0.0001 using a Student’s unpaired t-test against controls (n ≥ 12).
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5.3.3 Mitochondrial nucleoid distribution in myotubes from optic atrophy patients 
Investigation of nucleoid distribution was conducted concurrently with mitochondrial 
fragmentation analysis in DOA+, OA and Wolfram syndrome primary myotubes using DNA 
staining followed by confocal microscopy and parametric image analysis (Figure 5-8). 
Staining with the DNA-specific dye Quant-iT™ PicoGreen® ® allowed the measurement of 
mitochondrial nucleoid size distribution and their object number within cells.  
The Object Analyzer module from Huygens software allowed the measurement of 
volume of each DNA object within a specific region of interest (ROI) of a cell. Each object 
volume was standardised by the cell’s ROI area and then expressed as a logarithmic function. 
Resulting size ranges were divided into bins and expressed as percentage per analysed cell. 
The number fragment within each bin from each cell was averaged (n ≥ 12 cells) for each cell 
line. The resulting distribution of object size standardised to respective ROIs was then 
expressed as a percentage number fragment /cell line /size bin and represented as a 
distribution graph. The result from each cell line was then average per disease group (Figures 
5-9 to 5-11). 
The modified Kolmogorov-Smirnov test can be used as a distribution normality test. 
This statistical test indicated that the percentage nucleoid distribution in each group was not 
normally distributed (KS test for normality: Control, p >0.0001; DOA+, p > 0.0001, OA, p > 
0.0001; WFS1, p >0.0001; Table 5-3). This was represented by the presence of a slight tail 
for highest size ranges for all disease groups. 
The non parametric Mann-Whitney test comparing overall size distribution in heathy 
controls with those from patient cell lines revealed no significant difference (DOA+: p = 
0.8455; OA: p = 0.7290 and WFS1: p = 0.7869; Table 5-3). . 
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Figure 5-8 Maximum intensity projection of Quant-iT™ PicoGreen® staining within 
primary myotube lines 
Staining of DNA/nucleoid molecules was performed with PicoGreen® (Molecular Probes, 
Life technologies). Images of primary myotubes were captured using Nikon Ti confocal 
microscope objective (x63) followed by Computerised Image deconvolution using Huygens 
Essential deconvolution wizard. Representative images of a myotube from control (A) and 
myotubes from DOA+ (B), OA (C) and WFS1 patients (D). Scale bars represent 10μm. 
 
A- Control 
B-DOA+ 
C- OA 
D- WFS1 
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Figure 5-9 Distribution of mtDNA\nucleoid size in DOA+ (A) and control (B) primary myotubes 
Percentage distribution of nucleoid size in DOA+ patient myotubes (blue bars) compared with the distribution of nucleoids found in the control group 
(green bars). All values were corrected for unit area and percentage distribution of nucleoids in each cell analysed. Error bars represent the standard 
error of the mean (SEM). Statistical analysis found in Table 5-3.  
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Figure 5-10 Distribution of mtDNA/nucleoid size in OA (A) and control (B) primary myotubes 
Percentage distribution of nucleoid size in OA-derived myotubes (pink bars) compared with the distribution of nucleoids found in the control group 
(green bars). All values were corrected for unit area and percentage distribution of nucleoids in each cell analysed. Error bars represent the standard 
error of the mean (SEM). Statistical analysis found in Table 5-3.  
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Figure 5-11 Distribution of mtDNA/nucleoid size in WFS1 (A) and control (B) primary myotubes 
Percentage distribution of nucleoid size in WFS1-derived myotubes (purple bars) compared with the distribution of nucleoids found in the control 
group (green bars). All values were corrected for unit area and percentage distribution of nucleoids in each cell analysed. Error bars represent the 
standard error of the mean (SEM). Statistical analysis found in Table 5-3.  
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     Kolmogorov-Smirnoff test of normality 
  Control   DOA+   OA   WFS1 
Passsed Normality: <0.0001   <0.0001   <0.0001   <0.0001 
  No   No   No   No 
  Mann-Whitney test of significance 
      DOA+   OA   WFS1 
Vs Controls:     0.8456   0.729   0.7869 
                
        
Table 5-3 Statistical analysis of nucleoid/mtDNA distribution in control, DOA+, OA and WFS1 primary myotubes 
A  Kolmogorov –Smirnoff test was used to quantify deviance from normal distribution of mitochondrial nucleoids in control (N = 33), DOA+ (N = 
47), OA (N = 45) and WFS1 (N =10) groups.  A Mann –Whitney test was used to measure any significant bias in percentage nucleoid distribution 
between control and patient group.  (p ≤ 0.05 is * significance; p ≤ 0.01 is ** significance, p ≤ 0.001 is *** significance, p ≤ 0.0001 is **** 
significance). 
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Despite no statistical difference between healthy controls and disease groups, Figure 
5-9 shows a slight shift in size distribution towards the right indicating a slight increase in 
nucleoid size. Analysis of size distribution within each individuals, which was carried out by 
Dr Ian Wilson, detected that the shift was mainly due to one patient (MyoDOA+ (2)) who 
presented with significantly bigger mitochondrial DNA clumps than other patients (Appendix 
G-1 and G-2). 
In addition to the analysis of mitochondrial nucleoid size distribution, total number of 
nucleoid objects in ROI within each cell was also measured and averaged per cell line and 
then by disease group. This analysis revealed a marked decrease in object numbers in the 
individuals MyoDOA+(2) (p<0.0001), MyoDOA+(3) (p = 0.0003) and MyoDOA+(4) (p = 
0.0205) (Appendix Figure G-3). Overall nucleoid number was then statisticaly reduced in 
the DOA+ group. There was greater variation in the OA group with a proliferation of objects 
detected in MyoOA(2)(p = 0.0246) and a depletion in MyoOA(4) (Pp =  0.0012) (Appendix 
Figure G-3), leading to a similar trend overall in the OA group compared to the healthy 
control group (Figure 5-12). The cell line derived from the WFS1 patient had normal 
numbers of mtDNA objects/area analysed (P = 0.2189) (Figure 5-12). 
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Figure 5-12 Total number of mtDNA objects detected per unit area of cell analysed. 
The mean of the number of nucleoid/mtDNA objects detected per unit area of the cell in 
DOA+ (n = 47), OA (n = 45) and WFS1 (n = 10) was quantified and compared against control 
(n = 33). Error bars represent the standard error of the mean. *** P ≤ 0.001 using a Student’s 
unpaired t-test.
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5.3.4 Mitochondrial nucleoid distribution within mitochondrial network in patients with 
optic atrophy 
To investigate the distribution of nucleoids within the mitochondrial network (Figure 5-13) two 
parameters were analysed, ‘Total number of nucleoids/ mitochondrial fragment’ and ‘Total number 
of nucleoids/ total mitochondrial length’. 
The first parameter indicated a non-significant difference in the number of nucleoids per 
mitochondrial fragment between control, OA (p = 0.0780) and WFS1 (p = 0.8306) groups. A 
significant decrease in the number of nucleoids/mitochondrial fragment was detected in the DOA+ 
group (p < 0.0001), suggesting that each mitochondrial fragment contained significantly less 
nucleoids in the DOA+ group than in the control group (Figure 5-14A). 
The second parameter ‘Total number of nucleoids/ total mitochondrial length’ also indicated 
a significant decrease in the number of nucleoids within the ‘DOA+’ group (P <0.0001). A 
significant decrease in the number of nucleoids distributed along the total mitochondrial length was 
also detected in the OA group when compared against controls (p <0.0009) while the number of 
nucleoids/ total length was non-significant for the WFS1 group (p = 0.3702) (Figure 5-14B). 
 
 
Figure 5-13 Mitochondrial DNA distribution within the mitochondrial network 
Composite image of combined MitoTracker® Red CMXRos and Quant-iT™ PicoGreen® ® 
staining illustrating the mtDNA/nucleoid distribution (green) within the mitochondrial network 
(red) of a representative DOA+ primary myotube 
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Figure 5-14 Quantification of the number of nucleoid\ mitochondrial fragment and the 
number of nucleoids\total mitochondrial length. 
(A) The mean of the number of nucleoid objects corrected against the number of mitochondrial 
fragments in each cell was quantified per group, Control (N=33); DOA+ (N= 47); OA (N= 45); 
WFS1 (N= 10). DOA+, OA and WFS1 groups were statistically compared against control. (B)The 
total number of nucleoid objects corrected against the total mitochondrial length in each cell was 
also quantified per group; Control (N = 33); DOA+ (N = 47); OA (N = 45); WFS1 (N = 10) and 
statistically compared against control. A Student’s unpaired t-test was used in all statistical analyses 
to measure significance.  (P < 0.05 is non-significant; P ≤ 0.05 is * of significance; p ≤ 0.01 is ** 
significance; p ≤ 0.001 is *** significance, P ≤ 0.0001 is **** significance.
(A) (B) 
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5.4  Discussion 
5.4.1 Mitochondrial network fragmentation in DOA+ and OA patient myotubes  
The present study indicated increased fragmentation of the mitochondrial network in DOA+ 
and OA myotubes, however no significant morphological difference was detected in Wolfram 
syndrome myotubes. This increase in mitochondrial fragmentation in DOA was consistent 
with previous reports (Chen et al., 2005; Agier et al., 2012). In addition, greater 
fragmentation was detected in the DOA+ network when compared with mitochondria from 
the OA network, an observation which was consistent with the analysis of primary fibroblasts 
from DOA+ and OA patients (Section 4.3.3). Consistently, a similar trend between fibroblast 
and myotube lines from both cohorts of patients was detected with total mitochondrial length. 
Although trends were similar, more obvious changes in morphology were observed in DOA 
fibroblasts compared with controls than in the myotube study. This might be more related to 
the sample size included in the respective cohorts than cell type related (Fibroblast study: 
n=200, Myotube study: n~46), although this hypothesis can not be neglected. 
As discussed in the previous chapter in fibroblast cell lines (Section 4.4.2), mitochondrial 
expansion and fragmentation in DOA cell lines is in agreement with experimental validation 
studies performed by Agier and colleagues (2012) who also found an increased aspect ratio 
score indicating greater total mitochondrial length when compared against controls. This 
increase in total length was not attributed to OPA1 or DRP1 steady-state (Agier et al., 2012) 
but instead may be a compensatory mechanism due to Opa1 mutations. Mutated OPA1 may 
result in disrupted cristae, impaired mitochondrial dynamics efficiency and a reduced 
efficiency to assemble respiratory chain complexes and supercomplexes (Cogliati et al., 
2013). Although the study in fibroblasts did not give evidence of it, this may culminate in a 
reduced rate of ATP production (Zanna et al., 2008), however in view of recent reports 
linking OPA1 and mitochondrial maintenance, this remodelling of mitochondrial network 
might be associated with remodelling of mitochondrial nucleoid structure and numbers. 
 
 166 
 
5.4.2 mtDNA size distribution is mildly affected in DOA+ myotubes associated with 
marked mtDNA nucleoid depletion 
Previous experimental endeavours in the field have quantified the level and/or 
distribution of mtDNA/nucleoids both in primary human lines and animal models of mtDNA 
disturbance. In this study, a significant depletion of total mtDNA/nucleoids was found in the 
DOA+ group while no significant change in level was found in either OA or WFS1 primary 
myotubes. This observation is consistent with OPA1/MFN1 and two mouse models in which 
disruption of either outer or inner mitochondrial membrane fusion can result in both mtDNA 
depletion and multiple mtDNA deletions (Chen et al., 2010; 2012). It is also consistent with 
data obtained from mouse embryonic fibroblasts (MEFS) showing that increased 
mitochondrial fragmentation and reduced fusion efficiency could result in a depletion of 
nucleoids and mtDNA content (Chen et al., 2007). 
MtDNA instability can also arise secondary to pathogenic mutations in POLG, a core 
mtDNA replication factor found within the nucleoid structure, TFAM, a peripheral factor 
involved in packaging and stability of mtDNA and Twinkle, a mitochondrial helicase essential 
for mtDNA replication. These constituents of the mitochondrial nucleoid all demonstrated a 
marked depletion of mtDNA either in animal models or primary patient-derived tissues. 
(Ashley et al., 2008; Dai et al., 2013; Milenkovic et al., 2013; Larsson et al., 1998; Ekstrand 
et al., 2004 ; Sanchez-Martinez et al., 2012; Matsushima and Kaguni, 2007). Based on these 
observations, it is therefore not surprising that a subset of OPA1 mutations found in the 
GTPase domain may disrupt mtDNA maintenance and lead to a depletion of mtDNA 
molecules.  
The experiments conducted in the present study have not only quantified the 
mtDNA/nucleoid population, but they have also demonstrated the number of 
mtDNA/nucleoids relative to both the size and number of fragments within the mitochondrial 
network. Our data indicate a severe depletion of mtDNA/nucleoids coupled with excessive 
mitochondrial fragmentation in DOA+ primary myotubes. Quantification of 
mtDNA/nucleoids relative to the total length and number of fragments within the 
mitochondrial network also showed this depletion in the DOA+ mitochondrial network. No 
significant difference in nucleoid number per total fragments or total mitochondrial length 
was detected in either OA or WFS1 primary myotubes. Quantifying mtDNA number by this 
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technique is more semiquantitative than RTqPCR, however, RTqPCR analysis conducted by a 
colleague subsequenct to this analysis in myoblasts confirmed a trend for mitochondrial 
depletion (unpublished). 
Quantification of the percentage distribution and size of nucleoid foci and statistical 
analysis using a Mann-Whitney test for non-normal distribution indicated there was no 
disruption of nucleoid morphology (clumping) found in DOA+, OA and WFS1 myotube 
groups. A decrease in the number of detectable nucleoids without a shift in nucleoid 
distribution (clumping) was noted in primary fibroblasts with Alpers syndrome (Ashley et al., 
2008). This may indicate that DOA+ mtDNA/nucleoids may generally deplete by a similar 
mechanism. The existence of this mechanism warrants further investigation. A second 
hypothesis to explain this observation includes the topological status of these mtDNA 
molecules. He and Colleagues observed a decrease of the cytochemical Quant-iT™ 
PicoGreen® staining upon silencing of ATAD3 (He et al., 2007). They concluded that 
although Quant-iT™ PicoGreen® is a useful cytochemical stain for marking mtDNA, the 
signal intensity is dependent on whether the mtDNA molecule is present in a relaxed or 
supercoiled state. A relaxed mitochondrial state results in a greater uptake of Quant-iT™ 
PicoGreen® and produces a signal of greater intensity, whereas supercoiled mtDNA 
molecules do not take up Quant-iT™ PicoGreen® as efficiently and therefore, they produce a 
lower intensity stain. Further investigation would require separation and identification of 
topoisomerases through a 1D or 2D agarose gel electrophoresis which would determine the 
supercoiled state of mtDNA in a qualitative manner. Overall, it may be that OPA1 mutations 
lead to a disruption of mtDNA structure, which could have consequences for both 
mitochondrial transcription and replication rates. Both hypotheses suggest a defect in mtDNA 
homeostasis. 
 Analysis of mtDNA/nucleoid distribution in individual myotube lines found both mild 
clumping and a reduction in the total number of mtDNA/nucleoids in MyoDOA+(2). 
Mitochondria found in this line were significantly larger than controls, with longer average 
length and volume, consistent with possible swelling. This clumping and abnormal 
mitochondrial morphology may be due to an impairment of fusion caused by abnormal OPA1 
processing and further investigations are needed. Impaired mitochondrial fusion in MEFs has 
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previously been linked with altered nucleoid distribution and morphology, and these 
abnormalities likely contribute to the observed mtDNA depletion (Chen et al., 2007). 
Our results are also consistent with the work by Elachouri and colleagues who showed 
a skew in mtDNA/nucleoid distribution towards a subpopulation of nucleoids with higher 
fluorescent intensity, indicative of either an increase in nucleoid size or nucleoid clumping in 
OPA1 exon 4b silenced Hela cells. These observations also agrees with the overexpression of 
TFAM or Twinkle which has been attributed to an increase of nucleoid size, however this 
increase in Quant-iT™ PicoGreen® fluorescence may also be a consequence of a shift in 
distribution towards increased clumping.   
Analysis of WFS1 myotubes, as a disease control, showed no significant difference in 
the number of nucleoids with respect to each mitochondrial fragment or with respect to the 
total mitochondrial length. Therefore, it would appear that, at least for this WFS1 primary 
myotube line, the c.409_424dup16 mutation does not have a direct effect on mitochondrial 
fragmentation or nucleoid distribution within the network. 
 
5.4.3 Conclusion 
Consisent with our previous study using patient-derived OPA1 fibroblasts, mitochondrial 
fragmentation was more pronounced in DOA+ patients. This was accompanied by a decrease 
in mitochondrial DNA objects suggesting a depletion in nucleoids/mitochondria along the 
mitochondrial network, and this could possibly be due to an impairment of fusion. This 
observation emphasises the biochemical disparity between the dominant-negative effect of 
OPA1 misense mutations compared with mutations, such as deletions and slice site mutations, 
which result in haploinsufficiency. Interestingly, myotubes derived from a patient carrying a 
pathogenic WFS1 mutation (c.409_424dup16) did not display aberrant mitochondrial 
morphology or nucleoid distribution when compared with controls. This would indicate that 
the pathogenic mechanisms linked to this specific WFS1 mutation is not directly related with 
impaired mitochondrial dynamics or abnormal nuceloid distribution within the mitochondrial 
network. 
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Chapter 6  
 
 
 
      Novel Homozygous OPA1 Mutation in a 
……..Consanguineous Israeli Family  
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6.1 Introduction 
Infantile mitochondrial encephalopathy and congenital hypertrophic cardiomyopathy are 
defined as a group of primary mitochondrial heterogenous disorders which present with 
severe OXPHOS impairment primarily in patient neuronal tissue (cerebellum, spinal cord, 
brain stem, thalamus, basal ganglia) but also in heart and liver. These disorders usually 
manifest either in the prenatal stage or in the first year of life and can manifest with severe 
neurological, hepatic and respiratory disturbances (Uziel et al., 2011). Individually rare, 
disorders of the OXPHOS system affect up to 1 in 5,000 individuals in the European 
population (Thorburn et al., 2004).  
The underlying genetic aetiology of these disorders is complex with many pathogenic 
variants recently discovered in both mitochondrial and nuclear encoded OXPHOS subunits, 
assembly factors of OXPHOS, factors which affect mtDNA replication and maintenance and 
factors involved in mitochondrial translation (Table 6-1). Pathogenic variants which affect 
mtDNA replication and maintenance have been shown to either cause a severe depletion of 
mtDNA copy number or a proliferation of mtDNA deletions associated with an inherent error 
in replication (Naviaux et al.,1999; Naviaux and Nguyen, 2004; Spinazzola et al., 2006; 
Elpeleg et al., 2005; Ghezzi et al., 2010; Goto et al., 1990; Hammans et al., 1991; Silvestri et 
al., 1993). This disruption of mtDNA maintenance can have a deleterious effect on the 
efficiency of OXPHOS to produce chemical ATP energy. Given the fact that approximately 
1,500 proteins are believed to be within the mitochondria and contribute to its function (Lopez 
et al., 2000), eliciting the underlying pathological variants of these conditions can be a clinical 
challenge. 
A novel homozygous OPA1 variant, c.1601T>G (p.Leu534Arg), was identified in two 
affected sisters from a consanguineous family of Arab-Muslim origin using a combination of 
homozygosity mapping (performed with an Affymetrix Gene-Chip Human Mapping 50k Xba 
array and a Gene-Chip Human Mapping 250k MspI array) to identify regions of genomic 
homozygosity and whole exome analysis (Hiseq 2000, mean coverage depth x65.9) to 
identify any potential pathogenic variants in these regions. The c.1601T>G OPA1 variant has 
not been previously reported in the 63,000 exome sequences found in the Exome Aggregation 
Consortium (ExAC) and it was not detected in 120 in-house controls. The two sisters 
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presented with similar neurological defects including optic atrophy, failure to thrive, 
neuromuscular weakness, cardiomyopathy and a fatal mitochondrial encephalopathy. Both of 
them died within 12 months after birth. 
Previous biochemical exploration of these sisters obtained from a collaboration with 
Dr. Ann Saada and Dr. Ronen Spiegel revealed elevated serum alanine and lactate levels 
detected in both patients, indicative of a metabolic disorder. COX/SDH histopathological 
staining of muscle biopsy did not reveal any COX deficiency.  Transmission electron 
microscopy (TEM) provided evidence of a defect in mitochondrial  inner mitochondrial 
fusion (Figure 6-1) and complex activity of mitochondrial OXPHOS demonstrated a marked 
global decrease, which was more severely depressed for complexes I and IV (Table 6-2). This 
disruption of OXPHOS may have a pathological impact on tissues with high energy 
consumption (nervous, cardiac, hepatic and retinal), as represented by the symptoms. 
 In this study, I further investigated the pathogenic nature of this novel homozygous 
OPA1 variant, c.1601T>G (p.Leu534Arg) as the likely cause of the fatal clinical phenotype in 
these two affected sisters. 
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Figure 6-1 Mitochondrial ultrastructure imaged using transmission electron microscopy 
of patient III-4 muscle biopsy. 
Enlarged mitochondria with a fusion defect were detected in patient III-2 (A) and (B). 
Irregular mitochondrial ultrastructure in the IMM of patient III-2 (B) Electron microscopy 
image obtained from collaboration with Drs Ronan Spiegal and Ann Saada 
Figure reproduced from Spiegel, Saada, Flannery et al., 2016, supplementary material. 
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Disease  OXPHOS Complex Affected Genotype 
 Infantile-onset spinocerebellar ataxia 
 
  
Leigh Syndrome  I MTND2,MTND3,MTND5, MTND6 
    NDUFS1,NDUFS3,NDUFS4,NDUFS7,NDUFS8,NDUFA2,NDUFV1,NDUFAF2 
    C8ORF38, C200RF7, FOXRED1 
  II SHDA 
  III UQCRQ 
  IV COX10,COX15, SURF1,TACO1 
  V MTATP6 
  Multiple complexes C12ORF65,EFG1 
   
French-Canadian Leigh Syndrome IV LRPPRC 
Leuko-encephalopathy I NDUFV1, NUBPL 
  II SDHAF1 
  IV COX6B1, SURF1 
  I,III TUFM 
  I,III,IV EARS2 
 Leuko-encephalopathy with Ataxia I MARS2 
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Disease  OXPHOS Complex affected Genotype 
Encephalo-cardiomyopathy     
Encephalo-cardiomyopathy I NDUFS2, NDUFV2, NDUFA11,NDUFAF4, ACAD9 
  II SDHA 
  III MTO1 
  IV SCO2,COX15 
      
Cardiomyopathy V TMEM70, SLC25A3 
  Unknown DNAJC19, TAZ 
 Hepatoencephalopathy 
 
  
Hepatoencephalopathy I  Twinkle 
  IV SCO1 
  Multiple Complexes EFG1 
   
Alpers-Huttenlocher Syndrome I,III,IV POLG1, MPV17, DGOUK,FARS2 
 
Table 6-1 Causative genes identified in patients with mitochondrial OXPHOS disorders.  
Table adapted from Uziel et al., 2011.  
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Assay  Patient III-2 Patient III-4 Controls±SD (n=50) 
Complex I  0.047 (24%) 0.050 (25%) 0.199±0.043 
Complex I+III 0.087 (40%) n.d. 0.217±0.599 
Complex II 0.099 (64%) 0.091 (59%) 0.154±0.024 
Complex II+III 0.100 (65%) 0.053 (34%) 0.153±0.039 
Complex III 0.934 (46%) n.d. 2.01±0.40 
Complex IV 0.270 (21%) 0.230 (22%) 1.03±0.24 
Complex V  0.151 (44%) n.d. 0.34±0.096 
    
Table 6-2 Measurement of enzymatic activities of the OXPHOS system in Patient III-2, 
III-4 and control tissue  
mU/U citrate synthase (% of control levels); n.d.-not determined. Data from OXPHOS 
complex activities obtained from the collaboration with Drs Ronan Spiegal and Ann Saada 
Table data reproduced from Spiegal, Saada, Flannery et al., 2015. 
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6.2 Materials and Methods 
6.2.1 Family history 
Two consanguineous female patients of Arab-Muslim origin were investigated. Patient III-2 
was born prematurely at 35 weeks. She presented with multiple episodes of hypotonic, 
opisthotonic posturing, weak cry and abnormal eye pursuits. Progression was characterised 
with a failure to thrive and severe neurodevelopmental delay. Following the onset of 
hypertrophic cardiomyopathy, the patient died at 10 months of age from an apnoeic episode. 
Patient III-4 was born at term but quickly developed (within 2 days) generalised 
hypotonia and opisthotonic postering. Echocardioraphy detected a thickening of the left 
ventricular myocardium. Disease progression was again characterised by a failure to thrive, 
hypertrophic cardiomyopathy, neurodevelopmental delay, muscle wasting and sensorineural 
deafness. Opthalmological investigation conducted at 6 months revealed a mild disc pallor 
and electrophysiological investigation showed weakened visual-evoked potentials indicative 
of degeneration.The patient died at 11 months of age from an apnoeic episode. 
The parents are first degree cousins with no apparent neurological or visual disruption. 
Exome sequencing analysis revealed that both sisters had a homozygous OPA1 variant 
(c.1601T>G; p.Leu534Arg). Further analysis confirmed that each parent and the two brothers 
carried this heterozygous OPA1 variant but were apparently healthy. The mode of inheritance 
appears to be recessive with no other known affected family members (Figure 6-2). 
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Figure 6-2: Pedigree from Israeli family with suspected pathogenic OPA1 mutation   
Affected family members are coloured in black. Parents are first-degree cousins of Arab-
Muslim origin. Individuals III-2 and III-4 are affected daughters with the homozygous 
c.1601T>G (p.Leu534Arg) OPA1 variant.  
 
6.2.2 Protein extraction from Muscle Tissue 
Muscle biopsies were performed at 11 months and 1 month of age in patient III-2 and III-4, 
respectively. Protein was extracted from muscle homogenates from patient III-2 and four 
biological controls (four females aged between 19-23 years old).  
6.2.3 Western blot analysis 
Western blot analysis was conducted as described in Section 3.3. Briefly, 25µg of protein was 
loaded onto each lane from four control muscle homogenates and muscle homogenate from 
patient III-2. Following SDS-PAGE and blotting protein transfer, PVDF membrane was 
probed for OPA1 and GAPDH (1:1000 dilution) for 1 hour at room temperature. Membrane 
was incubated with secondary anti-mouse antibody (1:1000) for 1 hour / room temperature 
and visualised using biospectrum 500 imaging system. Densitometric analysis of western blot 
bands was conducted using ImageJ.  
(I) 
(II) 
(III) 
I-1 I-2 I-3 I-4 
II-1 II-2 
III-1 III-2 III-3 III-4 
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6.2.4 DNA extraction from Muscle Tissue 
DNA was extracted from muscle tissue from patients’ III-2, III-4 and two biological controls 
(two females aged between 19-20 years old) using the protocol described in Section 3.5.2.  
6.2.5 mtDNA multiple deletion measurement  
To investigate the presence of multiple mtDNA deletions in patient and control samples a 
11kb long range PCR was conducted with the TaKaRa LA TaqTM pcr system on DNA muscle 
homogenate as described in Section 3.12. 
6.2.6 Real-Time PCR analysis of mtDNA copy number 
The mtDNA copy number quantification in control and patient tissue was investigated using a 
qPCR (ND1/B2M) assay as described in Section 3.10. The assay was used to quantify 
mtDNA content in two patients (Patient III-2 and Patient III-4) and two controls from 
extracted muscle biopsy. These two control muscle biopsies were gender-matched and the 
youngest muscle biopsies in storage were used for quantification with a mean age of 20 years. 
Real-time quantification of mtDNA was conducted in triplicate. 
6.2.7 Conservation analysis and pathogenicity scoring 
To determine if the leucine residue was evolutionarily conserved, the OPA1 amino acid 
sequence from a select group of outlying species was chosen for alignment. These sequences 
were acquired from the National Centre for Biotechnology Information (NCBI) protein 
database. In each case, OPA1 isoform 1 was chosen for alignment. These sequences were 
imported and aligned with BioEdit Sequence Alignment Editor (Obtained from 
http://www.mbio.ncsu.edu/bioedit/bioedit.html ) 
6.2.8 Modelling of OPA1 protein structure  
Homology modelling was performed between residues 220-960 of human OPA1 (gi 
18860834 ref NM.130833.1) based on the closest known structural homologue of OPA1 (June 
2015), Interferon-Induced GTP-binding protein MX2: FFAS Score -82.7, sequence identity 
16% (http://ffas.sanfordburnham.org/ffas-cgi/cgi/ffas.pl) This template was modelling with 
SCWRL server (http://www1.jcsg.org/scripts/prod/scwrl) with settings set to default. 
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Mutagenesis of p.Leu534Arg in protein model and illustration of GTP-binding domain of 
OPA1 was performed manually using PyMOL (Delano Scientific).  
6.2.9 Statistical Analysis 
Unpaired Student’s t-test was performed using Graphpad prism version 5.0 for windows, 
Graphpad software , San Diego California USA, www.graphpad.com 
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6.3 Results 
6.3.1 Conservation of OPA1 p.Leu534Arg residue 
A multiple sequence alignment was generated to determine the evolutionary conservation of 
OPA1 p.Leu534Arg relative in six other outlying species (Figure 6.3). The leucine amino 
acid appears to be highly conserved in both mammalian and lower invertebrate species. 
Evolutionary divergence occurs in yeast (S. Cerevisiae and S. Pombe) indicating that this 
mutated region of OPA1 has been conserved since early evolutionary history and may impart 
an important structural or functional role. 
 
 
 
 
 
 
Figure 6-3 Multiple Sequence Alignment of OPA1 protein 
Multiple sequence alignment of OPA1 gene region (residue Ala495- Lys568) with suspected 
pathogenic OPA1 missense variant in different species. The black rectangle indicates the 
position of the missense variant p.Leu534Arg in Homo sapiens and six other outlying species. 
Sequences were aligned using BioEdit Sequence Alignment Editor. 
6.3.2 Pathogenicity scoring of OPA1 p.Leu534Arg variant  
Pathogenicity scoring is an in silico method used to predict the likelihood of a genetic variant 
to result in a pathological change which may be responsible for a disease phenotype. This in 
silico analysis was applied to the Leu534Arg OPA1 mutation with online pathogenicity 
software ‘Mutation Taster’ and ‘SIFT’ (Sorting Intolerant from Tolerant). Both pathogenicity 
programs predicted a disease causing pathogenic variant for p.Leu534Arg with a Mutation 
Taster prediction of ‘disease causing’ with a probability of 0.999 and SIFT prediction of 
‘Damaging’ with a score of 100% (Table 6-2).  
Ala-495 Lys-568 Leu534Arg GTPase catalytic domain 
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Program Score 
Mutation Taster Disease causing; probability 0.999 
SIFT Damaging; Score 100% 
  
Table 6-3 Pathogenicity Scoring of OPA1 variant 
OPA1 variant p.Leu534Arg pathogenicity report generated by online software Mutation 
Taster and SIFT. 
 
6.3.3 Modelling of OPA1 p.Leu534Arg mutant protein 
A theoretical model of OPA1 protein was generated to illustrate any structural changes which 
may occur as a consequence of the pathogenic p.Leu534Arg mutation. This OPA1 model was 
created by first using the FFAS server to identify the most structurally homologous protein to 
OPA1 and then modelled using the SCWRL online modeller with default settings, and 
manipulated using PyMol (Delano Scientific). The L534 residue (white) is in close proximity 
to the GTP binding domain of OPA1 (red). The missense change to Arginine introduces a 
much larger and more polar amino acid to this site which may result in structural instability 
near this GTP binding domain (Figure 6-4). 
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Figure 6-4 In Silico Modelling of OPA1 
(A) Modelling performed by Devorah Soiferman (Professor Ora Sheuler-Furman’s 
collaboration, Isreal) which illustrates the proximity of the L534 residue (white) to the GTP-
binding domain (multi-coloured) The GTP domain binding site is illustrated in magenta. 
Modelling was performed using I-tasser server (Yang et al., 2015). The template for 
modelling was derived from Yan et al., 2011b; (B) Homologous modelling performed by 
Padraig Flannery (Dr Yu-Wai-Mans lab)  of OPA1 protein using the ‘Fold and Functions 
Assignment System (FFAS)’ server to determine the most structurally homologous protein to 
OPA1 (Interferon –Induced GTP-binding protein MX2 (FFAS Score -84; Seq Id: 15%) to use 
as model. SCWRL modeller and PyMol for generation of protein model and manual 
manipulation of image. White spheres illustrate the position o f the L534R variant , red 
spheres illustrate the relative position of the catalytic GTPase domain (C) maginified position 
(A) (B) 
(C) (D) 
L534 L534 
L534 L534R 
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of the L534 residue in wild-type OPA1 (D) Magnified position of the L534R residue in 
mutated OPA1 protein.  
 
6.3.4 Proband OPA1 protein expression 
Western blot analysis was conducted on muscle homogenate from patient III-2 and four 
biological controls (age approximately 20 years old). Blotting of patient III-4 could not be 
conducted due to limited sample size. Analysis revealed a significant reduction of OPA1 
protein levels (p≤0.05) compared with controls indicating that the c.1601T>G; p.Leu534Arg 
change resulted in a marked decrease of OPA1 expression in muscle tissue (Figure 6-5). 
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Figure 6-5 Western blot analysis conducted between patient III-2 and controls. 
Representative western blot analysis of OPA1 normalised against GAPDH and mean of four 
biological controls (A). Quantification analysis performed in three independent experiments 
on patient muscle with three females and one male muscle controls aged between19-23. 
Control in green bar and patient value in purple bar are shown. Error bars represent standard 
error of the mean. An unpaired Student’s t-test was used in statistical comparison between 
patient and controls (* p < 0.05)(B). 
 
 
 
Ctrl1 Ctrl2 Ctrl3 Ctrl4 III-2 
OPA1 
GAPDH 
90-100kDa 
37kDa 
(A) 
(B) 
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6.3.5 MtDNA copy number analysis 
Investigation of mtDNA copy number in patient muscle tissue was conducted using a real-
time PCR assay to measure the ratio of mtDNA (ND1 gene) relative to Nuclear DNA (B2M 
gene). Analysis was conducted from the muscle homogenate of two negative controls (age 
approximately 20 years old) and two patients (patient III-2, Patient III-4). A significant 
mtDNA depletion (78% in both affected sisters) was detected in both affected patients relative 
to controls (p<0.0001) (Figure 6-6) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-6 Comparison of mtDNA copy number between OPA1 patients and controls 
mtDNA copy number was assessed using real-time PCR measuring ND1 mtDNA gene copy 
number and normalised to nuclear B2M gene. Controls: n=2 ); OPA1 Patients:  Patient III-2 
and Patient III-4. Error bars represent standard error of the mean. Statistical analysis 
performed with Student’s unpaired t-test (**** p < 0.0001).  
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6.3.6 mtDNA deletion analysis 
To determine if the reduction of OPA1 protein levels may result in the accumulation of 
mtDNA deletions which may lead to an inhibition of OXPHOS, a long-range PCR was 
conducted in muscle tissue to detect alternative mtDNA species at a lower molecular weight 
than the wild-type molecule (16,569 bps). Analysis was performed on three controls (two 
negative controls (lane 1 and 2) and one positive control (lane 3)) and both patients (patient 
III-2, patient III-4). Fig 6.4. Amplification of patient mtDNA revealed no additional mtDNA 
species other than wild-type amplicon (11kbs). This indicates that there are no mtDNA 
deletions detected in patient mtDNA (Figure 6-7). 
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Figure 6-7 Long-range PCR of mtDNA derived from control and patient muscle 
homogenates 
Long range PCR amplification products of human muscle mtDNA. Forward primers nt6222-
6240 and reverse primers nt16122-16153 of mtDNA yielded an amplicon of 11kbs. Lane 1 
and 2 are amplicons of negative control mtDNA from muscle homogenate. Lane 3 is an 
amplicon of mtDNA from a multiple deletion positive control. Lane 4 and 5 are amplicons 
from patients III-2 and III-4. 
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6.4 Discussion 
Two sisters of Arab Muslim origin were diagnosed with fatal mitochondrial encephalopathy 
and congenital hypertrophic cardiomyopathy. Due to a family history of consanguinuity, these 
patients were investigated using a combination of homozygosity mapping and whole-exome 
sequencing analysis which highlighted a novel homozygous variant (p.Leu534Arg) in the 
OPA1 gene.  
To further confirm OPA1 involvement in the syndrome, both in silico and biochemical 
analyses were carried out. Bioinformatic analysis of OPA1 sequence conservation indicated 
that the p.Leu534Arg change occurred in a highly conserved region of OPA1 within the 
GTPase domain. Variants which display a high degree of evolutionary conservation are likely 
to impart an important structural or functional role and are more likely to be deleterious than 
variants within regions without evolutionary constraint. This was confirmed using online 
pathogenicity software Mutation taster2 and SIFT, which predicted the OPA1 change to be 
highly likely pathogenic.   
Significantly reduced levels of OPA1 protein in patient III-2 muscle biopsy suggested 
that the homozygous p.Leu534Arg may have deleterious effects on the protein function and/or 
structure. Dysfunction of OPA1 is demonstrated through abnormal IMM fusion and 
ultrastructure detected through TEM analysis (Figure 6-1). Although not located strictly 
within the GTPase domain, modelling of the OPA1 protein illustrated the proximity of the 
mutated residue to the GTPase domain. Pathogenic missense variants found in the GTPase 
domain of OPA1 are typically associated with a more severe form of DOA with extra-ocular 
features which include sensorineural deafness, ataxia, myopathy and peripheral neuropathy 
(DOA+). Novel OPA1 GTPase variants have also been found which extend the clinical 
spectrum of DOA+ by presentation with oththalmoplegia, ptosis, polyneuropathy and PEO 
(Liskova et al., 2013; Zeviani et al., 2008; Hudson et al., 2008). This illustrates how the 
pathological disruption of OPA1 may lead to complex multisystemic neurological disorders. 
(Liskova et al., 2013). The severe clinical phenotype of these two patients would appear to be 
consistent with these previous observations.  
Dysfunction of mtDNA replication in encephalopathy can manifest as either depletion 
in mtDNA copy number or the accumulation of mtDNA deletions which may lead to a 
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proliferation of mutated mtDNA copies. Both of these mechanisms may explain the 
generalised dysfunction of the OXPHOS system. Previous investigation of patients with 
OPA1 defect and broad multisystemic features found in DOA+ have shown the accumulation 
of mtDNA mutations to be an important pathogenic mechanism responsible for this broad 
symptomatic spectrum (Amati-Bonneau et al., 2008; Husdon et al., 2008). Our patients, 
however, did not harbour multiple mitochondrial deletions. This could be linked to the 
premature age of fatality of these two patients (under 1 year-old). Indeed, the accumulation of 
mtDNA deletions at detectable levels is often not observed before adolescence (Elpeleg et al., 
2002).  
Despite no mtDNA deletions detected, investigation of both affected sisters revealed a 
striking depletion of the mtDNA copy number (78% reduction). A marked depletion of 
mtDNA is typical in cases of infantile mitochondrial encephalopathy because multiple 
mtDNA deletions which are also known to underpin these disorders, are first required to 
clonally expand before they reach a threshold in the mtDNA population sufficient for a 
clinical presentation within an affected tissue (Elpeleg et al., 2002; Stewart and Chinnery, 
2015).  This may be linked to the recently observed role of OPA1 in mtDNA replication 
(Elachouri et al., 2011). Elachouri and colleagues demonstrated that isoforms of OPA1 which 
contain exon 4b have a role in anchoring the mitochondrial nucleoid to the IMM, a necessary 
step for mtDNA replication (Elachouri et al., 2011). This was supported by siRNA 
knockdown of OPA1 in Hela cells and isolated rat RGCs which resulted in a depletion of 
mtDNA and a partial inhibition of OXPHOS (Kushnareva et al., 2013).  
The suggested mechanism for OPA1 pathogenicity in this mitochondrial 
encephalopathy may consist of a multi-prolonged attack to reduce OXPHOS efficiency. The 
decrease in structural stability and potential decrease in GTPase activity induced by the 
p.Leu534Arg change may hamper mtDNA maintenance, disrupt cristae structure as revealed 
by TEM and supported by siRNA knockdown of OPA1 (Kushnareva et al., 2013) and disrupt 
OXPHOS complex assembly (Zanna et al,. 2008; Cogliati et al., 2013). Dysregulation of 
cristae may also promote the release of pro-apoptotic factors such as cytochrome c which may 
contribute to fatal encephalopathy and cardiomyopathy. Recent investigation of an OPA1 
mouse model support the involvement of pathogenic OPA1 variants which contribute to 
mtDNA instability and late-onset cardiomyopathy (Chen et al., 2012).  
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Investigation of OPA1 during embyogenesis in zebrafish has revealed its requirement 
for normal development (Rahn et al., 2013). In parallel, a previous homozygous OPA1 mouse 
model, introducing an OPA1 protein truncation in all four OPA1 transcripts was developed by 
Chen and colleagues (2012). It was hypothesised to lead to a complete reduction of OPA1 
expression and, consequently, embryonic lethality further reinforcing OPA1 involvement in 
development. The presence of a homozygous missense variant rather than a nonsense 
mutation may explain why this variant persisted to the post-natal stage. The rarity of 
pathological homozygous OPA1 variants is highlighted by the fact that this is the first 
recorded case found in the general population. 
 In addition to being the first report of OPA1 homozygosity, these two cases have 
broadened the clinical spectrum of OPA1-inherited disorders to include infantile 
mitochondrial encephalomyopathy and cardiomyopathy. It also further highlights the 
diagnostic power of whole-exome analysis for patients with molecularly undefined genetic 
disorders. 
 
The collaborative work presented in this chapter has been published in the Journal of Medical 
Genetics. 
 
Spiegel, R. Saada, A., Flannery, P.J., Burté, F., Soiferman, S., Khayat, M., Eisner Sagüés, 
V., Vladovski, E., Taylor, R.W., Bindoff, L.A., Shaag, A., Mandel, H., Furman, O., Shalev, 
S.A., Elpeleg, O., Yu-Wai-Man, P. Fatal infantile mitochondrial encephalomyopathy and 
hypertrophic cardiomyopathy associated with homozygous OPA1 mutations. J Med Genet. 
2016;53(2):127-31. 
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Whole-Exome Analysis of a Patient Cohort with 
Inherited Optic Atrophy 
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7.1 Introduction  
In recent years, the advancement of next-generation sequencing (NGS) technologies has 
allowed the development of a useful tool in the diagnostic assessment of patient genetic 
disorders (Shashi et al., 2014; Liew et al., 2013; Lee et al., 2014; Yang et al., 2013, 2014). 
This has been especially possible given decreased costs, increased speed of sequencing and 
increased shared annotation of genetic variants (Jamuar and Tan, 2015). NGS can be defined 
as either a whole-genome sequencing (WGS) or whole-exome sequencing (WES) technology. 
For WGS, patient DNA is extracted and isolated to determine the complete sequence 
of the genome. This sequence is aligned and compared against a reference sequence and the 
variants are annotated to identify distinct mutations in a patients’ genetic code. This WGS 
analysis may typically identify three to four million variants in an individual patient 
(Biesecker et al., 2012). A search algorithm can also be implemented to determine if any 
distinct variants are known to be disease causing (Rizzo et al., 2012). However, even after this 
bioinformatic analysis, there may be hundreds of false positive disease causing variants 
identified.  
WES is similar to WGS except that sequencing and analysis is confined to exons 
which collectively compose the exome. The exome represents only 1% of the whole genome. 
The rationale behind WES to analyse the genetic code lies in the observation that 85% of 
known disease causing genes are located in the exome, which may represent an enriched 
subset of the genome containing pathogenic variants (Botstein et al., 2003; Majewski et al., 
2011). Similar to WGS, sequences from these exons are aligned against a reference and 
variants annotated to identify disease causing mutations. Approximately 10,000 or more 
variants may be identified in an individual exome (Rabbani et al., 2014). This may increase 
the efficiency of identifying the underlying aetiology of a genetic disorder.  
To conduct NGS analysis, genomic DNA is typically extracted from patient blood to 
undergo library preparation and whole genome or targeted exon capture using an appropriate 
kit. Samples are subsequenctly sequenced using a next generation sequencing platform to 
generate raw sequence reads of the exome in the form of FASTQ files of each patient sample.  
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FASTQ files are then transferred to an in-house bioinformatics team who process this 
data using an established in-house pipeline for (1) sequence quality control, (2) alignment to a 
genetic reference and (3) annotation. These processes are briefly described in Section 7.2. 
This pipeline generates an excel-tabulated format of the analysed sequencing data for further 
clinical and genetic analysis. 
In silico analysis of novel variant pathogenicity is conducted with publically available 
online pathogenicity softwares. SIFT is an algorithm designed by Kumar and colleagues 
(2009) which predicts potential pathogenicity of detected variant by identifying evolutionary 
constrained regions through sequence homology with the PSI-BLAST algorithm. SIFT then 
compiles an alignment of these homologous sequences and calculates the effect of every type 
of amino acid substitution at a particular position on protein function. It then uses this 
information to predict if a specific mutation is pathogenic.  
Polyphen-2 is another online algorithm developed by Adzhubei and colleagues (2010) 
which was designed to predict the pathogenicity of missense mutations. The algorithm uses 
eight sequence-based and three structure-based modes of prediction. The mutant and wild-
type alleles are compared to each other and a set of parameters are applied to multiple 
homologous sequence alignments (MHSA). These parameters include the probability of this 
variant allele arising from a polymorphism which is determined from amino-acid changes in 
these MHSA and how different the human protein is from the closest evolutionary divergant 
protein. The hypermutability of the site is also accounted for when predicting pathogenic 
probability. Finally, functional impact of this mutant allele is calculated using a naïve Bayes 
classifier (Bayes classifier is a machine learning classifier based upon Bayes mathematical 
model of probability assessment).  
Mutation taster is a third pathogenecity algorithm developed by Schwarz and 
colleagues (2014) designed to not only identify pathogenic variants which create alternative 
amino acid sequences but also predict pathogenicity of synonymous variants and variants in 
intronic regions. MutationTaster 2 also contains publically available SNP and indel data 
generated from the 1,000 genomes project (Abecasis et al., 2010), ClinVar (Landrum et al., 
2014) and HGMD (Human Gene Mutation Database) (Stenson et al., 2014).  An annotated 
variant can be categorized as neutral if it has been detected in a homozygous state more than 
four times within either the 1,000 genomes or HapMap databases. If the variant is already 
 194 
 
known to be pathogenic, this information can be retrieved from the ClinVar database. Similar 
to SIFT and Polyphen-2, MutationTaster2 scores the pathogenicity of a variant based on 
evolutionary conservation of the surrounding region and uses a number of integrated analyses 
based on genetic regulatory elements. In addition, the algorithm approximately predicts the 
pathogenicity of splice site defects only at known intron-exon boundaries. MutationTaster2 
improves upon older versions of MutationTaster by investigating variants at intron-exon 
junctions. Similar to these previous versions, MutationTaster2 uses a Bayes classifier to create 
genetic variant predictions. 
In the present study, WES analysis was performed on a cohort of fourteen patients 
(Ten females and four males), all clinically diagnosed with optic atrophy with ages ranging 
from 20-79 years. The underlying genetic aetiology of this cohort was unknown and previous 
mutation screenings performed in-house have excluded these patients for OPA9 and OPA1 
pathogenic variants. The overall aim of the study was to use WES analysis as a tool to explore 
the genetic aetiology underpinning this cohort of patients diagnosed with either pure optic 
atropy or optic atrophy associated with other systemic features which afflict the central or 
peripheral nervous systems. 
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7.2  Materials and Methods  
7.2.1 Assessment of appropriate control datasets for whole exome analysis 
To identify the most appropriate control exome database for WES analysis of this patient 
cohort, individual samples were filtered using a defined minor allele frequency (MAF) 
threshold of 5% to quantify the number of potential variants that were not found in control 
exomes: 1000 Genome Project, the National Heart, Lung and Blood Institute Exome 
Sequencing Project 6500 (http://evs.gs.washington.edu/EVS/), and the CG69 dataset 
(Abecasis et al., 2010, Drmanac et al., 2010) (Table 7-1).  This analysis demonstrated which 
databases contained the most variants found within the British population. The 1000 genomes 
project had the greatest number of variants in our patient cohort whereas the ESP6500 dataset 
had the least number of variants. 
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Table 7-7-1 Calling of variants in published databases for each individual patient. 
              
  
PFC-340 PFC-341 PFC-342 PFC-344 PFC-345 PFC-346 PFC-347 PFC-348 PFC-349 PFC-350 PFC-351 PFC-352 PFC-353 
Exonic/Splicing/non-synon 10912 10728 10862 10950 10812 10716 10844 9819 10866 11028 12091 11220 11141 
Not in ESP6500 2292 2188 2219 2182 2226 2169 2224 1516 2194 2304 2667 2260 2386 
Not in 1000G 996 986 948 962 1003 983 994 833 1003 1014 1385 1047 1295 
Not in CG69 1492 1467 1420 1470 1504 1469 1494 1323 1508 1506 1933 1547 1697 
Not in ESP6500, 1000G, 
CG69                           
Dominant  1368 1361 1396 1351 1434 1350 1347 1311 1398 1415 2272 1846 1561 
Recessive  201 168 146 181 164 181 199 182 176 186 191 155 188 
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The number of single nucleotide polymorphisms (SNPs) and their relative frequency in each 
database were then analysed by Dr. Gavin Hudson to determine the most appropriate 
databases to use for data filtration of the excel tabulated pipeline output. 
 
 
 
 
 
 
 
 
 
Figure 7-1 Distribution of variant frequency in the 1000 genomes project, ESP6500 and CG69.  
Comparison of these datasets highlighted a tight linear concordance of variant frequency (A) 
between the ESP6500 and the 1000 Genomes dataset. However when comparing variants 
between the 1000 genomes dataset and CG69 (B), there was a skew in the frequency of 
detected polymorphisms which highlight underlying differences either in the analysis and 
annotation pipelines used to generate these variants and/ or genetic frequency stratification 
between the populations used in these projects.  
 
A skew in the frequency of detected polymorphisms was observed when comparing the CG69 
and the ESP6500 datasets, whilst the ESP6500 and 1000 Genomes projects showed a linear 
relationship (Figure 7-1). Consequently, for analysis of my patient cohort, it was determined 
that the 1000 genomes project and the ESP6500 were to be used as a reference population for 
intersection filtering of genetic variation generated as an excel tabulated output from the WES 
in-house pipline.  
 
(B) (A) 
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7.2.2 Whole exome capture, alignment and annotation 
Patient genomic DNA was previously isolated from whole blood 
(DNeasy®,Qiagen,Valencia,CA) for whole exome analysis and outsourced to AROS ( AROS 
Applied Biotechnology A/S, Aarhus, Denmark) where DNA underwent library preparation 
and enrichment with a Nextera Rapid Capture Expanded Exomes Kit ( Illumina Inc., San 
Diego, USA). This kit includes greater than 340,000 95mer probes designed using the hg19 
reference genome (Manolio et al., 2009). It allows greater coverage of exons and includes 
sequencing data in surrounding non-coding regions (UTRS and miRNA binding sites). Raw 
sequencing data was generated with an Illumina HiSeq2500 platform in the form of a FASTQ 
file (Illumina Inc., San Diego, USA). The quality of these sequences was analysed using 
‘FASTQC’ and sequences deemed low quality are removed (reads with poly-N tail). High 
quality reads were then input into a WES pipeline for data processing before the final results 
were generated in excel format. 
  
7.2.3 GATK and Freebayes in-house pipelines 
These in-house pipelines were designed by the in-house bioinformatics team for WES 
analysis. Briefly, sequence reads were aligned to UCSC hg19 with the (Barrows-Wheeler) 
aligner (BWA) (Li and Durbin, 2009) and variants were detected with either the GATK or 
Freebayes callers using filtering parameters as defined by GATK Best Practise 
Recommendations. Detected variants were annotated using Ingenuity Variant Analysis (IVA)  
or Annovar (Wang et al., 2010). Annotated variants were tabulated into Excel (Microsoft 
Office) along with other parameters such as variant location, type, frequency, associated gene, 
etc for further clinical and biological analyses. These analyses are described below. 
 
7.2.4 Comparison of Freebayes and GATK variant callers 
In order to determine the best exome variant caller to use in whole exome analysis specific to 
my patient cohort, the cohort was first subdivided into categories based on disease phenotype 
(Table 7-3). These groups of patients were then analysed using the BWA aligner with either a 
GATK or Freebayes caller to detect variants by the in-house Mitochondria Bioinformatics 
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Team, IGM. The output generated by both of these callers was then filtered using the 1000 
genomes project and ESP6500 datasets to detect >1% of variants and annotated using IVA 
which uses a biological context filter with curatted data from the Ingenuity knowledge base to 
determine how many of these annotated variants are detected in either known optic atrophy 
genes or genetic diseases associated with optic atrophy.  
 IVA is an online tool designed to work as a functional annotator for whole genome 
and whole exome data.  It integrates both analytical tools and curated integrated content from 
online publication to analyse called genetic variants. IVA is a more versatile tool than 
ANNOVAR as it permits filtering of variants based on a number of adjustable predefined 
parameters such as mode of inheritance, quality of reads or variant frequency in population 
exome databases. Data readout includes all known relevant information on the variants of 
interest including pathogenicity and links to any relevant publications. The predefined filters 
used for the analysis of GATK and Freebayes variants included ‘Confidence’, ‘Common 
variants’, ‘Predicted Deleterious’ and ‘Biological Context’ (as detailed in Table 7-2). 
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  Confidence Call quality is at least 20 reads in any case or control 
  
Outside top 5% most exonically variable 100bp windows in healthy public genomes 
Common Variants Exclude common variants found greater than 1% of the exome (1) 1000 genomes project and (2) ESP6500 project. 
Predicted Deleterious Disease associated according to computed ACMG guidelines classification 
 
(1)Pathogenic 
 
(2)Likely Pathogenic 
 
Or are associated with Loss of Gene Function 
 
(1)Frameshift, in-frame indel or start\stop codon change 
  (2)Missense 
Biological Context Optic Atrophy 
  
Table 7-2 Predefined parameters in Ingenuity Variant Analysis (IVA) used to filter variants obtained from both the GATK and Freebayes 
Caller 
Variants which were predicted deleterious according to IVA were defined according to the American College of Medical Genetics and Genomics 
(ACMG) guidelines. 
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7.2.5 Quality control usingTi/Tv ratio in WES 
The Ti/Tv ratio is a metric of genetic polymorphisms generation. Development of a next-
generation sequencing framework for analysing genetic variation in combination with 
previous inter-species sequencing projects have demonstrated that the ratio between genetic 
transitions and transvertions is approximately 2.1 in human whole genomic samples and 2.8 
in human whole exonic samples (Depristo et al., 2011; Ebersberger et al., 2002; Freudenberg-
Hua et al., 2003). The reason for a higher Ti/Tv ratio in whole exome samples is because there 
are a greater degree of methylated cytosine found within CpG nucleotides within these 
samples which can easily undergo a deamination and transition to thymine. This number may 
vary depending on the individual sequenced or between different human populations. If this 
number is appreciably lower it could indicate false positive enrichment. The Ti/TV ratio was 
quantified by IVA in each whole exome sample and used as a parameter of WES caller 
quality. 
 
7.2.6 Filtering of WES excel data generated through GATK pipeline 
Once WES data in excel format was output from the in-house GATK pipeline, annotated 
variants were filtered according to variant type, frequency in control exome databases and 
other parameters such as predicted pathogenicity, evolutionary conservation and quality of 
WES reads. In addition, patients with a common phenotype were compared in a process 
known as ‘intersection filtering’ (Table 7-3) (Robinson et al., 2011).  
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Patient Gender Age OA Ataxia 
Peripheral 
Neuropathy 
Deafness Nystagmus Spasticity  Epilepsy  Dementia Diabetes 
Isolated OA                         
PFC-346 F 37 + - - - - - - -   
PFC-347 M 33 + - - - - - - -   
PFC-348 F 27 + - - - - - - -   
PFC-349 F 61 + - - - - - - -   
PFC-351 F 20 + - - - - - - -   
OA and deafness                       
PFC-344 F 78 + - - + - - - -   
PFC-352 M 25 + - - + - - - -   
OA and diabetes                       
PFC-341 F 38 +               + 
OA and peripheral neuropathy                     
PFC-340 F 64 + + - - - - - -   
PFC-342 F 54 + + + - - - - -   
PFC-345   53 + + - - - - - -   
  Recessive OA                       
PFC-350 F 20 + - - - + - - -   
PFC-351 F 20 + - - - - - - -   
PFC-353 F 45 + - - - - + + +   
            
Table 7-3 Cohort of patients investigated through whole exome analysis with clinical phenotype. OA group 1; Isolated OA, OA group 2; 
OA and Deafness, OA group 3; OA and diabetes, OA group 4; OA and Peripheral Neuropathy, OA group 5; Recessive OA. 
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Briefly, annotated variants were first filtered according to whether they were present in the 
exome or at intronic splice sites as opposed to surrounding intronic regions which may not 
impact protein quality, are less probable to impart on pathogenicity and have poorer coverage 
due to the design of WES. 
Due to the relative rareness of these conditions, annoted variants were selected at a 
minor allele frequency of either 1% or 5% within both the 1000 genomes project and the ESP 
6500 project to provide a subset of potential pathogenic variants.  
At this stage a number of different strategies may be employed, potential pathogenic variants 
in individuals may be further refined to identify those only in evolutionarily conserved 
regions using the GERP2 filter (Cooper et al., 2005). The ‘a priori’ hypothesis behind this 
filtering process suggests that pathogenic variants are likely to be located in functional regions 
of the genome which are not subject to selective evolutionary pressure. Pathogenicity of 
variants in these regions as determined through four alternative pathogenicity programs is 
typically high, given that mutations in evolutionary conserved regions is one of the main 
parameters often used to judge whether a variant may be pathogenic. 
For the remaining variants, patients with a common clinical phenotype may be 
selected for comparison, filtering out non-common genes and only selecting those which 
‘intersect’ or are common to both individuals (Li et al., 2012). This process may further limit 
the number of potential pathogenic candidates and is a typical strategy used to analyse 
sporadic cases or cases of non-related individuals. This intersection filtering may also be 
employed prior to the use of the GERP2 filter, particularly if no relavent variants are 
identified.  
Identified common variants between individuals with a similar or identical clinical 
phenotype are a strong candidate for potential pathogenicity. These variants can then be 
further analysed with pathogenicity programs SIFT, PolyPhen2 and Mutationtaster2 to 
estimate the pathogenic probability of these variants. A summary of the methods used to 
sequence and identify potential pathogenic variants in this cohort and illustrated in Figure 7-
2.  
 
 204 
 
7.2.7 Coverage of common genes associated with optic atrophy-related disorders 
Data analysis of relative gene coverage was calculated from sample alignment files using 
Bedtools v. 2.15.0 and Perl script. This analysis was conducted by Doctor Yaobo Xu PhD. 
Data was further analysed and graphed using excel (Microsoft, Reading, UK). 
 
7.2.8 Pathogenicity scoring 
Pathogenicity scoring was performed using three online tools designed to predict the 
probability of a variant identified through next-generation sequencing as being pathogenic. 
These tools included ‘Sorting Tolerant From inTolerant (SIFT), Polyphen-2 and Mutation 
taster (Kumar et al., 2009; Ng et al.,2001; 2003;2006)  
 SIFT threshold parameters to denote the degree of probability associated with variant 
pathogenicity which include ‘deleterious’ (<=0.05) and ‘tolerated’ (.0.05). 
 Parameters used to classify variants analysed by polyphen-2 pathogenicity software 
include ‘probably damaging (0.85), ‘possibly damaging’ (0.85-0.15) and ‘benign’ ( 0.15) 
and MutationTaster2 uses the following labels ‘ disease automatic’, ‘disease causing’,’ 
polymorphism’, ‘polymorphism automatic’ with a higher score indicating an increased 
probability of pathogenicity.  
 When analysing potential pathogenic variants from the optic atrophy cohort, these variants 
were analysed in parallel by MutationTaster2, SIFT and Polyphen-2 and variants was 
determined to be ‘likely’ pathogenic if two of these three algorithms determined the 
variant to be pathogenic.  
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Key Word Search
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SIFT/Polyphen2/ 
MutationTaster2
Outsourced Samples
 
 
Figure 7-2 Flowthrough schematic summarising the different stages necessary to 
sequence, align, call and annotate genetic variants in whole exome analysis.  
Excel tabulated output is further filtered and analysed to determine potential pathogenic 
variants. The probability of variant pathogenicity is determined using online tools.
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7.3 Results 
7.3.1 Comparison of the data resulting from different exonic pipeline callers  
Genomic variant location and translational variant impact were two parameters generated and 
compared following IVA of the annotated data (Figures 7-3 and 7-4; Table 7-4). This 
analysis produced the distribution of variants called by both GATK and Freebayes variant 
callers from each of the defined phenotypic groups. This showed a 3.4%-7.8% degree of 
crossover for heterozygous variants in OA groups 1 to 4 (described in Table 7-2). There was 
also a 19.7% ‘mutual’ detection for homozygous variants in OA group 5 (Table 7-4).  
Variants associated only with an optic atrophy phenotype also showed an 8.1%-22.2% 
of shared heterozygous variants for the OA group 1 to 4 and 17.4% homozygous variants 
between GATK and Freebayes. However more variants in known optic atrophy genes were 
detected in the GATK pipeline. This discrepancy may be due to a greater generation of novel 
variants by Freebayes, possibly due to a greater degree of false positive detection.  
The Ti/Tv ratio which was detected in samples called by Freebayes was between 1.3-
1.8 for 93% of our patient cohort, while exomes called using GATK generated a Ti/Tv ratio 
between 2.1 and 2.5 also in 93% of my patient cohort (Table 7-4). This ratio was probably 
lower than the 2.8 standard metric for whole-exome analysis as described in Section 7.2.5 due 
to Nextera whole-exome capture which also allows for genetic regions surrounding exons to 
be sequenced at a cost cheaper than whole genomic sequencing. 
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  GATK and Freebayes shared variants 
Heterozygous 3.4-7.8% 
Homozygous  19.70% 
GATK and Freebayes shared variants (Biological context OA) 
Heterozygous  8.1-22.2% 
Homozygous  17.40% 
  Ti/Tv 
Optimum  2.8 
Freebayes 1.3-1.8 
GATK 2.1-2.5 
  
Table 7-4 Crossover and quality scores of variants found between GATK and FreeBayes 
callers  
Identification of both shared heterozygous and homozygous variants between GATK and 
Freebayes callers and shared variants identified using the biological context filter (variants 
identified only in known optic atrophy related genes).  
 
The location and type of detected variants were also disparate between the two whole 
exome callers.These variants were mostly detected in intergenic regions by the Freebayes 
caller while the variants detected by GATK were detected in exonic regions (Figure 7-3). In 
addition, the Freebayes variant caller detected a greater proportion of SNPs, insertions and 
deletions as well as substitutions and complex variants not detected by the GATK caller 
(Figure 7-4).  
 Given the Ti/Tv ratio indicating a lesser degree of false positive discovery in the 
GATK pipeline, a greater degree of variants detected in known optic atrophy genes and in 
exonic regions and the fact that the genetic variance called in the 1000 genomes project and 
the ESP6500 datasets was generated using GATK, the GATK caller was chosen for the 
analysis of the present patient cohort.  
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Figure 7-3 Representative distribution of genomic locations  
Orange = exonic; Green = Intronic; Blue = ncRNA; Gray = 3’UTR; Red = Promotor; Light Blue = 5’ UTR. (B) Orange = SNP; Green = Deletion; Blue 
= Insertion; Gray = Insertion.  
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Figure 7-4 Representative distribution of the type of genetics variants with Freebayes and GATK caller. 
Orange  = SNP; Green = Deletion ; Blue = Insertion ; Gray = Substitution  
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7.3.2 Whole-exome coverage of known optic atrophy genes 
 
 
 
 
 
 
 
 
 
Figure 7-5 Whole- exome coverage data of ten representative genes associated with optic 
atrophy 
 
To determine the relative whole-exome sequencing coverage of the optic cohort, ten common 
genes associated with optic atrophy were selected and coverage data of the sequencing reads 
from these genes was determined by the in-house bioinformatics team (Figure 7-5). An 
average coverage of 78% was achived at a 20x sequencing depth across this panel of genes 
which conforms to the accepted coverage standard for whole exome analysis (Sims et al., 
2014).  
 
7.3.3 Intersection filtering by clinical phenotype  
Two alternative strategies were employed to analyse the present patient cohort, one based on 
intersection filtering of phenotypic groupings and the second based on filtering between 
patients irrespective of clinical presentation. The four phenotypic groups mentioned in 
Section 7.2.6 were first screened against the 1000 genomes and ESP6500 datasets to 
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determine the number of novel variants within each group. The MAF was set at 5% in order 
to capture as many rare variants as possible (Tables 7-5 and 7-6).  
Each grouping was filtered for both heterozygous and homozygous variants. Each of 
these genes was then investigated using the gene ontology database developed by the gene 
ontology consortium. This database provides classifications relating to several domains of 
cellular and molecular biology and provides an overview of known gene function. Once 
candidate gene lists were generated for each of the phenotypic groups, the number of gene 
hits in each group was quantified in an attempt to find a common novel optic atrophy 
candidate gene. The variants found in these genes were then manually assessed to determine if 
detected variants were due to obvious PCR read duplication error in low complexity regions. 
Most of the genes found using this method were detected due to common variants generated 
through sequencing bias and error in these low complexity regions. However it did highlight a 
SNP in WFS1 identified in OA group 2 ((c.2051C>T; Ala684Val) 1000 genomes project 
percentage frequency: 0; ESP6500 percentage frequency: 0; ExAc database: 0). Mutations in 
WFS1 are responsible for Wolfram syndrome, a disease characterised by optic atrophy, 
hearing loss and diabetes and so this was considered a likely pathogenic candidate. To further 
define the propensity of WFS1 variant c.2051C>T; p.Ala684Val to be disease causing in 
patients PFC-344 and PFC-352, the probability of pathogenicity of the variant was further 
investigated using online pathogenicity tools as described in Section 7.2.8. This analysis 
highlighted the pathogenicity of the c.1505C>T; Ala684Val variant (scores in Section 7.3.5) 
and furthermore it was previously documented in the literature as a variant known to cause 
optic atrophy and sensorineural deafness. This description matched the clinical presentation of 
patients PFC-344 and PFC-352 (Rendtorrf et al., 2011).  
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OA and Peripheral Neuropathy OA and Deafness Isolated OA 
Recessive 
OA 
 
PFC-340 PFC-344 PFC-346 PFC-350 
 
PFC-342 PFC-352 PFC-347 PFC-351 
 
PFC-345 
 
PFC-348 PFC-353 
   
PFC-349 
       PFC-351   
Dominant 111 193 41   
Recessive  93 104 52 79 
     
Table 7-5 Number of dominant and recessive variants after phenotypic intersection 
filtering of each phenotypic group. 
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Table 7-6 Dominant and recessive candidate genes after phenotypic intersection filtering.
           
  
Isolated 
OA 
OA and Deafness 
OA and Peripheral 
Neuropathy 
 
Isolated 
OA 
OA and 
Deafness 
OA and Peripheral 
Neuropathy 
Recessive OA 
group 
 
D
o
m
in
a
n
t 
ca
n
d
id
a
te
 g
en
es
 
FOXD4L5 ABCA12 OR1D5 FOXD4L5 
R
ec
es
si
v
e 
c
a
n
d
id
a
te
 g
en
es
 
COL18A1 AHSA1 ACSL6 COL18A1   
KCNN2 ATN1 OR6C76 KCNN2 CYFIP2 COL18A1 ATG3 DIXDC1   
NEK3 C2orf71 PIGQ NEK3 DIXDC1 DIXDC1 COL18A1 FOXD2   
OR11H12 CHL1 POU2F1 OR11H12 FOXD2 FOXD2 CTSA GRIA3   
POU2F1 CLYBL PRKCSH POU2F1 GRIA3 GRIA3 DIXDC1 GRM7   
TIMM23 CNTNAP2 PXDN TIMM23 HADHB GRM7 FOXD2 HADHB   
  EOMES SEPN1   MAPK8IP2 OLFM1 GRIA3 KCNN3   
  FOXC1 TIMM23   NCOR2 OR7C2 MAP3K1 MAP3K1   
  FOXD4L5 TOP1MT   OLFM1 OR8K3   MAPK8IP2   
  FSIP2 TPRN   OR7C2 POU4F2   NCOR2   
  OBP2A TSC2   PCLO SMPD1   OLFM1   
  OR11G2 UNQ514     TMIE   OR7C2   
  WFS1           PCLO   
                  STAU2   
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7.3.4 Intersection filtering of individual patients  
A second approach was adopted to analyse remaining patients for any potential gene 
candidates. This involved using a similar method previously described by Fogel and 
colleagues (2014). Two whole exome samples from non-optic atrophy patients sequenced in 
parallel were used as controls to screen for false positive variants generated through technical 
error that were detected in the analysis described previously in Section 7.2.5. These patients 
were diagnosed with vasovagal syncope with no known optic disturbances. Patients were 
screened using the 1000 genomes and ESP6500 datasets at a MAF frequency less than or 
equal to 1% to identify extremely rare pathogenic variants. A threshold of 1% was chosen as a 
reasonable threshold to limit the number of potential candidate genes. Only exonic and 
splicing regions were investigated in this analysis. Given the likelihood of pathogenic variants 
which lie in highly conserved genomic regions, only regions with a genomic evolutionary rate 
profiling (GERP) score greater than or equal to 2 were investigated. Once variants were 
filtered according to these parameters, a key word search was used to identify any relevant 
genes which included terms such as ‘eye’, ‘nervous system’, ‘endoplasmic reticulum (ER)’ 
and ‘mitochondria’. This generated a list of potential candidate genes which were further 
filtered by comparing between any two patients in the entire optic atrophy cohort. This 
analysis resulted in 90 potential genes which were then screened using gene card, web of 
science, google scholar and the Ingenuity Knowledge Base to identify any genes related to 
optic atrophy or any secondary symptom.  
These genes were further investigated to select those which contained any two or more 
pathogenic variants present in at least two individuals of the cohort. Pathogenic variants were 
defined as any variant which was identified as potentially pathogenic in at least two different 
online pathogenicity tools. This analysis was to identify any potential common pathogenic 
gene between any two individuals underpinning an optic atrophy phenotype. These genes are 
listed in Table 7-7. Two potential pathogenic variant in WFS1 (c.977C>T; p.Ala326Val 
(1000 genomes project percentage frequency: 0; ESP6500 percentage frequency: 0.00008; 
ExAc percentage frequency 0.000025) and c.2452C>T; p.Arg818Cys (1000 genomes project 
precentage frequency 0.002; ESP6500 precentage frequency 0.005; ExAc: 0.0049) and 
numerous patients containing ATF5 variants were discovered following this analysis. Since 
the majority of cases of Wolfram Syndrome are recessivly inherited as previously described, 
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PFC-341 and PFC-351 were further scrutinised to determine if any other variants were 
detected by WES but filtered out due to the stringent parameters used to detect any potential 
pathogenic variants. This revealed a second variant in patient PFC-341 (c.1309G>C; p. 
Gly437Arg; ExAc percentage frequency:0.0000082) . Further analysis to determine 
inheritance pattern of these variants in described in Chapter 8. 
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Table 7-7 Candidate gene list generated for each optic atrophy patient   
This table illustrates genes containing at least one pathogenic variant in two or more patients 
which are associated with either an OA phenotype or any other additional phenotype which 
presents in this patient cohort. Only genes which have been predicted to be pathogenic in at 
least two pathogenicity tools are included. Genes are ranked in order of decreasing probability 
of pathogenicity.  
    Genes cDNA Protein PFC- 
ATP7B 
c.1682C>T p.Thr561Met 348 
c.1763C>T p.Ala588Val 353 
CACNA1S c.773G>A p.G258D 346,349 
KCND3 
c.497G>A p.Arg166His 340;349 
c.5C>A p.Ala2Glu 147 
GRIN2A 
c.2909G>A p.Arg970Gln 342 
c.2626A>T p.Ile876Phe 350 
NBAS c.1093G>C p.Asp365His 345,350 
WFS1 
c.977C>T p.Ala326Val 341 
c.2452C>T p.Arg818Cys 351 
SYNE1 
c.4162C>T p.Arg1388Trp 341 
c.13696G>A p.Asp4566Asn 147 
ATF5 
c.365T>C p.Leu122Pro 341,342,348,353,147 
c.376T>C p.Ser126Pro 341,342,348,353 
CTSB 
c.203G>A p.Arg68His 147 
c.391G>A p.Val131Met 348 
CUL7 
c.3253C>T p.Arg1085Cys 353 
c.2570C>T p.Thr857Met 340 
CEP290 
c.2417G>A p.Arg806Gln 353 
c.245G>A p.Arg82Gln 348 
COL24A1 
c.4235A>T p.Asp1412Val 350 
c.20G>A p.Arg7Lys 353 
TRPV4 
c.219G>A p.Glu733Lys 147 
c.1363G>A p.Val455Ile 348 
HDGF 
c.709C>T p.His237Tyr 341 
c.622C>T p.Arg208Trp 340 
DRAXIN c.178C>T p.Arg60Trp 350,347 
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7.3.5 Investigation of the probability of WFS1 variant pathogenicity  
The pathogenicity of the four WFS1 variants (p.Ala684Val, p.Ala326Val, p.Gly437Arg and 
p.Arg818Cys) identified were analysed using Mutationtaster2, Polyphen-2 and SIFT. The 
c.2505C>T (p.Ala684Val) variant found in PFC-344 and PFC-352 patients was identified as 
pathogenic by all three prediction programs with a Polyphen2 score of ‘0.992’ and a SIFT 
score of ‘0’. MutationTaster2 predicted the variant to be disease causing with a probability of 
0.999 because it was a known disease mutation identified through HGMD.  
Investigation of patient PFC-341 identified the p.Ala326Val variant in Polyphen2 as 
probably damaging with a score of 0.997, SIFT predicted a tolerated variant with a score of 
0.356 and MutationTaster2 predicting a disease causing gene with a probability of 0.999. 
MutationTaster2 also determined the variant to be a known disease mutation. An investigation 
of the p.Gly437Arg variant revealed that both Polyphen2 and MutationTaster2 predicted the 
variant to be benign with a Polyphen2 score of 0.029, MutationTaster2 score of predicted of 
1.42e-5. Further investigation of these three WFS1 variants was conducted in patient PFC-341 
in Chapter 8. Patient PFC-351, who harboured the p.Arg818Cys WFS1 variant, had a 
Polyphen2 score of ‘1’, a SIFT score of 0.03 and a MutationTaster2 score of ‘0.999’. 
MutationTaster2 also annotated the variant as a known disease mutation. Further investigation 
of these three WFS1 variants was conducted in patient PFC-341 in Chapter 8. 
 
7.3.6 Identification of two potential pathogenic variants in ATF5 
Intersection filtering of the WES cohort also identied two potential pathogenic missense 
variants in ATF5 p.Leu122Pro and p.Ser126Pro (Table 7-7). The presence of these two 
variants in a relatively large subset of optic atrophy patients (PFC-341, PFC-342, PFC-348, 
PFC-353 and PFC-147) may warrant further investigation. 
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7.4 Discussion 
Typically, WES study design includes either a cohort of family trios consisting for two 
unaffected parents and an affected child or as singleton cases in which a large cohort of 
unrelated affected individuals is analysed.  
 Evaluation of family trios can improve the accuracy and detection of causative 
pathogenic mutations by allowing variant filtration based on the genetic background of the 
affected individual (Hunt et al., 2014). As a consequence, many polymorphisms, both 
common and rare in the general population, may be removed from the analysis. This is best 
for recessive conditions in which homozygous or compound heterozygous variants can be 
segregated in both parents and child. Furthermore, variants found in affected individuals but 
not in unaffected parents due to artefactual sequencing error may also be determined.  
On the other hand, the use of sequencing data from family trios may also introduce 
additional cost and complexity in the analysis. It would require detailed clinical assessment of 
both parents and child with a reduced cohort of affected individuals in the final assessment.  
Technical complexity could also be introduced due to sample ‘missingness’ referring to 
alternative loci of low coverage within a family trio (Browning et al., 2009). ‘This may 
increase the number of polymorphisms and false positives after the filtration process. Other 
difficulties can also arise due to reduced penetrance of a pathogenic variant. A large and 
detailed pedigree would therefore be beneficial for segregation analysis in these cases.  
In this study, we opted to analyse a cohort of rigorously phenotyped OPA1-negative 
singleton cases who presented with optic atrophy. This design was chosen to provide a large 
cohort of affected individuals of unknown genetic aetiology but with similar clinical 
presentation. In addition, although it would be useful to include other unaffected family 
members for segregation analysis, limited access to parental DNA for many of these cases 
limited the scope of the analysis which could be performed.  
Based on this study design, variant frequencies within the patient cohort were 
associative and based upon population frequencies found within the 1000 genome and 
ESP6500 datasets.  
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Two different in-house bioinformatics pipelines with either a GATK haplotype or 
Freebayes caller were developed by the mitochondria bioinformatics team, IGM. In order to 
assess the best caller for sequencing analysis of this patient cohort, FASTQ files were 
processed through either the GATK or Freebayes pipelines and annotated using IVA. This 
investigation revealed that the GATK caller generated more SNPs in the exonic region than 
Freebayes with a lower Ti/Tv false positive variant score. Freebayes also called a number of 
insertions and deletions in the intergenic region which were not detected by GATK. Given the 
likelihood that Freebayes may be detecting greater degree of variants that are false-positive 
both in exonic regions and regions not likely to result in protein functional pathogenicity, the 
GATK caller was then chosen to perform variant calling for the optic atrophy cohort. 
Numerous different study designs with different capture kits have been implemented 
to achieve the greatest depth and coverage of the human exome. Despite a significant 
reduction in recent years, sequencing costs still remain substantial and a fine balance must be 
achieved between cost and robust sequencing with adequate depth and coverage in each 
sample analysed (Sims et al., 2014). The minimum threshold to achieve this is 10x deep 
sequencing coupled with 80% targeted capture of the exome, regardless of the exome capture 
kit or WES pipeline used to detect variants (Zhou et al., 2012; Thauvin-Robinet et al., 2013; 
Yu et al., 2013). This means a significant portion of the exome may not be covered due to 
LCRs and poor hybridisation of sequence capture probes in GC rich regions.  
To assess the degree of coverage in the optic atrophy cohort through this selected 
pipeline, a selection of ten optic atrophy genes were chosen and their coverage analysed by 
the mitochondria bioinformatics team, IGM. The percentage of bases captured in each gene 
across the entire cohort was quantified and ranged between 50-90% coverage. Average 
coverage was approximately 80% at 20x sequencing depth which is the quality standard 
required for WES analysis (Sims et al., 2014). 
Initial filtering of the entire optic atrophy cohort did not detect variants common to all 
patients, suggesting underlying genetic heterogeneity in patient presentation. In order to 
prevent pathogenic variants from being screened through whole cohort filtering, each of the 
patients was stratified according to their phenotype. This divided the cohort into five 
phenotypic groups described as OA group 1 ‘Isolated optic atrophy’, OA group 2 ‘Optic 
atrophy and deafness’, OA group 3 ‘Optic atrophy and diabetes, OA group 4 ‘Optic atrophy 
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and peripheral neruopathy’ and OA group 5 ‘Suspected recessive inheritance’. Patients from 
OA groups 1-5 which had more than one individual with a similar clinical phenotype other 
than OA were used in this analysis (Exception for OA and diabetes which contained a single 
patient member).  
In the initial intersection filtration method, the patient cohort were stratified according 
to their common phenotypic presentations. This led to the identification of a dominant WFS1 
variant identified in patients characterised with optic atrophy secondary to hearing impairment 
(OA group 2). Further investigation of this variant indicated that it was disease causing. A 
literature search revealed two publications by Rendtorff et al. (2011) and Tessa et al. (2001) 
describing dominant inheritance of the pathogenic WFS1 phenotype of two patients harboring 
the p.Ala684Val WFS1 variant. Additional heterozygous/homozygous variants detected in 
each of these groupings were found to be caused by misalignment error or PCR bias which 
occurred at LCRs of the genome.  
In the second method of intersection filtering which involved filtering of any two 
patients irrespective of clinical presentation, false-positives due to technical errors were 
minimised by using two ‘no optic atrophy’ disease controls. Also, to help reduce the number 
of likely polymorphic variants in the cohort, variants were screened using a GERP2 filter. 
This was used to screen for variants located in evolutionarily conserved regions of the 
genome. Investigation of these evolutionary conserved regions highlighted a number of 
interesting variants. A WFS1 missense variants (p.Ala326Val) was detected in PFC-341, 
Table 7-7. This patient presented with optic atrophy and diabetes, a common clinical 
phenotype associated with Wolfram syndrome. (Wolfram and Wagner, 1938; Cooper et al., 
1950; Paley and Tunbridge, 1956). Wolfram syndrome is typically a recessive condition 
which is acquired through compound heterozygous or homozygous inheritance. A literature 
search indicated that this variant was one of a number of variants that were identified through 
genetic screening of a cohort of patients diagnosed with Wolfram syndrome and psychiatric 
illness. However it has not yet been proven to be causally linked to the manifestation of 
Wolfram syndrome (Torres et al., 2001). Further analysis of this patient is described in 
Chapter 8.  
Furthermore, a second WFS1 variant (p.Arg818Cys) was also detected using this 
second method of intersection filtering.  This variant has been annotated as ‘disease causing’ 
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according to HGMD however a literature search indicated that there is much controversy 
surrounding the pathogenicity of this variant. It was initially described in a consanguineous 
Spanish family with homozygous inheritance diagnosed with Wolfram syndrome (Gomez-
Zaera et al., 2001). However it has also been detected in control cohorts of independent 
studies investigating Wolfram syndrome (Cryns et al., 2002; Martorell et al., 2003). 
Functional analysis is required to determine if it is truly pathogenic. Unfortunately, we were 
unable to obtain the relevent biological material to perform this analysis.  
Interestingly two potential pathogenic ATF5 heterozygous variants (p.Leu122Pro and 
p.Ser126Pro) were both discovered in four patients in the optic atrophy cohort and a single 
p.L122P variant was detected in a fifth (Table 7-7). ATF5 is a transcription factor that 
belongs to the response element binding protein family (CREB) and is involved in the ER 
stress reponse (Vinson, 2002). It is expressed as two alternative transcripts (ATFα and ATFβ) 
that differ only in their 5’ untranslated region (UTR) (Hansen et al., 2002). This UTR is 
similar to the one found in ATF4 and allows ATF4 and ATF5 transcripts to be preferentially 
translated upon induction of ER stress due to an overload of misfolded proteins. It typically 
operates to promote cellular/protein homeostasis in conjunction with ATF4, ATF6 and XBP1 
downsteam of phosphorylated EIF2α. However, once ER stress conditions reach a critical 
threshold, it can instead promote apoptotic cell death (Teske et al., 2013). Previously, ATF5 
was not thought to be expressed in differentiated neuronal tissue however recent experimental 
work conducted by Torres-Pereza and colleagues (2013) showed that ATF5 is widely 
expressed in differentiated mouse neurons. The ATF5 gene is not particularly large with only 
5,235 bases which encode a 282 amino acid protein. Further functional work would be 
required to confirm these potential pathological variants in optic atrophy. Other ER 
components involved of the UPR such as WFS1 have been associated with optic atrophy 
illustrating that, ER components involved in maintaining ER homeostasis may also have an 
impact on optic nerve degeneration.  
In conclusion, intersection filtering was employed both between individual patients 
and groups of patient with a similar clinical phenotype. These strategies aided in the 
identification of a number of pathogenic or potential pathogenic WFS1 variants which may 
suggest a greater incidence of Wolfram syndrome than has previously been reported in the 
British population.  
 222 
 
The number of confirmed and potential WFS1 cases (3/14 patients – 21%) is 
consistent with the current documented success rate for WES in monogenic disorders (25%) 
(Yang et al., 2013).  Further functional work to validate some of these variants is described in 
Chapter 8. Furthermore, stringent analysis between individual patients to identify highly rare 
potentially pathogenic variants in evolutionary conserved genomic regions have highlighted 
two novel ATF5 variants in 36% of my cohort (5/14 patients). Further investigation is 
required to determine if these variants influence an underlying clinical phenotype through in 
vitro manipulation of ER stress induced pathways.  
Inability to detect potential pathogenic variants in other member of the OA cohort 
reflect three limitations of study design. The first is that variant frequencies used in this 
analysis are merely associative. Variants of low frequency may reflect regions of poor 
coverage within each of the independent control studies used in this analysis or individuals 
within these control cohorts may only possess wild-type alleles for regions enriched with 
variants sequenced by our in-house pipeline. This can increase the number of polymorphisms 
left after intersection filtering.  The second is that WES is limited to only the exonic regions 
which are not of low complexity. Therefore, mutations in promotor regions, intronic regions 
and copy number variants will go undetected. Lastly, the lack of any definitive pathogenic 
gene other than WFS1 also likely reflects the genetic heterogeneity of optic neuropathies 
which could be ameliorated by a larger OA cohort. 
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Chapter 8  
 
 
 
WFS1 Mutations in Patients with Inherited Optic 
Atrophy 
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8.1 Introduction 
Wolfram syndrome was first described by Dr Donald Wolfram from the Mayo Clinic in 1938 
in a case series of four siblings diagnosed diabetes insipidus, diabetes mellitus, optic atrophy 
and deafness (DIDMOAD) (Wolfram and Wagner, 1938). The condition has been 
characterised with classical symptoms: diabetes insipidus, diabetes mellitus, optic atrophy 
and/or deafness (DIDMOAD). The EURO-WABB is an EU rare diseases registry for 
Wolfram syndrome, Alström syndrome, Bardet-Biedl syndrome and other rare diabetes 
syndromes (Farmer et al., 2013). Based on the latest EURO-WABB consensus guidelines, 
both optic atrophy and diabetes mellitus are considered as major criteria for the diagnosis of 
Wolfram.syndrome(http://www.orpha.net/national/data/IEEN/www/uploads/Wolfram2014.pd
f, accessed July 10, 2016). 
 Autosomal recessive WFS1 mutations were identified in patients with classical 
Wolfram syndrome (Strom et al., 1998). WFS1 encodes for Wolframin, a transmembrane 
endoplasmic reticulum protein that plays a critical role in calcium homeostasis and stress in 
the unfolded protein response (Takei et al., 2006; Yamada et al., 2006; Yamaguchi et al., 
2004).With the advent of genetic screening and through clinical assessment, the 
manifestations and mutational spectrum of pathogenic WFS1 mutations has expanded rapidly 
over the past few years. Over 200 case reports have been published so far and in addition to 
the classical DIDMOAD, other associated features include neurological deficits, psychiatric 
disturbances, urological dysfunction and gastrointestinal abnormalities. Fatal complications 
such as central apnea leading to aspiration pneumonia can also arise and the average lifespan 
of a patient diagnosed with Wolfram syndrome is 30-40 years old (De Heredia et al., 2013).  
Patients can also present with a more limited form of the disease, referred to as Wolfram-like 
syndromes,  including isolated sensorineural hearing loss, cataracts and diabetes (Bai et al., 
2014; Goncalves et al., 2014; Berry et al., 2013; Chacon-Camacho et al., 2013; Bonnycastle et 
al., 2013; Valero et al., 2008). 
The majority of patients with Wolfram syndrome or Wolfram-like syndromes, harbour 
homozygous or compound heterozygous WFS1 mutations. More recently, there have been a 
number of reports of patients carrying dominant WFS1 mutations, especially in association 
with low frequency sensorineural hearing loss, diabetes mellitus and autosomal dominant 
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optic atrophy (Rendtorrf et al., 2011; Khanim et al.,2001; Middle et al., 2000; Hogewind et 
al., 2010; Eiberg et al., 2006; Wasson et al., 2008). The studies that have been published so 
far have revealed variable genotype-phenotype correlations for recessive and dominant WFS1 
mutations. A recent study performed by Chaussenot and colleagues suggested that WFS1 
mutations located at or near the C-terminus are more likely to be associated with psychiatric 
illness whereas those located at or near the N-terminus have a  lower likelihood of causing 
neurological complications (Chaussenot et al., 2011). In addition, they also found that 
homozygous loss-of-function mutations, such as nonsense or frameshift mutations, which 
result in a marked reduction in WFS1 protein level are more likely to be associated with 
early-onset diabetes mellitus and optic atrophy. This early onset of optic atrophy and diabetes 
is consistent with the findings of other independent studies (Cano et al., 2007; Rohayem et 
al., 2011; Matsunaga et al., 2014). 
A systematic review of 49 published studies was performed by De Heredia and 
colleagues in which patients were stratified into groups based upon: (1) complete loss of 
WFS1 protein level, (2) dominant-negative WFS1 mutations, or (3) haploinsufficient WFS1 
mutations (De Heredia et al., 2013).  Compared with the other studies mentioned earlier, this 
analysis of 412 patients came up with different genotype-phenotype correlations. 
Interestingly, in this patient cohort, diabetes mellitus and optic atrophy were not always the 
first two manifesting clinical features. Disease progression was characterised by the 
development of diabetes mellitus (10 years old), optic atrophy (10-20 years old), diabetes 
insipidus (10-30 years old), sensorineural hearing loss (10-38 years old), and/or neurological 
defects (5-55 years old) (De Heredia et al., 2013). The age at onset of diabetes mellitus, 
hearing defects, and diabetes insipidus were found to depend on the patient's genotypic class. 
In terms of disease severity, dominant negative WFS1 mutations were associated with more 
rapid progression, in particular for optic atrophy, sensorineural deafness and diabetes mellitus 
(De Heredia et al., 2013) 
In this part of my PhD project, I further investigated the functional consequences of 
the WFS1 variants that have been identified with WES in our cohort of patients with 
undiagnosed inherited optic atrophy (Table 8-1). Moreover, given the unexpected high 
prevalence of pathogenic WFS1 mutations, Sanger sequencing was carried out for the 
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remaining patients in our optic atrophy cohort to look for possible WFS1 variants that might 
have been missed in regions not well covered by WES.  
 
      
Patient  Gender Age Clinical Presentation  cDNA Protein 
341 F 38 
OA and diabetes 
mellitus 
c.977C>T p.Ala326Val 
341 F 38 
OA and diabetes 
mellitus 
c.1309G>C p.Gly437Arg 
344 F 78 OA and hearing loss c.2051C>T p.Ala684Val 
352 M 25 OA and hearing loss  c.2051C>T p.Ala684Val 
351 F 19 OA c.2452C>T p.Arg818Cys 
      
Table 8-1 Cohort of patients with WFS1 variants identified through WES.  
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8.2 Materials and Methods 
8.2.1 DNA extraction from blood  
Whole Blood Genomic Extraction kit (Nucleon) was used to extract DNA from the blood of 
the parents of patient PFC-341 as described in Section 3.5.1. In addition, DNA previously 
extracted from patients PFC-341, PFC-344 and PFC-352’s blood and stored at -80°C were 
used. 
 
8.2.2 WFS1 Sanger sequencing 
Pathogenicity of WFS1 variants was determined ‘in silico’as described in Section 7.2.4 using 
online programs MutationTaster2, SIFT and Polyphen-2. The WFS1 variants identified with 
whole-exome sequencing was confirmed with both forward and reverse Sanger sequencing as 
described in Section 3.13. These sequenced amplicons were compared against WFS1 mRNA 
transcript variant 1 (NM_006005.3) and protein (NP_005996.2)) using Seqscape v 2.6 
(Applied Biosystems). DNA was extracted from blood samples obtained from the parents of 
patient PFC-341 to confirm the mode of inheritance. 
 
8.2.3 Western blot analysis of patient with compound heterozygous WFS1 variants 
Western blot analysis of patient ‘PFC-341’ was carried out as described in Section 3.3. 
Briefly, protein from three primary fibroblast biological replicates was extracted and probed 
using a primary WFS1 anti-rabbit antibody (cat: 11558-1-AP; Proteintech) overnight using a 
1:1000 antibody dilution. This was washed three times in TTBS (Sigma-Aldrich) for 10 
minutes before an anti-rabbit secondary antibody was applied for 1 hour at room temperature. 
The western blot membrane was re-washed with TTBS 4 times with each wash lasting 5 
minutes before antibody detection. Protein bands were imaged using an ECL kit (Biorad) and 
an Amersham Imager 600 (GE Healthcare Lifesciences). 
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8.2.4 Modelling of WFS1 protein 
A theoretical model of the WFS1 protein was generated to illustrate any structural changes 
induced by mutations in WFS1. Similar to the model generated for OPA1 as described 
previously in Section 6.3.3, the WFS1 structural model was generated by using the FFAS 
server to locate the most structurally homologous protein to WFS1, namely, maltose-binding 
periplasmic protein (score: -8.69; sequence identity: 9%, http://ffas.sanfordburnham.org/ffas-
cgi/cgi/ffas.p). This protein was then modelled using the SCWRL server with default settings. 
Pymol (Delano Scientific, https://www.pymol.org/) was used to manipulate the WFS1 model 
and introduce any changes due to specific mutations using the mutagenesis tool.  
 
8.2.5 WFS1 screening 
Exons 2-8 and surrounding intronic regions were PCR amplified and sequenced using 11 
M13-tagged primer pairs (Table 8-2). Sanger sequencing of WFS1 in my whole exome cohort 
was carried out as previously described in Section 3.13. These sequenced amplicons were 
also compared against WFS1 mRNA transcript variant 1 (NM_006005.3) and protein 
(NP_005996.2)) using Seqscape v 2.6 (Applied Biosystems). The genetic variants identified 
were analysed for pathogenicity using MutationTaster2, SIFT and Polyphen-2 as previously 
described (Section 7.3.3). Any identified WFS1 variants were reversed sequenced to exclude 
any errors due to PCR amplification.  
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Table 8-2 Primers details in PCR amplification of select WFS1 exons.  
 
Exons of WFS1 which were not covered through 20x whole exome sequencing were 
selectively targeted,PCR amplified and Sanger sequenced to determine if any pathogenic 
variants of WFS1 may lie hidden in these genomic regions. All primers were designed using 
Genbank accession number NM_006005. Each primer contains an M13 tag to facilitate single 
primer sequencing. Sequencing conditions used to quantify mtDNA copy number are 
described in Section 3.10.2. 
 
 
 
 
 
 
 
 
    
Exon  
Size 
(bp) 
Forward (Sequence 5'-3') Reverse Sequence (3'-5') 
2 491 TCAGCGAGATCCTGTATGGA AGCTGCACAATGCTGAACTG 
4 579 TCCATGCATTGATGGTGAGC AATTTCCCAACAGCATCACC 
5 495 CCCTGGTAACCAAGTCCTGA GCACGGTCTCTACAGGAAGG 
7 684 GTCACCCGTGCTGTGAGAA GGCACGGCTGTAAGACACTC 
8(a) 482 TTTCAAGGGCACCTACTGCT CCATGTTGGTCTCCTTCCAG 
8(b) 599 ACATGCTCCCGTTCTTCATC CACTGGTGCATGCCTGTC 
8(c) 384 GGTCAAGCTCATCCTGGTGT AGCAGCTTAAGGCGACAGAG 
8(d) 540 AAGAGGAAGTAGCCGATGGA CAACCTGGATGTGGAGCAG 
8(e) 497 GTCAGAGGGAGGCGTGAGAT GGGATGCAGTCCTTGCTG 
    
 230 
 
8.3 Results 
8.3.1 Confirmation of variant c.3452C>T(p.Arg818Cys) in patient PFC -351 
The c.C3452T (p.R818C) WFS1 variant in patient  PFC-351 that was detected with WES was 
confirmed by both forward and reverse Sanger sequencing (Figure 8-1). 
 
 
 
 
 
 
 
 
 
Figure 8-1 Sequencing chromatogram illustrating the c.C3452T WFS1 variant detected 
in patient PFC-351 
 
 
 
 
 
 
          Patient PFC-351 
c.3452C<T 
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8.3.2 Confirmation of variants c.1309G<C (p.Gly437Arg) and c.977C>T 
(p.Ala326Val) in patient PFC -341 
Clinical examination of patient PFC-341 was performed by Dr Yu-Wai-Man. Fundus 
examination showed bilateral optic atrophy and significant thinning of the peripapillary retinal 
nerve fibre layer was confirmed with optical coherence tomography (OCT) imaging (Figure 
8-2). Sanger sequencing confirmed the c.1309G<C (p.Gly437Arg) and c.977C<T 
(p.Arg326Val) WFS1 variants in patient PFC-341. Sanger sequencing was also carried out in 
both parents to confirm the mode of inheritance (Figure 8-3A). The father harboured the 
c.1309G>C (p.Gly437Arg) variant whereas the mother harboured the c.977C<T 
(p.Ala326Val) variant, indicating a compound heterozygous mode of inheritance for patient 
PFC-341 (Figure 8-3B). 
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Figure 8-2 Ophthalmological findings for patient PFC-341  
(A) Bilateral optic atrophy is demonstrated on fundoscopic examination (RE = right eye, LE = 
left eye). (B) Optical coherence tomography (OCT) measurements were obtained with the 
high-resolution spectral-domain CirrusTM platform (Carl Zeiss Meditec, Dublin, CA). The 
average retinal nerve fibre layer thickness was 67m in the right eye (OD) and 63m in the 
left eye (OS). (C) The analysis software automatically selects the appropriate normative range 
for the patient and the peripapillary RNFL measurements (dark traces) are represented within 
colour-coded distribution centiles (bottom panel): (i) red < 1%, (ii) yellow 1-5%, and (iii) 
green 5-95%. 
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Figure 8-3 (A) Family pedigree; (B) Sequencing chromatogram of the proband and his 
unaffected parents; and (C) WFS1 protein alignment and degree of evolutionary 
conservation. 
WFS1 Ala326Val 
WFS1 Gly437Arg 
289 Lys 362Leu 
401 His 471 Leu 
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The pathogenicity of the WFS1 variants found in patient PFC-341, c.1309G<C (p.Gly437Arg) 
and c.977C<T (p.Ala326Val), was further investigated with western blot analysis. WFS1 
protein levels in the patient’s fibroblasts showed a significant decrease compared with 
controls to about half normal levels. 
 
 
 
 
 
 
 
 
Figure 8-4 Western blot analysis of WFS1 in patient PFC-341.  
Western blot normalised against GAPDH and mean of two biological controls. An unpaired 
Student’s T-test was used for statistical comparison (p ≤0.001, *** significance). 
 
8.3.3 Confirmation of variant c.2051C<T (p.Ala684Val) in patients PFC-344 and 
PFC-352 
Clinical examination of patient PFC-344 was performed by Dr Yu-Wai-Man (Figure 8-5). 
Sanger sequencing confirmed the presence of the c.2051C<T (p.Ala684Val) WFS1 variant 
that was detected with WES (Figure 8-5).  
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Figure 8-5 Ophthalmological findings for patient PFC-344 
(A) Bilateral optic atrophy was observed on fundoscopic examination (RE = right eye, LE = 
left eye). (B) Optical coherence tomography (OCT) measurements were obtained with the 
high-resolution spectral-domain CirrusTM platform (Carl Zeiss Meditec, Dublin, CA). The 
average retinal nerve fibre layer thickness was 48m in the right eye (OD) and 53m in the 
left eye (OS). (C) The analysis software automatically selects the appropriate normative range 
for the patient and the peripapillary RNFL measurements (dark traces) are represented within 
colour-coded distribution centiles (bottom panel): (i) red < 1%, (ii) yellow 1-5%, and (iii) 
green 5-95%. 
(B) 
(A) 
(C) 
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Figure 8-6 Sequencing chromatogram illustrating the c.2051C<T WFS1 variant detected 
in patient PFC-344 
8.3.4 Confirmation of variant c.2051C<T (p.Ala684Val) in patient PFC-352 
Sanger sequencing confirmed the c.2051C<T (p.Ala684Val) WFS1 variant in patient PFC-352 
(Figure 8-7).  
 
 
 
 
 
 
 
Figure 8-7 Sequencing chromatogram illustrating the c.2051C<T WFS1 variant detected 
in patient PFC-352 
c.2051C<T 
c.2051C<T 
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8.3.5 Protein modelling of the impact of WFS1 mutations  
WFS1 is an 890 amino acid protein with the closest known structural homologue being 
Maltose-binding periplasmic protein (sequence identity: 9%) (Figure 8-8). The precise 
protein folding of WFS1 and how pathogenic mutations may impact on its structure and 
function are still poorly defined in the literature. Modelling of the c.2051C<T (p.Ala684Val) 
variant indicates that it lies structurally within the degron, a target for Smurf-1 mediated 
degradation of WFS1 by the ubiquitin-proteasome system, which is an important mechanism 
for regulating the unfolded protein response in the ER (Guo et al., 2011). Interestingly, an 
investigation of single heterozygous variants identified in patients with wolfram syndrome in 
the Euro-Wabb WFS1 database (https://lovd.euro-wabb.org/home.php?select_db=WFS1) 
indicate that almost all of these variants are located in exon 8 and they affect protein regions 
located within the ER (membrane and lumen) rathen than the cytoplasmic compartment. 
Heterozygous WFS1 mutations that have been linked specifically with optic atrophy and 
sensorineural hearing loss also appear to cluster exclusively in the protein region located 
within the ER lumen, with the exception of a single sporadic case reported by Cryns and 
colleagues (2002). The WFS1 missense variants, c.977C<T (p.Ala326Val) and c.1309G<C 
(p.Gly437Arg) are both located within the ER membrane, but due to the compound 
heterozygous nature of these variants with both contributing to disease pathogenicity, it is 
more difficult to structurally ascertain their impact on WFS1 protein function. 
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Figure 8-8 In silico modelling of the WFS1 protein and induced conformational changes. 
Structural protein modelling of WFS1 was determined with the ‘Fold and Functions 
Assignment (FFAS)’ server, SCWRL modeller and PyMol for manual manipulation of image. 
The red spheres indicate the position of the either the wild type or mutant amino acid. WFS1 
model with: (A) Ala326 amino acid; (B) Ala326Val amino acid change; (C) Gly437 amino 
acid; (D) Gly437Arg amino acid change; (E) Ala684 amino acid; (F) Ala684Val amino acid 
change. (A), (B), (C) and (D) illustrate recessive WFS1 mutations, whereas (E) and (F) 
illustrate dominant WFS1 mutations. 
(A) (B) 
(C) 
(D) 
(E) (F) 
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8.3.6 Screening of the remaining patients in our whole-exome cohort for potentially 
pathogenic WFS1 variants  
Analysis of our WES raw data indicate that only approximately 80% of the WFS1 gene is 
covered and called by the Illumina HiSeq2500 and GATK in-house pipeline. To ensure that 
no other pathogenic WFS1 variants were missed in these unsequenced regions, WFS1 Sanger 
sequencing was carried out for the other patients in our whole-exome cohort. Table 8-3 
indicates the WFS1 variants that were detected and confirmed with reverse sequencing within 
the 20% uncovered WES region. These WFS1 variants were then analysed using three online 
pathogenicity programs to determine whether these could account for the patient’s optic 
atrophy phenotype. Most of the identified missense variants were predicted to be benign in 
nature (Appendix Table H1). However, the c.631G<C (p.Asp211Gly), c.2165T<C 
(p.Met722Thr), c.2653C<G (p.Pro885Thr), and c.1810T<A (p.Cys604Ser) variants were 
identified as potentially pathogenic and require further investigation. 
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Nucleotide Change  
Protein 
Change 
ExAC database 
Euro-WAB 
database 
SIFT POLYPHEN2 Provean SIFT  Polyphen2  Provean PFC- 
c.631G<C p.Asp211Gly NA NA Damaging benign Deleterious 0.03 0.001 -2.78 147 
c.2165T<C p.Met722Thr NA NA Tolerated possibly damaging Deleterious 0.09 0.95 -2.56 342 
c.2653C<G p.Pro885Thr NA NA Tolerated probably damaging Deleterious 2.86 1 -6.75 346 
c.1810T<A p.Cys604Ser NA NA Tolerated possibly damaging Deleterious 0.27 0.82 -2.95 347 
           
Table 8-3 Potentially pathogenic WFS1 missense variants detected and confirmed with Sanger sequencing and their relative pathogenicity 
scores. 
SIFT, POLYPHEN2 and Provean were used to analyse each variant and their respective scores are indicated. The presence of these variants in the 
Euro-WABB WFS1 database, which contains the largest collection of up-to-date variants, was also investigated (September 2015).
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8.4 Discussion 
WES was performed on a cohort of 14 patients with optic atrophy and/or additional extra-
ocular features and four of these patients (28%) harboured potentially pathogenic WFS1 
variants. Sanger sequencing confirmed the presence of each of these variants: c.2051C<T 
(p.Ala684Val), c.977C<T (p.Ala326Val), c.1309G<C (p.Gly437Arg) and c.2452C<T 
(p.Arg818Cys). Two patients (PFC-344 and PFC-352) with optic atrophy and deafness 
carried a previously reported pathogenic variant c.2051C<T (p.Ala684Val), which was 
identified in a family with multiple affected family members segregating both optic atrophy 
and sensorineural deafness (Rendtorff et al., 2011). The pathogenic nature of this variant was 
confirmed functionally in Hek293 cells with a significant decrease in WFS1 level indicative 
of either structural instability or haploinsufficiency. The mechanisms by which the mutant 
WFS1 protein (p.Ala684Val) result in optic atrophy and deafness remain unclear, but it might 
be associated with mtDNA instability, which is a mechanism that has also been observed with 
the OPA1 p.Arg455His mutation (Rendtorff et al., 2011).   
Based on the Euro-Wabb WFS1 database, almost all heterozygous missense variants 
that result in optic atrophy and deafness, or isolated sensorineural hearing loss, are located 
near the C-terminal domain within the ER lumen. These missense mutations appear to cluster 
around the degron locus (Guo et al., 2011), which is located in the final 100 amino acids 
before the C terminus. Chassenot and colleagues have also reported that the majority of 
patients with Wolfram syndrome who developed neurological symptoms had compound 
heterozygous missense mutations located either within the transmembrane domains or 
towards the C-terminus of the protein (Chaussenot et al., 2011). Therefore, heterozygous 
missense mutations, such as c.2051C<T (p.Ala684Val), may lead to cellular dysfunction by 
interfering with ER stress mechanisms or the interaction between WFS1 and another 
transmembrane protein ATF6α, a mechanism which acts as a negative regulator of the 
unfolded protein response (UPR) (Fonseca et al., 2010) In addition, the fact that many of 
these missense mutations are located at or near the degron may suggest that ER stress 
mechanisms are impaired because of a dysfunctional interaction between WFS1 and 
SMURF1, which is a ligase required for maintaining steady-state WFS1 levels under different 
physiological conditions (Guo et al., 2011). Further research is currently ongoing to 
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determine how WFS1 mutations lead to neurological complications in patients with Wolfram 
syndrome. 
Patient PFC-341 harboured two previously unreported WFS1 variants, c.C977T 
(p.Ala326Val) and c.1309G<C (p.Gly437Arg). Patient PFC-341 presented with optic atrophy 
and diabetes mellitus. Both of his parents were clinically unaffected with no evidence of 
subclinical optic nerve dysfunction or diabetes. Segregation analysis revealed that each parent 
harboured one of these two variants and the proband was therefore compound heterozygous. 
Further functional analysis to assess the pathogenicity of these variants was conducted using 
western blot analysis and a significant decrease in level of the WFS1 protein was found, 
indicative of a possible haploinsufficient mechanism or instability of the mutant protein. 
Pathogenic WFS1 mutations are typically either homozygous or compound heterozygous with 
the majority of mutations classified as inactivating (Cryns et al., 2003). Compound 
heterozygosity with pathogenic missense variants is rare and it has been speculated that these 
mutation carriers would present with a clinically milder form of Wolfram syndrome, limited 
to optic atrophy and diabetes mellitus (Rigoli et al., 2011). This hypothesis would be 
consistent with the milder phenotype of patient PFC-341. Sanger sequencing confirmed the 
c.2452C<T (p.Arg818Cys) WFS1 variant in patient PFC-351 and additional functional 
analysis will be required to fully determine its pathogenicity. 
 As detailed in the WES analysis of our optic atrophy patient cohort (Chapter 7), the 
genetic aetiology of ten patients remains unknown.  It is interesting that two SNPs in ATF5 
(Table 7-6), which is a gene associated with the ER stress response, were found in 5/14 
(36%) patients. These SNPS are extremely rare in control population databases (1000 
genomes project and ESP6500). They were not present in two controls sequenced on the same 
plate to exclude technical PCR bias and they were also not found in our in-house control 
database. The relevance of these ATF5 variants will need to be investigated to determine if 
they are a possible risk factors for the development of optic neuropathy.  
Only 80% of the WFS1 exonic regions were appropriately covered with WES analysis 
and it is possible that other pathogenic variants might have been missed in the unsequenced 
regions. These regions were therefore screened with Sanger sequencing and the detected 
variants were analysed using the online SIFT, POLYPHEN2 and Provean pathogenicity 
programmes. A number of missense WFS1 variants were detected, which were confirmed by 
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reverse sequencing, and determined as possibly pathogenic (Table 8-2). Although these 
variants were not found in the Euro-WABB WFS1 database, further functional work is needed 
to determine if they are truly pathogenic. 
The prevalence of Wolfram syndrome has previously been estimated at 1 in 770,000 
in the UK population, but this was based on a clinical diagnostic criteria before the 
identification of WFS1 as the major causative gene (Barrett et al., 1995). Other reported 
prevalence figures are 1 in 500,000 in Germany (Rohayem et al., 2011) and 1 in 710,000 in 
Japan (Matsunaga et al., 2014). A much higher figure of 1 in 68,000 has been found in 
Lebanon and this has been ascribed to higher level of consanguinity and/or a potential founder 
even this region of the world (Zalloua et al., 2008). Lombardo and colleagues suggest that 
Wolfram syndrome and the prevalence of pathogenic WFS1 mutations may be underreported 
in non-consanguineous European populations (Lombardo et al., 2014). Our data is consistent 
with this as evidenced by the identification of confirmed pathogenic WFS1 mutations in 3/14 
patients with suspected inherited optic atrophy that had previously been found to be OPA1-
negative. Furthemore, it is clear that dominant WFS1 mutations represent an important genetic 
subgroup and the spectrum of clinical features has expanded from classical DIDMOAD to 
more limited forms of the disease characterised by varying combinations of optic atrophy, 
deafness and diabetes mellitus. Long-term prospective studies are needed to better assess the 
natural history of dominant and recessive WFS1 mutations, which will be crucial for 
designing future treatment trials. 
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Chapter 9  
 
 
 
       General Discussion 
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Inherited optic neuropathies are an important cause of chronic visual morbidity and they 
affect at least 1 in 10,000 individuals in the UK population (Yu-Wai-Man et al., 2014). The 
pathophysiology of this group of disorders is intrinsically linked with mitochondrial 
dysfunction and the two classical paradigms are LHON, which is caused by primary mtDNA 
mutations, and DOA secondary to pathogenic OPA1 mutations. Recessive forms of optic 
neuropathy are rarer and they are characterised by both genetic and phenotypic heterogeneity, 
with clinical features ranging from isolated optic atrophy to severe early-onset syndromic 
optic atrophy associated with debilitating neurological features and neurodevelopmental 
defects. Wolfram syndrome is the most common recessive optic atrophy and interestingly, the 
major causative gene, WFS1, encodes for an ER transmembrane protein, highlighting the 
complex interplay and crosstalk between the mitochondrial and ER compartments. A growing 
list of nuclear genes causing optic atrophy is being identified with the technological 
revolution of next-generation exome and whole genome sequencing. These exciting 
discoveries are providing major insights into the pathological mechanisms that eventually 
contribute to RGC loss and neurodegeneration. In addition to impaired mitochondrial 
bioenergetics and elevated ROS levels, it is now clear that disturbed mitochondrial dynamics, 
mtDNA instability and impaired mitochondrial quality control also play a role in triggering or 
potentiating RGC loss (Figure 9-1) (Burté et al., 2015; Yu-Wai-Man and Chinnery, 2012). 
We are still at the start of a long road to fully understand the complex interplay between these 
pathological pathways and how these ultimately result in tissue specificity and progressive 
neurodegeneration. 
As part of my PhD work, I have further investigated the expanding clinical 
manifestations and the disease mechanisms that contribute to OPA1-related dominant optic 
atophy. To do so, I made use of primary fibroblast cell lines established from two contrasting 
phenotypic patient groups, one with pure optic atrophy (OA) and the other with patients that 
had developed more severe extraocular features (DOA+). The data obtained with this OPA1 
cell model revealed a striking mitochondrial fragmentation pattern when compared to 
controls. Interestingly, there was significantly greater fragmentation in the DOA+ group 
compared with the OA group, which had not been reported previously. The differences in 
mitochondrial fragmentation might be associated with the underlying subtype of OPA1 
mutations that are more likely to be associated with DOA+ phenotypes (Zeviani, 2008; Yu-
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Wai-Man et al., 2010b). Missense OPA1 mutations involving the GTPase domain carry an 
increased risk of DOA+ phenotypes, presumably because the mutant mRNA is translated and 
the resulting aberrant protein is not immediately degraded by cellular quality control 
mechanisms. This hypothesis is consistent with the normal levels of OPA1 found in fibroblast 
cell lines from patients with DOA+ phenotypes. In contrast, the majority of OPA1 mutations 
result in haploinsufficiency due to nonsense mediated decay and with the wild-type allele 
accounting for the approximately 50% expression of OPA1 (Schimpf et al. 2008). 
 
 
 Figure 9-1 Disease mechanisms implicated in common inherited optic neuropathies -     
.LHON, DOA and Wolfram syndrome 
(1) Disturbed calcium homoeostasis from both the ER and cytosol have been implicated 
as potential dysfunctions in DOA and Wolfram syndrome(Jahani-Asl et al., 2011; 
Kamei et al., 2005; Dayanithi et al., 2010; Cagalinec et al., 2016) Increased calcium 
retention within the mitochondrial compartment could induce mitochondrial swelling 
and impaired SIMH in DOA as detected in chapter 4. Hypothetically, this calcium 
could alter the Krebs cycle as a compensatory effect to OXPHOS dysfunction 
(Traaseth et al., 2004). (2) Impaired rate of ATP production from OXPHOS 
implicating either a complex I (LHON)(Wallace et al., 1988; Huoponen et al., 1991; 
Johns et al., 1992)  and/or complex IV (DOA) defect (Zanna et al., 2008; Chevrollier 
et al., 2008) which could also exasperate levels of ROS (Carelli et al., 2004; Tang et 
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al., 2009; Millet et al., 2016). Disturbed cristae morphology may also impinge on the 
efficiency of OXPHOS while the release of cytochrome C, typically sequestered 
within these cristae compartments, can induce apoptosis (Gonzalves et al., 2005; 
Kuwana et al., 2002; Lutter et al., 2000). (3) Dysfunctional mtDNA maintenance in 
models of optic neuropathy can induce mtDNA depletion (Kim et al., 2005; Chen et 
al., 2012; Speigal et al., 2016; Chapter 5 results), mtDNA proliferation as a potential 
OXPHOS compensatory effect, (Sitarz et al., 2012; Yu-Wai-Man et al., 2010b; Yen et 
al., 2002) or disturb the distribution of mtDNA within the mitochondrial network 
(Elachouri et al., 2011; Chapter 5 results) (4) Increased mitophagy has been detected 
in models of DOA (White et al., 2009; Sarzi et al., 2012) and Wolfram syndrome          
(Caglinec et al., 2016). (5) Mitochondrial fragmentation is a hallmark of DOA 
(Olichon et al., 2003; Zanna et al., 2008; Chevrollier et al., 2012) with DOA+ 
displaying a more severe fragmentation pattern than OA (Chapter 4). In addition, OA 
mitochondrial morphology demonstrates abnormal SIMH under stressed metabolic 
conditions (Chapter 4). Mitochondrial fusion rates were also impaired in DOA (Zanna 
et al., 2008) and Wolfram syndrome (Cagalinec et al., 2016). This may disturb 
complementation between mitochondrial organelles.(6) Glutatemate excitotoxicity and 
reduced anti-oxidant defences are especially pertinent for retinal ganglion cells 
(Nguyen et al., 2011; Millet et al., 2016). (7) The anterograde/retrograde transport of 
mitochondria are dependent on ATP and mitochondrial dynamics and so may be 
particularly pertinent to retinal gangion cell dysfunction (Safiulina and Kaasik, 2013). 
 
Once translated, the OPA1 protein is targeted for integration into the IMM where short 
and long isoforms oligomerise into multimeric complexes (Yamaguchi et al., 2008; Frezza et 
al., 2006). A possible explanation for the increased fragmentation of the mitochondrial 
network in DOA+ may be that both wild-type and pathogenic OPA1 oligomers self assemble 
to create malformed and unstable OPA1 complexes, which further impair normal IMM 
fusion. In OA, the wild-type OPA1 oligomers form fewer multimeric complexes, but they are 
functional and therefore, these could minimise the impact on mitochondrial morphology. 
Based on our results, the increase in mitochondrial fragmentation in DOA+ and OA 
fibroblasts does not seem to be secondary to a severe mitochondrial OXPHOS defect or to 
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disruption of mtDNA maintenance, suggesting that the observed fragmentation is more likely 
the direct consequence of the impaired OPA1 fusional abilities (Chapter 4). Quantification of 
the mitochondrial network showed an exaggerated increase in both mitochondrial length and 
volume, consistent with pathological mitochondrial swelling. A more pronounced effect was 
observed in the OA group under stressful oxidative conditions and this could reflect activation 
of SIMH as a compensatory protective mechanism (Tondera et al., 2009). 
To further investigate the link between OPA1 mutations and mtDNA instability, I 
quantified mtDNA/nucleoid level and distribution, and how these relate with the 
mitochondrial fragmentation patterns observed in DOA+ and OA fibroblasts and myotubes. In 
both cell models, DOA+ was associated with a significantly higher number of mitochondrial 
fragments compared with OA or controls. This further supports our hypothesis that the 
severity of mitochondrial fragmentation is an important parameter that correlates with disease 
severity. It will be very interesting to investigate other tissue types, in particular RGCs, which 
are the neuronal populations that are prefentially affected in DOA. The greater extent of 
mitochondrial fragmentation could also impact on mitochondrial quality control by impairing 
the complementation of mutant mtDNA molecules by wild-type molecules through content 
mixing (Chen et al., 2010; Nakada et al., 2009). An elegant study performed by Elachouri 
and colleagues demonstrated mechanistically how a specific OPA1 peptide sequence encoded 
by exon 4b was likely responsible for anchoring mtDNA nucleoids to the IMM, thereby 
facilitating proper mtDNA replication (Elachouri et al., 2011). It is therefore plausible that a 
reduction in the level of OPA1 could impact on mtDNA number and nucleoid distribution. Of 
note, a recently published study has highlighted how ER-mitochondria contacts regulate 
mtDNA replication in relation to mitochondrial division in human cells (Lewis et al., 2016). 
MtDNA replication is undoubtedly a complex process and it is clear that disturbance at any 
point can result in human disease. In our study, I did not find any major difference in 
mtDNA/nucleoid distribution between DOA+ and OA compared with controls, but there was 
a significant decrease in the number of mtDNA/nucleoids when correlated with the 
mitochondrial fragmentation patterns. A significant decrease in mtDNA/nucleoid content was 
detected in both DOA+ and OA groups relative to total mitochondrial length. This difference 
is likely due to the greater total mitochondrial length that has been reported in OPA1-mutant 
fibroblasts (Agier et al., 2012), but it could also indicate a relative depletion of 
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mtDNA/nucleoid copies due to impaired fusion or mtDNA maintenance. Further work is 
required to explore the mechanisms that underlie these observations and the possible 
pathological link with mitochondrial quality control. 
 Although optic atrophy remains the defining feature of DOA, the clinical 
manifestations observed in OPA1-related disease have now expanded to include chronic 
progressive external ophthalmoplegia (CPEO) and other extraocular features such as ataxia, 
myopathy and peripheral neuropathy. The association of optic atrophy with spastic paraplegia, 
resembling cases that fit the historical description of Behr syndrome, has been well described 
in several unrelated OPA1 mutation carriers (Bonneau et al., 2014; Carelli et al., 2015b; Yu-
Wai-Man and Chinnery, 2015). The development of this syndromic form of DOA has been 
ascribed to the deleterious synergistic consequences of compound heterozygous OPA1 
mutations, in particular the recurrent c.1146A>G (p.Ile382Met) missense mutation, which can 
occur in combination with a deep intronic mutation (Bonifert et al., 2014). Remarkably, two 
Italian families carrying different OPA1 missense mutations have been reported with an 
atypical combination of parkinsonism, dementia and CPEO, but with only subclinical optic 
neuropathy (Carelli et al., 2015). In my PhD project, I have further extended the genetic 
complexity of OPA1 disease by confirming a novel homozygous OPA1 mutation as the 
underlying molecular defect in two affected sisters of Arab Muslim origin, born to 
consanguineous parents, and who developed a fatal infantile encephalomyopathy with 
hypertrophic cardiomyopathy and optic atrophy. Intriguingly, the muscle biopsy from one 
sister instead showed marked mtDNA depletion rather than multiple mtDNA deletions, which 
could explain the severity of the clinical phenotype (Spiegel et al., 2016). The expanding 
clinical and genetic heterogeneity linked to DOA plus phenotypes only serves to emphasize 
the more global neurodegenerative impact of pathogenic OPA1 mutations, which can extend 
far beyond the inner retina and the anterior visual pathways. 
Whole-exome sequencing (WES) has proven a powerful tool in determining the 
underlying genetic basis of rare monogenic disorders. As part of my PhD project, I analysed 
WES data for a cohort of 14 patients with suspected inherited optic atrophy, but who had been 
found to be negative for a number of known optic atrophy genes, namely OPA1, OPA3, 
C12orf65 and RTN4IP1. Pathogenic WFS1 mutations were identified in 3 patients and highly 
suspected in one additional patient, accounting for a nearly 30% positive hit rate. The genetic 
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aetiology for the remaining patients in our cohort remain unknown and further work, 
including whole genome sequencing, and ongoing collaborations will be crucial if we are to 
uncover new, but relatively rare, optic atrophy genes. Recessive WFS1 mutations were 
originally found in patients with early-onset severe Wolfram syndrome that developed 
diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) (Barrett et al., 
1995). WFS1 encodes for wolframin, a transmembrane endoplasmic reticulum protein that 
plays a critical role in calcium homeostasis and interorganellar cross-talk at mitochondria 
associated membranes (MAMs) (Lu et al., 2014; Hoppins and Nunnari, 2012). The molecular 
elucidation of Wolfram syndrome has uncovered the intimate dynamic interactions between 
mitochondria and the endoplasmic reticulum, and how dysfunction in one compartment can 
detrimentally affect the other, and vice versa (Burté et al., 2015; Murley and Nunnari, 2016). 
Importantly, these disturbances are highly relevant to normal RGC physiology and it is highly 
likely that new optic atrophy genes will be uncovered that directly or indirectly affect MAM 
function. WFS1 mutations have now been confirmed to be an important cause of DOA and 
they can cause a more limited phenotype, which, remarkably, can sometimes be restricted to 
the optic nerve. The variable tissue specificity observed with both OPA1 and WFS1 mutations 
raise fundamental questions about the secondary genetic and environmental modifiers, 
including possible epigenetic influence, that are influencing their downstream consequences 
on cellular function. 
 In conclusion, my PhD work has provided new insights into OPA1-related disease 
mechanisms and how these might impact on the severity of the patient’s phenotype. OPA1 
mutations can sometimes behave recessively and we have described the first report of a novel 
homozygous OPA1 mutation, which was associated with a fatal infantile mitochondrial 
encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy. The phenotypic 
manifestations of DOA+ will likely expand further with wider clinical access to WES. A 
similar development has occurred for WFS1 mutations and screening for this specific gene 
should no longer be limited to patients with the DIDMOAD “full house”. Indeed, WFS1 
mutations should now be actively sought in patients with suspected inherited optic atrophy 
who have been found to be OPA1 negative. There are currently no effective treatments for 
patients with inherited optic neuropathies and there are significant challenges in drug 
development and clinical trials for this group of disorders. Despite these difficulties, there 
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have been major advances in our understanding of the genetic and pathophysiological basis of 
inherited optic neuropathies, and the hope is that these breakthroughs will eventually translate 
into tangible benefits for patients experiencing progressive visual loss. 
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Appendix A OPA1 protein levels 
 
 
 
 
Figure A-1 Quantification of OPA1 in primary patient fibroblasts witt pure dominant optic 
atrophy and dominant optic atrophy plus  
Levels of OPA1 were standardised to GAPDH and control lines (N = 4) for each DOA+ and 
OA fibroblast cell line. Error bars represent the standard error of the mean (SEM). The 
individual DOA+ and OA fiboblast cell lines were analysed using the Student’s unpaired t-
test to determine the level of significance compared with controls (ns > 0.05; * ≤ 0.05; ** ≤ 
0.01; *** ≤ 0.001; **** ≤ 0.0001). 
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                     Figure A-2 Representative western blot of OPA1 and GAPDH in (A) DOA+ and (B) OA primary fibroblasts 
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Appendix B OPA1 gene expression 
 
 
Figure B-1Quantification of OPA1 mRNA expression  in individual DOA+ and OA primary 
fibroblasts. 
Error bars represent the standard error of the mean (SEM). A Student’s unpaired t-test was 
used to statistically measure DOA+ and OA groups relative to controls (ns > 0.05; * ≤ 0.05; 
** ≤ 0.01; *** ≤ 0.001; **** ≤ 0.0001). 
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Appendix C Mitochondrial network analysis 
 
 
 
 
 
 
 
Figure C-1Quantification of the Total length and Volume of individual lines from both DOA+ and OA groups under glucose (5mM) and 
galactose (5mM) conditions. 
 Total network length (A) and total network volume (B) were quantified under glucose (blue) and galactose (red) conditions. Error bars represent the 
standard error of the mean. A Student’s unpaired t-test was used for statistical comparison between DOA+, OA and controls. control (ns > 0.05; * ≤ 
0.05; ** ≤ 0.01; *** ≤ 0.001; **** ≤ 0.0001). 
 256 
 
 
 
 
 
 
 
 
 
Figure C-2Mitochondrial fragmentation of the network in individual patient and control primary fibroblasts.  
Average number of mitochondrial fragments (A) were measured using Huygens Object analyser software in fibroblasts imaged following either 24 
hour incubation with 5mM glucose (blue) or 48 hour incubation with 5mM galactose (red). Average fragment length (B) and average fragment volume 
(C) were calculated as described in section 4.2.4. Error bars represent the standard error of the mean (SEM).* p  0.05, ** p  0.01, *** p  0.001 and 
**** p  0.0001 using a Student’s unpaired t-test against controls (n=200). 
 
(A) 
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Appendix D Mitochondrial maintenance analysis 
 
 
 
 
 
 
 
Figure D-1 mtDNA maintenance markers in individual primary fibroblast lines from DOA+ and OA patients.   
MtDNA copy number was measured using real-time PCR and normalised to nuclear encoded B2M copy number (A). TFAM was measured using real-
time PCR and standardised against mean -actin and B2M gene expression (B). Both mitochondrial maintenance markers were expressed compared to 
mean of three different control cell lines (n=3). Error bars represent the standard error of the mean (SEM). * p ≤ 0.05 using a Student’s unpaired t-test 
against controls. 
(A) (B) 
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Appendix E  OXPHOS disturbances 
 
 
 
 
 
 
Figure E-1 Relative expression of OXPHOS complex subunits corrected against GAPDH in 
individual DOA+  primary fibroblasts compared to control.  
Densitometric analysis of NDUFB8 (A), SDHA (B), COXII (C) and ATP5A (D). OXPHOS 
subunit immunoblots was performed using ImageJ and each subunit densitometry normalised 
to GAPDH. Ratios were expressed compared to mean of three different control cell lines 
(n=3). Error bars represent standard error of the mean. A Student’s unpaired t-test was used to 
statistically compare DOA+and OA with control (ns > 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001; 
**** ≤ 0.0001). 
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Figure E-2 Relative expression of OXPHOS complex subunits corrected against GAPDH in 
individual OA  primary fibroblasts compared to control. 
Densitometric analysis of NDUFB8 (A), SDHA (B), COXII (C) and ATP5A (D). OXPHOS 
subunit immunoblots was performed using ImageJ and each subunit densitometry normalised 
to GAPDH. Ratios were expressed compared to mean of three different control cell lines 
(n=3). Error bars represent standard error of the mean. A Student’s unpaired t-test was used to 
statistically compare DOA+and OA with control (ns >0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001; 
****≤ 0.0001). 
(A) (B) 
(C) (D) 
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Figure E-3  Representative western blots of mitochondrial OXPHOS complex subunits in (A) DOA+(2), DOA+(3) and DOA+(4) and (B) 
DOA+(1) primary fibroblasts 
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Figure E-4 Representative western blot of mitochondrial OXPHOS complex subunits in 
OA primary fibroblasts 
SDHA-70kDa 
ATP5A-55kDa 
GAPDH-37kDa 
COXII-17kDa 
NDUFB8-14kDa 
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Figure E-5 Quantification of the levels of ATP produced through OXPHOS and the 
glycolytic pathway incubated in (A) 5mM glucose, (B) 5mM glucose and oligomycin, (C) 
5mM glucose and d-deoxyglucose and (D) 5mM glucose with d-deoxyglucose and 
oligomycin within control DOA+ and OA groups.  
A Student’s unpaired t-test was used to statistically compare DOA+ and OA with controls (ns 
> 0.05; * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001; ****≤ 0.0001). 
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Appendix F  Mitochondrial network analysis in myotubes 
 
 
 
 
 
 
Figure F-1 Total mitochondrial length and volume measured in individual DOA+ primary myotube lines. 
 Total fragment length (A)  and (B) Total fragment volume of primary myotube DOA+ lines were compared statistically against group primary control 
myotubes using a Student’s umpaired t-test (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). 
(A) (B) 
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Figure F-2Average mitochondrial length, volume measured and total number of mitochondrial fragments in DOA+ primary myotubes 
Average mitochondrial length (B) and volume (C) were calculated as a ratio between total length/ volume and total number of mitochondrial fragments 
(A).  Variation between DOA+ primary myotube lines and grouped control was statistically analysed using a Student’s unpaired t-test (* p ≤ 0.05; ** p 
≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001) 
(A) (B) (C) 
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Figure F-3Total mitochondrial length and volume measured in primary OA myotubes.  
Variation of total mitochondrial length (A) and volume (B) between individual myotubes lines and grouped control was statistically analysed using a 
Student’s unpaired t-test (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001) 
(B) (A) 
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Figure F-4Average mitochondrial length, volume and total number of mitochondrial fragments in individual OA primary myotube lines.  
Average mitochondrial length (B) and volume (C) was calculated as a ratio between total length/volume and the total number of mitochondrial 
fragments (A). Variation between average mitochondrial OA myotube lines was compared statistically to control using a Student’s unpaired t-test (* p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001)
(A) (B) (C) 
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Appendix G Mitochondrial nucleoid distribution 
 
 
 
 
 
 
 
 
 
 
 
Figure G-1 Nucleoid distribution dot plot of individual DOA+ and OA primary 
myoblasts  
The size of each blot represents the weighted number of mtDNA/ nucleoid objects present in 
each individual myoblast cell. Graph was generated by Dr. Ian Wilson.  
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Figure G-2 Box-plot of average mtDNA/nucleoid distribution in each individual 
myoblast line  
Box-plot generated by Dr. Ian Wilson.  
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Figure G-3 Total number of nucleoids/mtDNA in each individual primary line per unit area of 
cell analysed 
The mean of the number of nucleoid/mtDNA objects detected per unit area of the cell in 
DOA+, OA and WFS1 lines (N ~ 11) was quantified and compared against control (N = 33). 
Error bars represent standard error of the mean. (p >0.05 is non-significant; p ≤ 0.05 * of 
significance; p ≤ 0.01 is ** of significance; p ≤0.001 is *** of significance; p ≤ 0.0001 is 
**** significance). 
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Appendix H  Benign variants found in WFS1 screen 
 
           DNA  Missense Change 
Euro-WAB 
database 
ExAc Frequency SIFT POLYPHEN2 Provean SIFT  Polyphen2  Provean PFC- 
c.634G<C p.Gly212Ala NA 0 Tolerated 
possibly 
damaging 
Neutral 0.26 0.571 -1.41 147 
c.637G<A p.Gly213Arg NA 0 Tolerated Benign Neutral 0.14 0.216 -2.06 147 
c.640G<A/641C<T/642G<T p.Ala214Ile NA 0 Tolerated Benign Neutral 0.22 0.221 -0.95 147 
c.645G<C p.Gln215His NA 0 Tolerated 
possibly 
damaging 
Neutral 0.13 0.884 -1.74 147 
c.977G<A p.Val333Ile Ganie et al., 2011 0.7818 Tolerated Benign Neutral 0.92 0.0001 0.36 147;349;350;342;345;346;351 
c.2470G<A p.Glu824Lys NA 0.000084 Tolerated 
probably 
damaging 
Neutral 2.86 1 -1.63 345 
c.56C<T p.Pro19Lys NA 0.000042 Damaging(low confidence) Benign Neutral 0.03 0 -0.99 349 
c.1832G<A p.Arg611His NA 0.5367 Tolerated Benign Neutral 0.1 0.146 -1.82 350;147;353;346;341 
c.2565A<G p.Ser855Pro NA 0.00058 Tolerated Benign Neutral 0.28 0.34 -2.023 353 
c.1367G<A p.Arg456His NA 0.057 Tolerated 
Probably 
damaging 
Neutral 0.12 1 -1.31 349 
           
Table H-1WFS1 Missense variants detected and confirmed with Sanger sequencing and their relative pathogenicity scores. 
SIFT, POLYPHEN2 and Provean were used to analyse each variant and their respective scores are indicated. The presence of these variants in the 
Euro-Wab WFS1 database which contains the largest collection of up-to-date variants was also investigated (September 2015)
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